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Abstract 
 
The aim of this thesis is to investigate aspects of molecular evolution and enzyme 
engineering using the experimental evolution of Tobacco Etch Virus cysteine 
protease (TEV) as a model. I map key features of the local fitness landscape and 
characterise how they affect details of enzyme evolution. 
In order to investigate the evolution of core active site machinery, I mutated the 
nucleophile of TEV to serine. The differing chemical properties of oxygen and 
sulphur force the enzyme into a fitness valley with a >104-fold activity reduction. 
Nevertheless, directed evolution was able to recover function, resulting in an 
enzyme able to utilise either nucleophile. High-throughput screening and 
sequencing revealed how the array of possible beneficial mutations changes as 
the enzyme evolves. Potential adaptive mutations are abundant at each step 
along the evolutionary trajectory, enriched around the active site periphery.  
It is currently unclear how seemingly neutral mutations affect further adaptive 
evolution. I used high-throughput directed evolution to accumulate neutral 
variation in large, evolving enzyme populations and deep sequencing to 
reconstruct the complex evolutionary dynamics within the lineages. Specifically 
I was able to observe the emergence of robust enzymes with improved mutation 
tolerance whose descendants overtake later populations.  
Lastly, I investigate how evolvability towards new substrate specificities changed 
along these neutral lineages, dissecting the different determinants of immediate 
and long-term evolvability. Results demonstrate the utility of evolutionary 
understanding to protease engineering. 
Together, these experiments forward our understanding of the molecular details 
of both fundamental evolution and enzyme engineering.   
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Å Angstrom (10-10 meters) 
Aa Amino acid 
AraC Arabinose inhibitor 
Bla β-lactamase 
BLIP β-lactamase inhibitory protein 
Cat Chloramphenicol acetyltransferase 
CFP Cyan fluorescent protein 
C-Y(x) Cyan and yellow fluorescent protein, linked by sequence ‘x’ 
DE Directed evolution 
DFE Distribution of fitness effects 
DNA Deoxyribonucleic acid 
dNTP Deoxy nucleotide tri-phosphate 
E. coli Escherichia coli bacteria 
epPCR Error-prone polymerase chain reaction 
FACS Fluorescence activated cell sorting 
FRET Fluorescence resonance energy transfer 
HT-SAS High throughput screening and sequencing 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
LacI Lac inhibitor 
Nt nucleotide 
PCR Polymerase chain reaction 
PDB Protein database (a repository of solved protein structures) 
pH Hydrogen ion potential (measure of bulk solution acidity) 
pKa Acid dissociation constant (measure of specific residue acidity) 
Population 
(x,y) 
A population of enzymes having undergone ‘x’ rounds of 
neutral evolution and ‘y’ rounds of adaptive evolution 
TEM1 A class of β-lactamases commonly found in E. coli 
TEV 
     wtTEV 
     TEVCys 
Tobacco Etch Virus nuclear inclusion 1 cysteine protease 
           In the context of discussing population evolution 
           In the context of discussing different nucleophiles 
TEVAla C151A mutant of TEV 
TEVSer C151S mutant of TEV 
TM Temperature at which 50% of a protein has melted 
YFP Yellow fluorescent protein 
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Chapter A - Introduction 
1 
Chapter A -  Introduction 
1 SUMMARY 
This section introduces the key concepts of enzymes and their evolution 
that underpin the later chapters. Additionally it describes experimental 
evolution methods and explains some of what these have revealed about 
evolution and evolvability. It concludes with a brief overview of the 
results chapters. 
 
 2  
2 ENZYMES AND EVOLUTION 
2.1 CATALYSIS OF CHEMICAL REACTIONS 
Enzymes are the biological catalysts that perform almost all chemical 
reactions that occur in an organism. They are produced as a linear 
polymer of amino acids but fold up into a 3D structure (defined by their 
sequence) to bring together a few key amino acids into a precise 
arrangement (the active site) to perform chemistry1. These residues are 
responsible for binding a substrate and lowering the activation energy 
required for its conversion to product2 (Figure A-1). This lower 
activation energy determines the rate of the catalysed reaction 
(kcat/KM)3. Enzymes do this so efficiently that some reactions that 
naturally take millions of years can be catalysed in seconds4.  
 
Figure A-1 | Energetics of enzyme catalysis 
A free energy profile (ΔG) of an abstract reaction of substrate to product (S→P) catalysed 
by enzyme (E). Uncatalysed the reaction passes through a high energy transition state 
(S‡). When catalysed by an enzyme, however, it binds to form a complex (E·S) which 
passes through a lower energy transition state (E·S‡). Finally the product complex (E·P) 
dissociates to release free product. The lower transition state energy means that the 
catalysed rate kcat/KM is much faster than the uncatalysed rate kuncat. (Adapted from 
reference3) 
Activation energy is lowered by a combination of factors, some or all of 
which are used in different enzymes: Electrostatic stabilisation of 
kcat/KM
kuncatΔG
E.S
E.P
E+P
ES‡
S‡
E+S
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charge build-up on high energy transition states, the provision of 
general acids and bases, exclusion of solvent, orientation of substrates 
in reactions with more than one, and sometimes formation of a 
transient covalent bond. These effects are achieved using the backbone 
of the protein, the side chain functional groups and organic and 
inorganic cofactors such as metals and cytochromes. 
The active site, is made up of a large, interconnected network of 
cooperative residues5–7. Some directly contact the substrate and are 
involved in lowering transition state energy by the mechanisms listed 
above. Others play a supporting role in orienting, supporting and 
tuning the electronegativity of these. Although active site residues 
must be precisely orientated, they are commonly polar or charged1 and 
hence repel each other. Internal active site repulsion is compensated 
for by the enzyme having a stable structure around them provided by a 
well packed, hydrophobic core scaffold8,9 which accounts for much of 
the rest of the protein. 
Despite this stable fold, it’s important to note that enzymes are not 
static entities. They’re not even particularly rigid entities8,10. Enzymes 
are highly flexible and hence exist as an ensemble of conformations 
that are constantly interconverting. These motions range from very 
fast and small (such as side chain rotation11,12) to large and slow (such 
as loop or whole domain movements13–15). The role of these dynamics 
in activity is controversial16–19 but what is clear is that many enzymes 
have several distinct conformations which optimise the various 
requirements of substrate binding, catalysis and product release. Some 
enzymes will change between these states during their catalytic 
cycle2,13–15,19.  
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2.2 NUCLEOPHILIC CATALYSIS AND CATALYTIC TRIADS 
One method of lowering a reaction’s activation energy is to split it into 
two easier reactions by nucleophilic, covalent catalysis. In this specific 
case, a single residue has great importance to the mechanism since it is 
tuned by its neighbours to lower its pKa and increase the availability of 
the deprotonated form. This nucleophile firstly attacks the substrate to 
form a covalent bond which is subsequently hydrolysed by activated 
water20. Each of these two steps requires lower energy than the 
uncatalysed reaction, increasing its rate. 
A common method for generating a nucleophilic residue for catalysis 
is by using an Acid-Base-Nucleophile catalytic triad21,22. The triad 
forms a charge-relay network to polarise and activate the nucleophile, 
which attacks the substrate, forming a covalent intermediate which is 
then hydrolysed to regenerate free enzyme (Figure A-2). 
 
Figure A-2 | Common elements of nucleophilic catalysis using a catalytic triad 
(a) The enzyme (black) performs a nucleophilic attack on substrate (red) via a tetrahedral 
intermediate to eject the first product, leaving an acyl-enzyme intermediate. (b) The 
intermediate is hydrolysed by an activated water molecule via a second tetrahedral 
intermediate to release the second product and regenerate free enzyme. 
a
b
 
Nucleophile 
A chemical species capable 
of forming new bonds by 
donating electrons 
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This motif is so effective that the same geometry has arisen at least 25 
times independently21,23 as a means of catalysing group transfer24,25 
and hydrolysis22 reactions (including proteolysis). The two most 
commonly used nucleophiles are the oxygen (alcohol) of serine and the 
sulphur (thiol) of cysteine21,22. I introduce the evolution and 
significance of different nucleophiles in greater detail in Chapter C. 
In addition to covalent catalysis, the triad and surrounding residues 
coordinate additional mechanistic effects. General acid catalysis 
protonates leaving groups. General base catalysis activates the water 
that hydrolyses the intermediate. Backbone electrostatics in the 
oxyanion hole stabilise charge build-up on transition states and 
intermediates along the reaction pathway. Additional residues assist in 
binding substrate and, in some enzymes, coordinating large structural 
movements involved in the catalytic cycle such as lid opening and 
closing13,14. 
2.3 PROMISCUITY 
Having described how enzymes achieve catalysis of their target 
substrate, it is useful to introduce catalysis of alternative substrates. 
Classically, enzymes have been viewed as catalysing only one reaction. 
Over recent decades, however, it has become increasingly clear that 
besides efficiently catalysing their target reaction, enzymes often also 
have a set of side-activities. The ability to catalyse more than one 
reaction with the same active site is known as promiscuity26. 
Promiscuity is subcategorised into 3 classes describing in what way 
these reactions differ. Catalytic promiscuity refers to an enzyme that 
can cleave two different types of chemical bond, for example the 
hydrolysis of phosphonate and sulphate bonds by Pseudomonas 
aeruginosa arylsulfatase27. Substrate promiscuity is when an enzyme 
can bind several related substrates to perform the same catalysis on 
 
Enzyme Promiscuity 
The ability of an enzyme to 
catalyse more than one 
reaction 
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them, for example some P450 enzymes can oxidise hundreds of 
substrates28. Lastly, product promiscuity occurs when an enzyme 
converts a substrate into a high energy intermediate (e.g. the 
conversion of E,E farnesyl diphosphate to a reactive cation by γ-
humulene synthase), which can then be resolved to a variety of 
different products29. 
The origins of promiscuity are still unclear. In many enzymes there is 
no evidence that promiscuity has been specifically selected for. In these 
cases it seems likely that promiscuous activities are simply the 
accidental by-products of extreme catalytic activity for the native 
reaction and the difficulty of discriminating between similar 
substrates. Lack of strong counter-selection against promiscuous 
activities allows their evolutionary persistence30. For example clotting 
proteases such as thrombin merely need to be specific enough not to 
cause accidental cleavage. 
Conversely some promiscuous enzymes are likely the result of direct 
selection for multiple activities such as enzymes that scavenge 
nutrients or remove environmental toxins (e.g. P450 oxidases28, serum 
paraoxonases31 and phosphotriesterases32). Occasionally promiscuity 
can be exquisitely refined such as the ribosome. To function it must 
catalyse the polymerisation of any of 20 natural amino acids (substrate 
promiscuity), but specifically organised, based on the sequence of an 
mRNA template rather than mere random polymerisation. In this way 
controlled promiscuity is necessary for its function. 
2.4 DIVERGENT MOLECULAR EVOLUTION 
Divergent evolution of proteins has created a wide array of enzymes 
descended from a common ancestor, but now encompassing a wide 
range of activities33,34. The widest evolutionary category that we can 
currently place around a set of enzymes is a superfamily which 
 
Divergent evolution 
The accumulation of 
differences between genes 
that share a common 
ancestor 
 
Superfamily 
The largest set of proteins 
for which common ancestry 
can be inferred 
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describes a group of enzymes with common ancestry inferred by fold 
and mechanistic similarity. The divergence of gene sequences occurs 
through two main process: Adaptive evolution (natural selection for 
improved or altered function35,36) and neutral evolution (the 
accumulation of mutations that have little or no effect on function 
leading to genetic drift37,38). 
Evidence for the importance of promiscuous activities as a starting 
point for adaptive evolution comes, in part, from comparative studies 
of existing proteins39. The promiscuous activity of one member of a 
protein superfamily is often the native activity of another member of 
that family such as in the aminotransferase40 or alkaline phosphatase 
superfamilies41–43 (Figure A-3). Cross-wise promiscuity implies that 
divergent evolution has (partially) specialised each member towards 
one of a set of similar activities. For example, the pesticide-degrading 
phosphotriesterase still shows promiscuous activity towards the 
substrate of the enzyme from which it is descended44. Similarly, type III 
antifreeze is descended from sialic acid synthase, which itself shows 
promiscuous ice-binding activity45. 
 
Figure A-3 | Crosswise catalytic promiscuity in the alkaline phosphatase superfamily 
Shown are the hydrolase enzymes Alkaline Phosphatase (AP), nucleotide 
pyrophosphatase/ phosphodiesterase (NPP), phosphonate monoester hydrolase (PMH) 
and aryl sulfatase (AS). Each enzyme is shown with its native substrate in the circles. 
Promiscuous activities are indicated by connecting lines. (Adapted from reference43) 
The promiscuity of enzymes is a key feature in modern models of 
molecular evolution. All models of gene diversification by duplication 
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rely on some level of promiscuous activity either before or after gene 
duplication46. Classical neofunctionalisation models postulate that 
after a gene duplicates, one copy is released from selective pressure for 
the parental function47. This paralog accumulates mutations that 
either deactivate it (pseudogenisation48, Figure A-4a) or create new 
activities (Figure A-4b). Conversely, subfunctionalisation models 
assume some level of promiscuous activity before duplication such that 
when a gene duplicates each copy can specialise towards one of the 
parent activities49 (Figure A-4c). 
 
Figure A-4 | Neo- and sub- functionalization after gene duplication 
(a) A gene duplicates but one copy loses function as it mutates to random sequence. (b) 
A gene duplicates and mutations in one copy endow it with new function. (c) A 
promiscuous gene duplicates allowing each copy to specialise towards one function. 
Both neo- and sub- functionalization theories fail to explain some 
aspects of molecular evolution. In neofunctionalisation, the relative 
abundance of deleterious mutations over beneficial mutations50 makes 
the likelihood that beneficial mutations will accumulate in a duplicated 
gene before it succumbs to pseudogenisation very low. Conversely, for 
subfunctionalisation to explain the development of the large range of 
contemporary functions, requires the assumption that a large number 
of genes are promiscuous. Indeed it has sometimes been misinterpreted 
to imply that ancestral genes were all promiscuous and have linearly 
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become more specialised over time, however several papers have 
attempted to clear up this confusion30,51. 
Modern models tend to lie somewhere in between these extremes 
whereby some degree of promiscuity likely exists before duplication. 
Which model best explains divergent evolution is likely to be protein 
specific and depend on the relative strength of selection, the 
prevalence of beneficial promiscuity, and the trade-offs between 
activities50. Duplication may be neutral or be selected for gene copy 
amplification52 or relief of constraints if optimisation of the new 
activity trades-off with the native45,53,54. 
Through these divergent evolution processes, all new genes are 
generated (with the rare exception of de-novo gene birth55). The 
evolution of enzyme active sites is constrained by chemical 
requirements on function. Other residues are less constrained and so 
their evolutionary divergence is more dominated by genetic drift (i.e. 
accumulation of neutral mutations). Therefore, active site residues 
tend to evolve more slowly except during periods where there is 
selection for change in function56,57. Additionally, whilst 
unconstrained residues evolve independently, some residues are highly 
dependent on the identity of their neighbours. Interactions between 
residues cause them to co-evolve as ‘protein sectors’58,59 (Figure A-5). 
  
Figure A-5 | Protein co-evolution sectors 
Structure of rat trypsin (PDB 3tgi) with co-evolutionary sectors shown as surfaces and 
substrate as sticks. Blue sector is the β-barrel scaffold. Green sector is the triad and barrel 
interface. Red sector is the main substrate binding pocket. (Adapted from reference58) 
S195Ser
His
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2.5 PROTEIN SEQUENCE SPACE AND FITNESS LANDSCAPES 
In order to understand evolution of the enormous diversity of protein 
sequence and function, it is helpful to talk of sequence space – an 
imagined array of all protein sequences. Formally, each residue in a 
protein is a dimension with 20 possible positions along that axis 
corresponding to the possible amino acids. Hence there are 400 
possible di-peptides arranged in a 20x20 space but that expands to 
10130 for even a small protein of 100 amino acids arranged in a space 
with 100 dimensions. Despite the diversity of protein superfamilies, 
however, sequence space is extremely sparsely populated by functional 
proteins60. Most random protein sequences have no fold or function. 
Enzyme superfamilies, therefore, exist as tiny clusters of active proteins 
in a vast empty space of non-functional sequence. 
A fitness landscape consists of adding an extra axis of fitness. For 
organisms, fitness formally describes the number of viable offspring 
that a particular genome sequence has. When discussing enzymes, 
however, it is common to define fitness as a particular function of 
interest61. Explicit fitness landscapes are overwhelmingly 
multidimensional but features of the topology are often represented in 
a 3D simplification (e.g by principal component analysis). This 
generates a landscape with two horizontal axes of sequence space and 
a vertical axis of fitness62 (Figure A-6). 
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Figure A-6 | Example fitness landscape 
A common representation of an abstract fitness landscape. Sequences are arranged in 
two horizontal dimensions in a simplified sequence space. The fitness of each sequence 
is then represented on the vertical axis. This leads to a surface where islands of functional 
sequences have higher vertical elevation (fitness) in a sea of non-functional sequences. 
Since each point is a different enzyme sequence, mutations link 
adjacent points on the fitness landscape. Adaptive evolution of a single 
gene can therefore be thought of as a gene moving uphill from point to 
point in the fitness landscape. Similarly a population of gene variants 
inhabit a cloud of sequences which evolve such that higher points are 
more likely to proliferate and lower points are purged, leading the 
population to move uphill each generation. In this way, the structure 
of the fitness landscape guides evolutionary trajectories63 and 
evolutionary trajectories report on fitness landscape structure62. 
In these landscapes there are a number of key features. The maximum 
peak height (the global maximum) represents the most active possible 
enzyme sequence. Some enzymes likely exist near these as they operate 
at the diffusion limit4,64,65 (i.e. diffusion of substrate in and product out 
limits rate) and so fundamentally cannot be any faster. If all mutations 
are additive, they can be acquired in any order (Figure A-7a). The 
landscape, then, is perfectly smooth, with only one peak and all 
sequences can evolve uphill to it (Figure A-7d). 
Conversely, if mutations interact with one another (epistasis Figure 
A-7b,c), the fitness landscape becomes rugged as the effect of a 
mutation depends on the genetic background of other mutations66,67. 
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Such interactions occur whenever one mutation alters the local 
environment of another residue (either by directly contacting it, or by 
inducing changes in the protein structure). For example in a disulphide 
bridge, a single cysteine has no effect on protein stability until a second 
is present at the correct location. At its most extreme interactions are 
so complex that the fitness is ‘uncorrelated’ with gene sequence and 
the topology of the landscape is random (Figure A-7f). 
 
Figure A-7 | Mutation epistasis and landscape ruggedness 
Two mutations a⟶A and b⟶B. (a) When effects are additive mutations can be acquired 
in any order. (b) Epistasis restricts uphill paths to the order ab⟶aB⟶AB. (c) Sign epistasis 
prevents both mutations existing together. (d) On a larger scale landscape, high additivity 
creates a single, smooth peak. (e,f) Increasing average epistasis between mutations 
creates an increasingly rugged landscape  
Most landscapes are likely in between these two extremes of 
ruggedness (Figure A-7e). Such landscapes contain many local maxima 
which, though not as high as the global maximum, are nevertheless the 
highest accessible nearby peak. These are sometimes referred to as 
multiple evolutionary solutions to a problem68,69. The number and 
separation of these peaks defines how accessible they are from each 
other (Figure A-8). 
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Additionally, clustering of peaks in regions of the fitness landscape (i.e. 
landscape structure) indicates that the solutions contained are similar. 
Such structure comes about when chemical or physical constraints 
cause some regions of a fitness landscape to be particularly sparse21 in 
functional sequences, whilst others regions are rich70–72. 
 
 
Figure A-8 | Fitness peak separation by valleys 
(a) If multiple fitness peaks are broad and close, then there are few valleys and a sequence 
starting at point 1 can evolve to the higher peaks 2 or 3. (b) If peaks are separated by 
wide, deep valleys then genes are trapped at their local optima. 
Several important caveats exist. It is important to note that, since the 
human mind struggles to think in greater than three dimensions, 3D 
topologies can mislead73,74. In particular it is not clear whether peaks 
are ever truly separated by fitness valleys in such multidimensional 
landscapes, or whether they are connected by vastly long neutral 
ridges75,76. Additionally, the fitness landscape is not static in time but 
dependent on the changing environment and evolution of other genes. 
It is hence more of a seascape77, further affecting how separated 
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adaptive peaks can actually be. Finally, since it is common to use 
function as a proxy for fitness when discussing enzymes, any 
promiscuous activities exist as overlapping landscapes that together 
will determine the ultimate fitness of the organism. 
With these limitations in mind fitness landscapes can still be an 
instructive way of thinking about evolution. It is fundamentally 
possible to measure (even if not visualise) some of the 
multidimensional parameters of landscape ruggedness and of peak 
number, height, separation, and clustering. Simplified 3D landscapes 
can then be used relative to each other to visually represent the relevant 
features (see section 3.4). 
2.6 THE DISTRIBUTION OF FITNESS EFFECTS 
The result of mutations to a particular sequence can be described by 
the Distribution of Fitness Effects (DFE), the spectrum of fitnesses of 
mutants. Mutations can be deleterious, neutral or beneficial (each to 
different degrees) and so the DFE describes the local fitness landscape 
within a ‘one mutation radius’ of the mutagenised sequence78. The 
relative frequencies of deleterious, neutral and beneficial mutation 
have large consequences for evolution. Selectionist theories proposed 
that almost all mutations were either deleterious or beneficial and 
hence variation in nature was exclusively adaptive35,36 (Figure A-9a). 
The neutral theory postulated that, in fact, many mutations were 
neutral and hence variation was the product of non-directional drift37 
(Figure A-9b). This was later refined in the nearly-neutral theory that 
posited that mutations that are only mildly deleterious are also 
frequently fixed in populations38 (Figure A-9c).  
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Figure A-9 | Possible distributions of fitness effects 
The relative proportions of different classes of mutations in (a) selectionist theories (b) 
neutral (qualitative data from references38,79) 
Studies of fitness landscapes have been largely theoretical73–76,80–82, 
relying either on mathematical and computation models or on 
bioinformatic measurements of natural diversity. Nevertheless, there 
are increasing attempts to study evolution in an experimental setting. 
Subsequent sections of this chapter will introduce some of the 
experimental work that is beginning to measure aspects of fitness 
landscapes and their effects on enzyme evolution. 
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3 EXPERIMENTAL EVOLUTION OF PROTEINS 
The study of evolution is largely based on extant organisms and their 
genes. However, research is often limited by the lack of fossils (and 
particularly the lack of ancient DNA sequences83–85) and incomplete 
knowledge of ancient environmental conditions. Experimental 
evolution has been used in various formats to understand underlying 
evolutionary processes in a controlled system. Experimental evolution 
has been performed on multicellular86 and unicellular87 eukaryotes, 
prokaryotes88, viruses89 as well as individual enzyme90–92, ribozyme93 
and replicator94,95 genes. Since experiments address topics as varied as 
the evolution of multicellularity87, maximum flight speed86 or heat 
adaptation96,97, I will concentrate here on the experimental evolution 
of enzyme genes. 
Evolution requires three things to occur: variation between replicators, 
that variation causes fitness differences upon which selection acts, and 
that this variation is heritable98. Directed evolution (DE) is a mimic of 
the natural evolution cycle in which a single gene is evolved by iterative 
rounds of mutagenesis, selection or screening, and amplification 
(Figure A-10). It is frequently used for protein engineering as an 
alternative to rational design99, but can also be used to investigate 
fundamental questions of enzyme evolution62. 
As a protein engineering tool, DE has been most successful in three 
areas. Firstly, improving enzyme stability for biotechnological use at 
high temperatures or in harsh solvents15,96. Secondly, for improving 
binding affinity of antibody therapeutics100 and the activity of de novo 
designed enzymes101. Thirdly in altering substrate specificity of 
existing enzymes102–105, again, often for use in industry99. 
 
Directed Evolution (DE) 
An experimental process of 
mutation, selection and 
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Figure A-10 | Directed evolution cycle 
An example of a directed evolution experiment with comparison to natural evolution. 
Inner circle indicates the 3 stages of the cycle with the natural process being mimicked in 
brackets. The outer circle demonstrates a typical experiment. 
Of course, selecting for improvement in the assayed function simply 
generates improvements in the assayed function. To understand how 
these are achieved, the properties of the evolving enzyme have to be 
measured. Improvement of the assayed activity can be due to 
improvements in enzyme catalytic activity (Figure A-11) or enzyme 
concentration. 
  
Figure A-11 | Directed evolution of a cytochrome P450 
Directed evolution of P450-BM3 (hydroxylase of fatty acids) for hydroxylation of propane 
to propanol (round 9 selection for increased stability). First panel shows how the assayed 
activity of turnover number increased. Second and third panels show the improvements 
of kinetic parameters kcat (catalysis) and KM (binding). Final panel shows the concomitant 
loss of T50 (thermal denaturation temperature). (Adapted from reference62) 
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Additionally, there is no guarantee that improvement on one substrate 
will improve activity on another. This is particularly important when 
the desired activity cannot be screened or selected for and so a ‘proxy’ 
substrate is used which can lead to evolutionary specialisation to the 
proxy without improving the desired activity. Consequently, choosing 
appropriate screening or selection conditions is vital for successful 
directed evolution. In sections 3.1-3.3 I will outline the variety of 
techniques that can be used for each of the three steps in the directed 
evolution cycle. 
3.1 GENERATING VARIATION 
The first step in performing a cycle of DE is the generation of a library 
of variant genes. Random sequence is vast (10130 possible sequences for 
a 100 amino acid protein) and extremely sparsely populated by 
functional proteins. Neither experimental106, nor natural107 evolution 
can ever get close to sampling so many sequences. Of course, natural 
evolution samples variant sequences close to functional protein 
sequences and this is imitated in DE by mutagenising an already 
functional gene (Figure A-12). 
The starting gene can be mutagenised by random point mutations (by 
chemical mutagens108 or error prone PCR109) and insertions and 
deletions (by transposons110, and S. Emond unpublished data). Gene 
recombination can be mimicked by DNA shuffling111 of several 
sequences (usually of more than 70% homology) to jump into regions 
of sequence space between the shuffled parent genes. Finally, specific 
regions of a gene can be systematically randomised112 for a more 
focused approach based on structure and function knowledge. 
Depending on the method, the library generated will vary in the 
proportion of functional variants it contains. Even if an organism is 
used to express the gene of interest, by mutagenising only that gene, 
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the rest of the organism’s genome remains the same and can be ignored 
for the evolution experiment (to the extent of providing a constant 
genetic environment). 
 
Figure A-12 | Mutagenesis methods 
Starting gene (left) and library of variants (right). Point mutations change single 
nucleotides, insertions and deletions add or remove sections of DNA, shuffling 
recombines two (or more) similar genes. 
3.2 DETECTING FITNESS DIFFERENCES 
Two main categories of method exist for isolating functional variants. 
Selection systems directly couple protein function to survival of the 
gene, whereas screening systems individually assay each variant and 
allow a quantitative threshold to be set for sorting a variant or 
population of variants of a desired activity. 
Selection for binding activity is conceptually simple. The target 
molecule is immobilised on a solid support, a library of variant proteins 
is flowed over it, poor binders are washed away, and the remaining 
bound variants recovered to isolate their genes113. Binding of an 
enzyme to immobilised covalent inhibitor has been also used as an 
attempt to isolate active catalysts4. This approach, however, only 
selects for single catalytic turnover and is not a good model of substrate 
binding or true substrate reactivity. If an enzyme activity can be made 
necessary for cell survival, either by synthesizing a vital metabolite, or 
Point 
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destroying a toxin, then cell survival is a function of enzyme 
activity114,115. Such systems are generally only limited in throughput 
by the transformation efficiency of cells. They are also less expensive 
and labour intensive than screening, however they are typically 
difficult to engineer, prone to artefacts and give no information on the 
range of activities present in the library. 
An alternative to selection is a screening system. Each variant gene is 
individually expressed and assayed to quantitatively measure the 
activity (most often by a colourgenic or fluorogenic product). The 
variants are then ranked and the experimenter decides which variants 
to use as temples for the next round of DE. Even the most high 
throughput assays usually have lower coverage than selection methods 
but give the advantage of producing detailed information on each one 
of the screened variants. This disaggregated data can also be used to 
characterise the distribution of activities in libraries which is not 
possible in simple selection systems. Screening systems, therefore, 
have advantages when it comes to experimentally characterising 
adaptive evolution and fitness landscapes. 
3.3 ENSURING HEREDITY 
When functional proteins have been isolated, it is necessary that their 
genes are too, therefore a genotype-phenotype link is required116 
(Figure A-13). This can be covalent, such as mRNA display where the 
mRNA gene is linked to the protein at the end of translation by 
puromycin106.  Alternatively the protein and its gene can be co-
localised by compartmentalisation in living cells117 or emulsion 
droplets118. The gene sequences isolated are then amplified by PCR or 
by transformed host bacteria. Either the single best sequence, or a pool 
of sequences can be used as the template for the next round of 
mutagenesis. The repeated cycles of Diversification-Selection-
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Amplification generate protein variants adapted to the applied 
selection pressures. 
 
Figure A-13 | Genotype-phenotype linkage methods 
As the protein is expressed, it can either be covalently linked to its gene (as in mRNA, left) 
or compartmentalized with it (cells or artificial compartments, right). Either way ensures 
that the gene can be isolated based on the activity of the encoded protein. 
3.4 HIGH THROUGHPUT SEQUENCING 
The maximum library size that can be screened for active variants (also 
called library coverage) is limited by the throughput of the assay. 
Additionally, the number of active variants chosen to be taken through 
to the next round of DE is limited by data analysis of their sequences. 
If a single variant is selected from one round to the next, each member 
of the lineage can be characterised in molecular detail but stochastic 
events by genetic drift have a larger effect. Conversely, at each round a 
pool of improved variants can be selected however it has, until recently, 
not been possible to know the sequences present in this gene pool. This 
trade-off between depth and breadth in DE studies has been partly 
alleviated by the rise of ‘next generation’ sequencing technologies. It 
has become feasible to sequence 105 or more gene variants and so it is 
possible to keep track of the composition of large, mixed pools of 
variants. 
Additionally, by sequencing a library of variants before and after an 
experimental selection, it is possible to measure the enrichment of 
functional sequences and the purging of non-functional sequences. 
Indeed, the degree of enrichment for each variant (its enrichment 
Gene
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factor) indicates the relative fitnesses of variants and therefore which 
residue mutations are adaptive to that selection. 
This technique has been used in two relevant ways, with a focus either 
on DNA sequence or on protein structure. If screening is performed in 
combination with next generation sequencing, each sequence can have 
a fitness ascribed to it and be laid out as an explicit fitness landscape119. 
For example, when 30nt DNA molecules were evolved to bind a 
protein target120, the local fitness landscape could be mapped to show 
two distinct broad optima, one higher than the other (Figure A-14). 
Sequences were observed to evolve uphill towards these peaks over 8 
rounds. These works are revealing the complexity of real fitness 
landscapes and in particular their tendency to have many peaks of 
similar fitness79,120–122. 
 
Figure A-14 | Experimentally measured fitness landscape of DNA binders  
6000 DNA sequences (30nt) were evolved to bind allophycocyanin protein for 8 rounds. 
(a) Phylogeny of successful binders in the final round. (b) Sequence space diagram of all 
sequences (dots) from all rounds with related sequences clustered together. Point colour 
indicates binding score (fitness). Arrows indicate two lineages starting from the red circle 
and evolving to the yellow circle. (c) The sequence space of (b) converted into a fitness 
landscape (smoothed), spheres indicate 150 randomly picked initial variants with lined 
depicting the direction of subsequent evolution by round 7. (Adapted from reference120) 
When adaptive and deleterious mutations are mapped on the protein’s 
structure they can indicate which regions are enriched in functional 
variation and which are constrained to the wild type amino acid122–126 
a b
c
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(Figure A-15). This can show structural and functional constraints that 
prevent adaptive mutation. Additionally, it can uncover regions where 
beneficial mutations are more common, acting as evolutionary 
hotspots. 
 
Figure A-15 | Sequence-function relationship mapped on protein structure 
Structure of WW domain as spheres (PDB 1jm q) bound to peptide as sticks. Colour 
indicated evolutionary constraint after mutants were selected for peptide binding, blue is 
constrained to wt residue, white is no residue preference, and red is preference for non-
wt residue. (Adapted from reference121) 
Together, these technologies and methods are beginning to allow the 
understanding of complex evolutionary processes that have 
traditionally not been possible to investigate in detail. Examples of 
such processes are the evolution of robustness and evolvability, the 
structure of real fitness landscapes and the experimental evolution of 
large populations. The rest of this chapter will introduce these topics 
and the rest of this thesis will consist of their investigation. 
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4 ROBUSTNESS 
4.1 GENOMIC AND PROTEIN ROBUSTNESS 
Genomes mutate by environmental damage and imperfect replication, 
yet they display remarkable tolerance. For example >95% of point 
mutations in C. elegans have no detectable effect127 and even 90% of 
single gene knockouts in E. coli are non-lethal128. This comes from 
robustness both at the genome level and protein level. Since Muller’s 
ratchet (the fixation of slightly deleterious mutations) tends to reduce 
robustness, selection pressures must exist that act to increase it (see 
Chapter D, 2.1). 
There are many mechanisms that provide genome robustness. For 
example, genetic redundancy129 reduces the effect of mutations in any 
one copy of a multi-copy gene. Additionally the flux through a 
metabolic pathway is typically limited by only a few of the steps, 
meaning that changes in function of many of the enzymes have little 
effect on fitness130,131. Similarly metabolic networks haven multiple 
alternative pathways to produce many key metabolites132. Protein 
mutation tolerance is the product of two main features: the structure 
of the genetic code and protein structural robustness133,134. 
Proteins are resistant to mutations because many sequences can fold 
into highly similar structural folds135. A protein adopts a limited 
ensemble of native conformations because those conformers have 
lower energy than unfolded and misfolded states (ΔΔG of 
folding)136,137. This is achieved by a distributed, internal network of 
cooperative interactions (hydrophobic, polar and covalent)138. Protein 
structural robustness results from few single mutations being 
sufficiently disruptive to compromise function. Proteins have also 
evolved to avoid aggregation139 as partially folded proteins can 
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combine to form large, repeating, insoluble fibrils and masses140. There 
is evidence that proteins show negative design features to reduce the 
exposure of aggregation-prone β-sheet motifs in their structures141. 
Additionally, there is some evidence that the genetic code itself may be 
optimised such that most point mutations lead to similar amino acids 
(conservative)142,143. These factors create a DFE of mutations that 
contains a high proportion of neutral and nearly-neutral mutations. 
Robustness is sometimes measured as the proportion of mutations that 
are neutral (roughly two thirds in proteins so far measured50,144,145). 
4.2 NEUTRAL NETWORKS 
This resistance to deleterious mutation allows access to a large neutral 
network of phenotypically equivalent genes146–148. Since many 
sequences have equivalent function, they can be imagined as existing 
on a broad, flat plateau on a fitness landscape. The more robust a 
protein, the more neutral neighbours it has149. Since some sequences 
have more neutral neighbours than others, the population is predicted 
to evolve towards these robust sequences149 (Figure A-16). This is 
sometimes called circum-neutrality and represents the movement of 
populations away from cliffs in the fitness landscape150. Experiments 
are beginning to confirm these predicted processes (see Chapter D). 
 
Figure A-16 | Neutral network 
Each circle represents a functional gene variant and lines represents point mutations 
between them. Light grid-regions are sequences with low fitness, dark regions have high 
fitness. (a) White circles have few neutral neighbours, black circles have many. Light grid-
regions contain no circles because those sequences have low fitness. (b) The population 
is predicted to evolve towards the centre and away from ‘fitness cliffs’ (dark arrows).  
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5 EVOLVABILITY 
5.1 DEFINITION AND QUANTIFICATION 
Just as evolution is the change of gene sequences over time, evolvability 
is the propensity for change over time. Early definitions were mostly 
concerned with heritability of variation and so whether that variation 
could lead to evolution. Later definitions are broader – the latent 
potential for further evolution. Evolvability is sometimes quantified as 
the percentage of mutations that lead to a particular trait. At its 
minimum, zero evolvability indicates that the evolution of a trait is 
impossible (e.g. enzyme rates faster than the diffusion limit or insects 
thicker than 16 cm151,152). Evolvability of 10-3 would mean that in a 200 
amino acid enzyme, only a single point mutation is adaptive. Higher 
evolvability indicates multiple possible solutions. In this sense, 
evolvability is dependent on the DFE of mutations. Neutral 
evolvability will depend on the proportion of mutations that are not 
deleterious, i.e. robustness. Adaptive evolvability will depend on the 
much smaller number of mutations that are beneficial to function and 
fitness. 
Experimentally measured DFEs are, in general, roughly bimodal 
(Figure A-17) whether for individual proteins79 or whole 
organisms153,154. Some studies have also identified a discrete nearly-
neutral set and measured the amount by which these mutations reduce 
fitness155. Additionally, the distribution of the rare set of beneficial 
mutations seems to be exponential with mutations of small effect being 
more common than mutations of large effect156–158. 
 
Evolvability 
The potential of a trait or 
sequence for further 
evolution (sometimes 
measured as the proportion 
of adaptive mutations) 
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Figure A-17 | Experimentally measured distributions of fitness effects 
In a DFE, the selection coefficient describes the relative enrichment by selection where 0 
indicates neutrality, -1 indicates lethality, and values >0 indicate benefit. (a) The 
proportions of different mutation effects expected by models and the observed DFE from 
mutagenesis of 9 residues of Heat Shock Protein 90 in yeast to all possible amino acids. 
The red line shows the DFE of non-synonymous mutations, the grey line shows the DFE 
of synonymous mutations. Observed DFE in (b) 66 Tobacco Etch Virus mutants and (c) 45 
ΦX174 virus mutants. (Adapted from references79,154) 
Estimates of the abundance of beneficial mutations span 5 orders of 
magnitude in different systems50,97,123,126,157–162 (Figure A-18). This 
range is unsurprising since one can imagine different selection 
pressures for which it would be more or less difficult to find adaptive 
mutations. 
  
Figure A-18 | Abundance of beneficial mutations 
The proportion of spontaneous mutations that are adaptive to different selection 
pressures in different organisms. E3 ligase and β-lactamase evolution was performed by 
mutagenesis of that gene only, other evolutions by whole genome mutagenesis. The ‘lab 
conditions’ of the Drosophila evolution are detailed in reference161 and references 
therein. (Data from references50,97,123,157–162) 
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5.2 DETERMINANTS OF EVOLVABILITY 
Evolvability depends on two aspects of a fitness landscape. Firstly, the 
population’s movement speed through a fitness landscape163 
(mutation164–166 and recombination111,167 rate). Secondly,  the 
structure of that landscape (pleiotropy168, chemical/physical 
constraints21 and epistasis169–172) can limit the number of accessible 
fitness peaks. 
Since functional sequences are not evenly distributed in sequence 
space, some biochemical properties are more readily accessible from 
some points in sequence space. Some key determinants the structure 
of the fitness landscape are detailed below. 
Pleiotropy occurs when a single mutation affects multiple traits173,174. 
It was originally used to describe genes or mutations that affect 
multiple traits in organisms such as butterfly wing spots175. In 
biochemistry it is used for underlying protein properties. For example, 
it is commonly observed that mutations increasing activity decrease 
stability61,176 (negative pleiotropy). Conversely, proteins often struggle 
to discriminate between similar substrates and mutations improving an 
adaptive activity may increase an anti-adaptive one168 (positive 
pleiotropy). For example when β-isopropylmalate dehydrogenase is 
evolved to use NADP+ instead of the native NAD+ as a cofactor, it is 
unable to distinguish between NADP+ and the more abundant 
NADPH (Figure A-19a). The NADPH acts as an inhibitor and inability 
to uncouple their affinities leads to constraint on efficiency with the 
NADP+ cofactor. Similarly, RuBisCO cannot perfectly distinguish 
between carbon dioxide and oxygen, causing energy wastage177,178. 
Pleiotropic effects, therefore, reduce the power of selection to 
independently optimise enzyme properties. 
 
Pleiotropy 
When a single mutation or 
gene has multiple effects 
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Figure A-19 | Measured determinants of evolvability 
(a) In β-isopropylmalate dehydrogenase being experimentally evolved to use NADP+ as a 
cofactor, the pleiotropic affinity for the more abundant NADPH causes inhibition. This 
positive pleiotropy prevents discrimination between the desired cofactor and the reduced 
inhibitor. Black circles are random point mutants and white circles are engineered 
variants. (b) In serine and cysteine proteases, the nucleophile cannot be replaced with 
threonine as all possible rotamers of threonine cause a clash between the γ-methyl and 
backbone or basic triad member. This constraint causes all threonine proteases to have 
their nucleophile at the N-terminus. (c) The distribution of enzyme activities. The fastest 
enzymes on the far right are constrained by the diffusion limit and hence there are no 
enzymes with kcat/KM > 1010 s-1M-1. (d) In β-lactamase evolved to cleave cefotaxime, the 
best mutant has 5 mutations. Of all 120 possible routes from the wt (-----) to the final 
mutant (+++++), only the 18 shown here give consistent step-wise increases in kcat/KM. 
Each circle is an enzyme variant, the number indicates kcat/KM, and arrows indicate 
mutations. Wider arrows indicate more probable mutations, dashed and solid arrows 
refer to correlated and equal fixation probability models. (Adapted from 
references4,21,168,170) 
Likewise, physical and chemical constraints prevent the evolution of 
some features. For example some proteases use threonine as their 
nucleophile. This has to be at the N-terminus of the protein since the 
methyl group sterically clashes with other residues in the enzyme in 
order to accommodate the substrate21 (Figure A-19b). Consequently, 
serine proteases can never have their nucleophile replaced with 
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threonine. In the same way, the speed of diffusion limits the maximum 
attainable rate of an enzyme or transport protein4,64,65 (Figure A-19c). 
Finally, epistasis is usually considered a constraining factor on 
evolution as the lack of a smooth landscape makes it harder for 
evolution to access fitness peaks172. In highly rugged landscapes, 
fitness valleys block access to some genes, and even if ridges exist that 
allow access, these may be rare or prohibitively long. For example, 5 
mutations together enable TEM1 β-lactamase to cleave cefotaxime (a 
3rd generation antibiotic). However, of the 120 possible pathways to 
this 5-mutant variant, only 7% were accessible to evolution as the 
remainder passed through fitness valleys170 (Figure A-19d). 
Conversely, a 5-mutant variant of epoxide hydrolase with altered 
specificity can be accessed by 46% of pathways179. 
5.3 EVOLUTION OF EVOLVABILITY 
Of particular contention is whether evolvability is itself 
evolvable163,180,181 or whether it is an intrinsic, unselected property of 
biological systems172. Initially the idea of evolvability as being, itself, 
evolvable made many biologists uncomfortable as it seems teleological 
(the product of foresight)182–184. 
Recent works are beginning to suggest that there may be mechanisms 
whereby evolvability can evolve. In some instances there is evidence 
that evolvability evolved as the accidental, pleiotropic by-product of 
direct selection of another trait185. Alternatively, an evolvability-
enhancing mutation might be indirectly selected by hitchhiking on the 
fitter variants it facilitates186 (second-order selection). 
These works have largely focussed on evolution of evolvability by the 
altered rate of mutation and recombination. There is now increasing 
interest in experimentally exploring whether populations can also 
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evolve towards regions of a fitness landscape187,188, which promote 
evolvability by being less constrained (see Chapter D) and hence 
possibly richer in beneficial mutations (see Chapter E). 
5.4 THEORETICAL AND APPLIED SIGNIFICANCE 
The study of evolvability has fundamental importance for 
understanding very long term evolution of protein superfamilies71,72 
and organism phyla and kingdoms180,189,190. A thorough 
understanding of the details of long term evolution will likely form part 
of the Extended Evolutionary Synthesis180,191–193 (the update to the 
Modern Synthesis). In addition, these phenomena have two main 
practical applications. For protein engineering we wish to increase 
evolvability, and in medicine and agriculture we wish to decrease it. 
Firstly, for protein engineering it is important to understand the factors 
that determine how much a protein function can be altered. In 
particular, both design and DE approaches aim to create changes 
rapidly through mutations with large effects194,195. Such mutations, 
however, commonly destroy enzyme function or at least reduce 
tolerance to further mutations134,176. Identifying evolvable proteins196 
and manipulating their evolvability will be increasingly necessary in 
order to achieve ever larger functional modification of enzymes. 
Secondly, many human pathologies are not static phenomena but 
capable of evolution. In medicine, bacteria, fungi, viruses and cancers 
evolve to escape host immune responses and to develop drug 
resistance197–199. In agriculture, plants are becoming resistant to  
common herbicides200 and insects to insecticides201. It is possible that 
we are facing the end of the effective life of most available 
antibiotics202. Predicting evolvability of our pathogens203 and devising 
strategies to slow or circumvent204 it will require deeper knowledge of 
the complex forces driving evolution at the molecular level. 
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6 TEV PROTEASE – A MODEL ENZYME 
For the work presented in this thesis, I use the nuclear inclusion 
cysteine protease of Tobacco Etch Virus (TEV protease) as a model 
enzyme which I shall introduce here. 
6.1 ORIGIN 
In order to minimise genome size, many viruses express their entire 
genome as one massive polyprotein which is subsequently cleaved into 
functional units by proteases205. Tobacco etch virus is a filamentous 
plant potyvirus (Figure A-20) for which proteolysis is largely performed 
by the nuclear inclusion cysteine protease206 to generate mature viral 
proteins. TEV protease can be expressed as an active but non-toxic, 
27kDa protein in E. coli207 and is commonly used as a biochemical tool 
for the sequence-specific cleavage of fusion proteins207,208. It is 
consequently well characterised and shows several properties that 
make it a useful model system for experimental evolution. 
 
Figure A-20 | Filamentous potyvirus 
The structure of the closely related tobacco mosaic virus based on (a) the X-ray crystal 
structure of the capsid protein (2tmv) and (b) scanning electron microscopy. (Adapted 
from references209,210) 
6.2 STRUCTURE AND FUNCTION 
The structure of TEV protease has been solved by X-ray 
crystallography211. It is comprised of two β-barrels and a flexible C-
a b
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terminal tail (Figure A-21) and displays homology to the chymotrypsin 
superfamily of proteases19 (see Chapter C). Covalent catalysis is 
performed with an Asp-His-Cys triad, split between the two barrels212 
(Asp on β1 and His and Cys on β2). The substrate is held as a β-
sheet213, forming an antiparallel interaction with the cleft between the 
barrels and a parallel interaction with the C-terminal tail. The enzyme 
therefore forms a binding tunnel around the substrate and side chain 
interactions control specificity (detailed description in section 6.3). 
Catalysis proceeds as described in Figure A-2. 
 
Figure A-21 | TEV protease β-barrels 
Structure of TEV protease. The double β-barrels that define the super family are 
highlighted in red. The final 15 amino acids (222-236) of the enzyme C-terminus are not 
visible in the structure as they are too flexible and the final 12 are not necessary for 
proteolytic activity214. (PDB 1lvb) 
As a biochemical tool, TEV protease has several limitations. It is prone 
to deactivation by self-cleavage (autolysis), though this can be 
abolished through a single S219V mutation in the internal cleavage 
site215. The protease expressed alone is also poorly soluble216 however 
several attempts have been made to improve its solubility through 
DE217 and computational design218. It has also been shown that 
expression can be improved208 by fusion to Maltose Binding Protein 
(MBP) which acts a solubility enhancing partner219. In the work 
β1
β2
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presented in later chapters I use the S219V variant of TEV fused to 
MBP for evolution. 
6.3 SPECIFICITY 
The reason for the use of TEV protease as a biochemical tool is its high 
sequence specificity. This specificity allows the controlled cleavage of 
proteins when the preferred sequence is inserted into flexible loops. It 
also makes it relatively non-toxic in vivo208 as the recognized sequence 
scarcely occurs in proteins. 
The preferred cleavage sequence was first identified by examining the 
cut sites in the native polyprotein substrate for recurring sequence220. 
The consensus for these native cut sites is ENLYFQ\S where ‘\’ denotes 
the cleaved peptide bond. Residues of the substrate are labelled P6 to 
P1 before the cut site and P1’ after the cut site. Early works also 
measured cleavage of an array of similar substrates to characterise how 
specific the protease was for the native sequence205,221. Studies have 
subsequently used sequencing of cleaved substrates from a pool of 
randomised sequences to determine preference patterns222,223. 
Though ENLYFQ\S is the optimal sequence, the protease is active to a 
greater or lesser extent on a range of substrates (i.e. shows some 
substrate promiscuity). The highest cleavage is of sequences closest to 
the consensus EXLYΦQ\φ where X is any residue, Φ is any large or 
medium hydrophobe and φ is any small hydrophobe205,221–223. 
Specificity is endowed by the large contact area between enzyme and 
substrate. Proteases such as trypsin have specificity for one residue 
before and after the cleaved bond due to a shallow binding cleft with 
only one or two pockets that bind the substrate side chains. 
Conversely, viral proteases such as TEV protease have a long C-
terminal tail which completely covers the substrate to create a binding 
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tunnel (Figure A-22a). This tunnel contains a set of tight binding 
pockets such that each side chain of the substrate peptide (P6 to P1’) is 
bound in a complementary site (S6 to S1’) (Figure A-22b)211.  
 
Figure A-22 | Substrate bound in the active site tunnel 
Surface model of TEV bound to uncleaved substrate (black), also showing the catalytic 
triad (red). (a) Substrate bound inside the active site and (b) enzyme cut through the plane 
of the active site to expose the internal organisation of the bound substrate (black) and 
triad (red). (TEV C151A nucleophile mutation - PDB 1lvb) 
In particular, peptide side chain P6-Glu contacts a network of three 
hydrogen bonds; P5-Asn points into the solvent, making no specific 
interactions (hence the absence of substrate consensus at this 
position); P4-Leu is buried in a hydrophobic pocket; P3-Tyr is held in a 
hydrophobic pocket with a short hydrogen bond at the end; P2-Phe is 
also surrounded by hydrophobes including the face of the triad 
histidine; P1-Gln forms four hydrogen bonds; and P1’-Ser is only 
partly enclosed in a shallow hydrophobic groove.  
Although rational design has had limited success in changing protease 
specificity, DE has been used to change the preferred residue either 
before224 or after114,214 the cleavage site. I discuss these works in 
Chapter E, 2.3, and approach specificity from an evolutionary point of 
view, attempting to change the specificity of multiple substrate 
residues simultaneously. 
a b
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7 OVERVIEW OF RESULTS 
In Chapter B, I describe the development of both a selection system and 
a screening system for protease activity detection and quantification. 
The screening system was then used for the subsequent evolution 
experiments of TEV protease. 
Chapter C addresses the evolution of key active site residues by 
mutating the nucleophile from cysteine to serine. DE using small 
libraries recovered protease activity and combining this with HT-SAS, 
I characterised the evolutionary trajectory and its flanking fitness 
landscape. 
I use high throughput DE and HT-SAS in Chapter D to investigate the 
evolution of protein robustness and tolerance to mutations. By 
selection only for retention of wild-type-like activity, I neutrally evolve 
a population of TEV protease genes. I use deep sequencing to 
reconstruct the complex phylogeny and show that robust sequences 
appear and that their tolerance to mutations allows their descendants 
to dominate later populations. 
To test whether these populations also show altered evolvability, in 
Chapter E I look at adaptive evolution towards new (possibly clinically 
relevant) substrate sequences. By quantifying changes in evolvability 
of the population I separate out two distinct mechanisms whereby 
neutral mutations can increase different aspects of evolvability. 
Finally, in Chapter F I draw these experiments together and comment 
on the characterisation of the fitness landscape surrounding TEV 
protease and its implications for evolvability and enzyme engineering. 
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Chapter B -  Selection and screening 
methods for protease directed evolution 
1 SUMMARY 
High throughput protease assays are necessary to detect fitness 
differences between variants and isolating those required for directed 
evolution. Both selection and screening systems were attempted. A cell 
survival selection system was constructed, in which the cleavage 
recognition sequence of Tobacco Etch Virus protease was successfully 
cloned into the toxic β-lactamase inhibitory protein. Though inhibitory 
activity was retained, co-expression of the protease did not reduce this 
inhibition to restore cell survival. In parallel, a screening system was 
adapted, based on the proteolytic destruction of fluorescence resonance 
energy transfer in a fusion of donor and acceptor fluorescent proteins. 
The assay was first optimised for 96-well plate lysate screening (in 
conjunction with P. Gatti-Lafranconi) and then for fluorescence-
activated cell sorting. The 96 well lysate screen proved the more sensitive 
method, but the cell sorting screen was high throughput enough to be 
mainly limited by cell transformation efficiency.  
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2 INTRODUCTION (SELECTION) 
In a directed evolution cycle of diversification, selection/screening and 
amplification, only the second step is protein specific. As discussed in 
Chapter A, 3.2, this requires either for the particular activity to be 
coupled to gene enrichment (selection) or for a high throughput assay 
(screening). As proteases are active on peptides, the substrate can be 
synthesised directly by ribosomes in vivo. This affords the opportunity 
of a cell-survival selection system based on the destruction of a toxic 
protein. Because the preference sequence is so long, it occurs by 
random once every 207=109 times and so is highly unlikely to occur in 
a protein. Additionally, TEV protease cleaves in unstructured regions, 
so the sequence needs to be in a flexible loop to be accessible. 
2.1 β-LACTAMASE INHIBITOR PROTEIN AND INHIBITION-RELIEF SELECTION 
In general, selection systems are high throughput and allow a fast and 
crude sweep of a large library225. By engineering a cleavage site into a 
lethal protein, cleavage by the protease should restore vitality and allow 
isolation of active genes. An inhibitor protein of β-lactamase was 
identified as a good candidate by P. Gatti-Lafranconi as the selection 
pressure could be tuned by varying the ampicillin concentration. 
E. coli cells expressing β-lactamase are able to survive on ampicillin as 
β-lactamase hydrolyses the antibiotic.  Co-expression of β-lactamase 
Inhibitor Protein (BLIP) in these cells prevents cell survival on 
ampicillin226. The structure of the interaction complex has been 
solved227 (Figure B-1) and the residues critical to this interaction 
mapped by mutagenic studies228. These demonstrated that BLIP 
competitively inhibits β-lactamase by binding over its active site and 
 
β-lactamase Inhibitor 
Protein (BLIP) 
A competitive inhibitor of 
the antibiotic resistance 
gene β-lactamase 
Chapter B - Selection and screening methods for protease directed evolution 
39 
inserting residues into the active site pocket. As β-lactamase is 
localised to the periplasm, export of BLIP is critical to function. 
 
Figure B-1 | BLIP in complex with β-lactamase 
Complex of BLIP (grey) and β-lactamase (white). The yellow loop indicates a putative sites 
for insertion of a protease cleavage sequence. (PDB file 3c7v). 
The proposed system consists of coupling the activity of the protease 
to cell survival by engineering a BLIP protein to act as a substrate of the 
protease (Figure B-2). The sequence must be inserted at a point that 
will not affect the binding of BLIP to β-lactamase whilst still being 
accessible to the protease. Cleavage of BLIP by the protease must 
destroy the interaction with β-lactamase. Thus, an active protease that 
is expressed in the periplasm would cleave BLIP, which could no longer 
inhibit β-lactamase, allowing cell survival on ampicillin. 
 
Figure B-2 | Scheme of how an active protease is coupled to cell survival 
Protease activity and cell survival are linked through a series of inhibitory interactions 
(described in text). 
The ampicillin concentration can be used to control the stringency of 
selection so that selection pressure can be adapted to the protease 
library being used. Selection generates a population enriched in 
functional variants. By mutating the inserted cleavage site, the system 
would be adaptable to any other protease that is sequence-specific 
enough to be non-toxic in E. coli but active enough to cleave BLIP. 
Protease BLIP Β-lactamase Ampicillin
Active protease Survival
Inactive protease Death
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3 RESULTS AND DISCUSSION (SELECTION) 
3.1 BLIP PLASMID ASSEMBLY 
For a functional selection system, it was important to ensure inhibition 
of β-lactamase by BLIP that is efficient enough to abolish ampicillin 
resistance but sensitive enough to have that resistance restored by 
BLIP’s proteolysis. To achieve this it was necessary to construct a 
custom plasmid that ensures 1:1 stoichiometry of BLIP to β-lactamase. 
Additionally, the lactose inhibitor (LacI) was required for controlling 
inducible expression and the chloramphenicol acetyltransferase (CAT) 
as an alternative antibiotic resistance marker when BLIP is being 
expressed. 
I therefore designed several cloning strategies, eventually constructing 
the plasmid pSB-BLIP (Figure B-3). β-lactamase was amplified from 
pUC18 by PCR (using primers blaF+blaR) which was ligated into 
pJET1.2/BLUNT to make pJET-bla. The pJET-Bla plasmid was 
subsequently digested and β-lactamase inserted into the multiple 
cloning site of pSU18. To insert wtBLIP as well as each loop variant, 
the BLIP gene and LacI were amplified by PCR from pGR32-BLIP 
(using primers blipF+blipR) and also inserted into the plasmid. The 
final plasmids were designated pSB-BLIP. 
Both β-lactamase and BLIP are preceded by the TEM1 signal sequence 
for export to the periplasm. Chloramphenicol acetyltransferase was 
included so that the plasmid can be maintained when ampicillin 
selection is not being applied. 
Chapter B - Selection and screening methods for protease directed evolution 
41 
 
Figure B-3 | pSB-BLIP plasmid map 
The plasmid used to express BLIP (and variants). Inside wedges indicate which starting 
plasmids were used to construct the final BLIP plasmid. Gene abbreviations are: BLIP = β-
lactamase inhibitory protein; LacI = Lactose inhibitor; Cat = Chloramphenicol 
acetyltransferase; Bla = β-lactamase. 
3.2 INSERTION OF CLEAVAGE SEQUENCE INTO BLIP PRESERVES FUNCTION 
In order for the ampicillin inhibition-relief selection system (Figure 
B-2) to function, a cleavable BLIP protein needed to be engineered. As 
previously stated, the position of the insert has to satisfy the following 
criteria: 
 The uncleaved loop in BLIP must not affect β-lactamase interaction 
 The loop must be exposed and accessible for the protease to cleave 
 Upon cleavage, the BLIP fragments must not inhibit β-lactamase 
I identified two possible sites based on analysis of the structure of the 
BLIP/β-lactamase complex (Figure B-4). Loop regions were chosen in 
the hope that they would better tolerate the presence of insertions and 
minimally disrupt the rest of the structure. Both insert sites are situated 
away from the interaction surface with β-lactamase. Finally both sites 
roughly bisect the protein so that residues essential to the 
interaction228,229 with β-lactamase are split between the two halves.  
pSB-BLIP
Lac operon
TEM1 signal sequence
Bla promoter
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Figure B-4 | Structure of BLIP showing insert sites 
BLIP is shown as cartoon with the insert loops 1 and 2 in yellow and key interaction 
residues in red. β-lactamase is shown as surface in the background. The structure is 
shown from (a) the front and (b) 90o to the side. (PDB file 3C7V) 
Loops were inserted using the USER cloning method12 with primers 
ins1F+ins1R and ins2F+ins2R to generate iBLIP and i2BLIP (Table B-1) 
in the original pGR32 plasmid. 
 
Table B-1 | Alignment of wild type BLIP and BLIP insert variants 
Residues known to strongly affect BLIP binding to β-lactamase are shown in red. 
The inserted loops are required to not impair inhibition of β-lactamase. 
I therefore developed an assay (with P. Gatti-Lafranconi) of the 
efficiency of BLIP inhibition of β-lactamase based on the serial dilution 
of a bacterial culture, spotted onto solid media. At high cellular 
concentration, low β-lactamase activity allows cell survival because 
ampicillin is cleared by the cumulative activity of many cells.  As cell 
concentration decreases, selection is more stringent. Addition of IPTG 
a b
2
2
1
1
i_BLIP MSIQHFRVALIPFFAAFCLPVFAHPEHHHHHHAGVMTGAKFTQIQFGMTRQQVLDIA
i2_BLIP MSIQHFRVALIPFFAAFCLPVFAHPEHHHHHHAGVMTGAKFTQIQFGMTRQQVLDIA
wt_BLIP MSIQHFRVALIPFFAAFCLPVFAHPEHHHHHHAGVMTGAKFTQIQFGMTRQQVLDIA
i_BLIP GAENCETGGSFGDSIHCRGHAAGDYYAYATFGFTSAAENLYFQNADAKVDSKSQEKL
i2_BLIP GAENCETGGSFGDSIHCRGHAAGDYYAYATFGFTSAA-------ADAKVDSKSQEKL
wt_BLIP GAENCETGGSFGDSIHCRGHAAGDYYAYATFGFTSAA-------ADAKVDSKSQEKL
i_BLIP LAPS-------APTLTLAKFNQVTVGMTRAQVLATVGQGSCTTWSEYYPAYPSTAGV
i2_BLIP LAPSENLYFQNAPTLTLAKFNQVTVGMTRAQVLATVGQGSCTTWSEYYPAYPSTAGV
wt_BLIP LAPS-------APTLTLAKFNQVTVGMTRAQVLATVGQGSCTTWSEYYPAYPSTAGV
i_BLIP TLSLSCFDVDGYSSTGFYRGSAHLWFTDGVLQGKRQWDLVF 205
i2_BLIP TLSLSCFDVDGYSSTGFYRGSAHLWFTDGVLQGKRQWDLVF 205
wt_BLIP TLSLSCFDVDGYSSTGFYRGSAHLWFTDGVLQGKRQWDLVF 198
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induces expression of the BLIP construct. Cells expressing wtBLIP, 
had to be roughly 100-fold more concentrated in order to achieve the 
same survival on 100 µg/µl ampicillin hence BLIP reduces β-lactamase 
activity by approximately 100-fold in this assay (Figure B-5, upper 
half). 
Having BLIP and β-lactamase expressed from a single plasmid (pSB-
BLIP) gave repeatable results by reducing the effects of relative gene 
copy number variation. Cells expressing i2BLIP showed no decreased 
survival on ampicillin indicating that the insert has disrupted BLIP 
inhibition of β-lactamase. Conversely, iBLIP was only 2- to 4-fold less 
effective than wtBLIP at inhibiting growth on ampicillin (Figure B-5, 
lower half). This indicates that iBLIP still functions as an effective 
inhibitor and hence the insert loop minimally interferes with the 
BLIP/β-lactamase interaction. Given this success, iBLIP was further 
characterised for cleavability by TEV. 
 
Figure B-5 | Comparison of wtBLIP and iBLIP 
Top10 cells are transformed with pSB-wtBLIP or pSB-iBLIP. As the cell culture is diluted 
there is no change in survival when IPTG is absent and BLIP is not induced. However, when 
IPTG is added cells are unable to survive at low cell density. Reduction in survival is 
comparable between wtBLIP and iBLIP. 100 µg/µl ampicillin, 400 µM IPTG (as indicated) 
at 37oC. 
3.3 TEV PROTEOLYSIS OF BLIP DOES NOT RESTORE CELL SURVIVAL 
The final goal of this system was to select for active TEV variants so 
the sensitivity of iBLIP to proteolysis and restoration of ampicillin 
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resistance was crucial. Several plasmids were constructed that encode 
TEV protease but vary in its fusion state, localisation and activity. 
MBP-TEV – TEV protease was provided on plasmid pMAT10 as an 
MBP fusion (P. Gatti-Lafranconi). As the resistance gene of pMAT10 
is β-lactamase, (β-lactamase is present on pSB-iBLIP so cannot be used 
as the resistance gene on the TEV protease-containing plasmid) I 
cloned the MBP-TEV fusion into pET28a which encodes kanamycin 
resistance to produce the plasmid pET28-MBPTEV.  
Signal sequence-TEV – As both β-lactamase and BLIP are exported to 
the periplasm, TEV needs to be co-localised in order to function. I 
therefore also cloned TEV protease alone into pET22b which contains 
the PelB signal sequence. The signal sequence and TEV protease 
sequence were then cloned together into pET28a (pET28-STEV). 
Inactive TEV – An appropriate negative control was needed for 
defining the system’s dynamic range. I therefore made the active site 
C151A mutation (TEVAla, previously shown to be inactive212) by 
targeted mutagenesis of pET28-STEV (primers tevaF+tevaR). Clones 
were confirmed by sequencing (T7F primer). The TEVAla gene was 
subsequently cloned into the pET28-MBPTEV plasmid. 
For the selection system to function, active protease must relieve iBLIP 
inhibition of β-lactamase. When co-expressed, TEV protease 
expressed in the cytosol (pET28-MBPTEV) has no effect on cell 
survival. Surprisingly, however, co-expression of TEV in the periplasm 
(pET28-STEV) also did not increase cell survival (Figure B-6) and was 
as ineffective as the inactive C151A mutant (pET28-STEVAla). This 
indicates that the expected inhibition relief of iBLIP cleavage by TEV 
does not occur. Likely explanations for this negative result include 
TEV mis-translocation, failure of TEV to cleave iBLIP, continued 
inhibitory function of the cleaved iBLIP. 
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Figure B-6 | Comparison of STEV and STEVAla 
BL21 cells are transformed with pSB-iBLIP and either pET28-STEV or pET28-STEVAla In the 
presence of IPTG, both iBLIP and the protease are expressed. There is no improvement in 
cell survival in the presence of the protease (as compared to the inactive alanine mutant 
control). 100 µg/µl ampicillin, 50 µg/µl kanamycin, 400 µM IPTG (as indicated) at 37oC. 
In order to understand which part of the pathway was not operating as 
planned, I expressed and purified both TEV and iBLIP. Purifications 
of iBLIP from whole lysate and periplasm only were performed. 
Expression of iBLIP was low (Figure B-7a) and multiple bands appeared 
around its expected size (21kDA) though it is unclear which, if any, was 
iBLIP. To characterise whether iBLIP is cleavable by TEV in vitro, the 
proteins were incubated together in TEV activity buffer. 
 
Figure B-7 | Purification and cleavage of iBLIP 
Nickel affinity purification if iBLIP (6 hour expression at 25 °C and preparation of periplasm 
by osmotic shock). (b) Co-incubation of 2 μM TEV and 2 μM iBLIP for 24 hr at 25 °C. 
Co-incubation of the iBLIP preparation with TEV in vitro gave no 
evidence of cleavage (Figure B-7b) since concentrations were so low. 
Together these results indicate that although the insertion of a cleavage 
loop into BLIP to create iBLIP was successful, this construct was not 
inactivated by co-expression of TEV. Troubleshooting of these 
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negative results was hindered by poor expression of the iBLIP 
construct. 
Given the difficulty in addressing the failure point in the system, a 
more manageable system might be the cleavage of a cytosolic, modular 
repressor with an accessible, flexible, cleavable linker between the 
DNA binding and transcription inhibition domains. A fully 
unstructured region would ensure TEV cleavage and separate domains 
would ensure separation and inactivation after cleavage. In fact, during 
the course of this work, just such a system was published114 with either 
histidine biosynthesis, antibiotic resistance or fluorescent protein 
genes downstream of the repressor.  
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4 INTRODUCTION (SCREENING) 
In parallel with work on the BLIP-based selection system, I worked 
with P. Gatti Lafranconi on a screening system. This was envisaged as 
both an alternative to cell survival selection as well as a possible lower 
throughput but higher detail addition for DE. 
4.1 DUAL-GFP FRET PAIR AND FLUORESCENCE SCREENING 
There are many assays for measuring the activity of purified protease. 
The throughput of most is not high enough for use in directed 
evolution208,221 (>102 variants screened per round). High throughput in 
vivo assays of protease activity tend to be constructed for sensitive 
detection of inactive proteases for the screening of inhibitors. A few 
methods, however, are good candidates for conversion to a screening 
system for directed evolution. A dual GFP-variant Fluorescence 
Resonance Energy Transfer (FRET) system117,230,231 was chosen for 
optimisation for protease library screening. 
FRET occurs when the emission wavelength of one fluorophore 
coincides with the excitation wavelength of another nearby 
fluorophore such that the energy is directly transferred across. Thus 
excitation of the first fluorophore leads to emission by the second. 
FRET decreases as the sixth power of the distance between the 
fluorophores. In the case of covalently bonded fluorophores, cleavage 
can be considered to completely abolish FRET. 
A dual-GFP FRET protease sensor117,230,231 has been adapted (with P. 
Gatti-Lafranconi) to be suitable for the directed evolution of Tobacco 
Etch Virus protease (TEV). A cyan GFP-variant (CyPet or CFP) is 
fused to a yellow GFP-variant (YPet or YFP) by a linker including the 
TEV substrate recognition sequence. The emission wavelength of CFP 
 
Fluorescence Resonance 
Energy Transfer (FRET)  
The transfer of energy from 
one fluorophore to another 
such that excitation of the 
first leads to emission by 
the second 
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and the excitation wavelength of YFP are very similar. When CFP is 
excited by a photon at 414 nm, the energy is transferred to YFP and 
emitted at 527 nm. Cleavage by TEV protease abolishes FRET (Figure 
B-8Error! Reference source not found.) such that when excited at 414 
nm, light is emitted from CFP at 475 nm. 
 
Figure B-8 | Proteolytic cleavage of a Dual-GFP fusion FRET-pair 
If the linker is intact, excitation at the absorbance wavelength of CFP (414nm) causes 
emission by YFP (527nm) due to FRET. If the linker is cleaved by a protease, FRET is 
abolished and emission is at the CFP wavelength (425nm). 
Cells co-expressing both the FRET sensor and TEV are induced and 
incubated so that cleavage occurs in vivo (in the cytosol). When CFP is 
excited, the ratio of CFP to YFP is used as an indicator of FRET 
efficiency and hence protease activity. This fluorescence ratio can 
either be measured in the cell lysate of a clonal population representing 
each variant (96 well plate screening) or in each individual cell by flow 
cytometry and Fluorescence Activated Cell Sorting (FACS). 
A particular benefit is that modifications of the same core assay can be 
used for in vitro kinetic characterisation of purified enzymes as well as 
the high-throughput in vivo screen ensuring consistency of substrate. 
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Flow cytometry 
The assay of cells by moving 
them individually past a 
laser and detector array in a 
thin stream of liquid 
 
Fluorescence Activated Cell 
Sorting  
The use of electrical charge 
in flow cytometry to select 
a sub-population of cells to 
a separate container 
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5 RESULTS AND DISCUSSION (SCREENING) 
5.1 C-Y(TEV) FRET-PAIR PLASMID ASSEMBLY 
I constructed a screening system based on the change in fluorescence 
of a substrate upon proteolysis. The CFP-YFP gene has previously been 
optimised for intramolecular FRET117 and caspase-3 cleavage. The 
initial stages of adapting the system for directed evolution was 
performed by P. Gatti-Lafranconi (introducing the TEV cleavage linker 
and hanging induction to L-arabinose to allow co-induction of 
substrate and protease. The substrate gene is on a plasmid also 
containing chloramphenicol acetyltransferase (Figure B-9) and the 
protease gene on a plasmid containing β-lactamase. Cells have to 
maintain both these plasmids when grown on ampicillin and 
chloramphenicol. 
 
Figure B-9 | pC-Y plasmid map 
The plasmid used to express C-Y. The wedges indicate which starting plasmids were used 
to construct the final pC-Y plasmid (the gap indicates synthetic oligonucleotides). Gene 
abbreviations: CFP = Cyan fluorescent protein; YFP = Yellow fluorescent protein; MBP = 
Maltose binding protein; AraC = Arabinose inhibitor; Cat = Chloramphenicol 
acetyltransferase. 
pC-Y
Linker containing 
cleavage sequence
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In order to facilitate the easy manipulation of linker sequence between 
CFP and YFP, I introduced restriction sites (XhoI, SpeI). Whole gene 
synthesis was necessary as mutagenic PCR was impossible due to the 
high sequence identity of CFP and YFP causing non-specific primer 
annealing. These sites allow the DNA encoding the protease cleavage 
sequence to be inserted with synthetic oligonucleotides. The linker 
(discussed in more detail in Chapter E) can be either a single sequence 
or a set of sequences with randomised positions (NNS codon). To 
begin with, I inserted the cleavage preference sequence of TEV 
protease to create pC-Y(tev): 
…GGSGGSENLYFQSGGSGGS… 
  Spacer – Cleavage seq - Spacer 
5.2 FLUORESCENCE OF C-Y(TEV) IS CHANGED BY TEV PROTEOLYSIS IN CELL LYSATE 
A cell lysate screen was optimised for the parallel assay of TEV mutant 
libraries of 102. Due to low solubility, TEV was expressed as a MBP 
fusion protein to provide a constant solubility buffer219 (Figure B-10a). 
Both the enzyme and substrate were cloned into plasmids that give L-
arabinose inducible expression so that co-expression is induced 
simultaneously. For expressing TEV without the MBP fusion for 
biophysical characterisation of the unfused enzyme, it was also cloned 
into pMAA NoMBP (Figure B-10b). 
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Figure B-10 | pMAA TEV plasmid map (±MBP) 
The plasmid used to express TEV when using the C-Y(x) substrate where ‘x’ can be any 
desired linker sequence. (b) The plasmid used to express TEV without MBP (for TM 
measurements). Inside wedges indicate which starting plasmids were used to construct 
the final plasmid. Gene abbreviations: TEV = Tobacco Etch Virus Protease (or variants); 
MBP = Maltose binding protein; AraC = Arabinose inhibitor; Bla = β-lactamase. 
I ran control screens comparing the FRET ratio of cells co-expressing 
the C-Y(tev) substrate with either wild type TEV, the C151A mutant 
(TEVAla), or MBP. In the absence of TEV, there was an emission peak 
at 525 nm (the emission wavelength of YFP indicative of FRET) (Figure 
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B-11). In the presence of TEV, emission was mostly at 475 nm (the 
emission wavelength of CFP). This gives a dynamic range of a 7-fold 
drop in FRET efficiency (525/475 nm) in the presence of TEV. This 
demonstrates that the FRET pair functions with the TEV cleavage 
sequence as a linker and that it can be successfully proteolysed. 
 
Figure B-11 | Effect of TEV protease on fluorescence in CFP-YFP FRET system 
Lysates of E. coli co-expressing the substrate C-Y(tev) an either MBP or TEV for 4 hours. 
(a) The fluorescence spectra of the lysates when excited at 414 nm (the excitation 
wavelength of CFP). (b) FRET ratio (525/475 nm) of lysates. Error bars are standard 
deviation and n=4. 
The FRET ratio was time dependent (Figure B-12). Over time, 
expression of the substrate increased FRET ratio, similarly longer co-
expression times with TEV lead to a lower FRET ratio. Readings were 
more repeatable at later time points as the signal to noise ratio drops. 
 
Figure B-12 | Time-course of lysate FRET ratios 
Lysates of E. coli co-expressing the substrate C-Y(tev) an either MBP (black) or TEV (red) 
for different times. Error bars indicate standard deviation of 8 biological replicates. 
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The assay can be performed in parallel in a 96 well plate on a library of 
protease variants generated by error prone PCR (epPCR) (Figure 
B-13a). Next generation sequencing (see Chapter D, 3.1) confirmed 
that variants each contained 1.5 nucleotide mutations on average 
(spread even along the gene) with 34% of these being silent mutations 
and <1% being frameshifts. The lysate assay allowed for screening of 
mutant library sizes of 102. The FRET ratios of mutants mostly cluster 
around the FRET ratios of cells co-expressing wild type TEV (cleaved 
substrate) or cells co-expressing MBP (uncleaved substrate) (Figure 
B-13b). 
 
Figure B-13 | Sample lysate screen of TEV mutant library 
96 well plate of E. coli lysates. All express C-Y(tev) but the culture in each well co-
expressed a different point mutant of TEV generated by random mutagenesis. (b) A 
histogram of two such plates showing the distribution of activities present in the library. 
5.3 TEV CLEAVES PURIFIED C-Y(TEV) IN VITRO 
All proteases and C-Y(tev) variants contain a His6 tag for nickel affinity 
purification. C-Y(tev) variants could be purified to high concentrations 
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(up to 90 µM) but TEV had poor solubility (maximum 4 µM). At low 
concentrations the fluorescence of C-Y(tev) variants was insufficient 
to measure FRET ratio however at concentrations above 0.5 µM FRET 
ratio was constant (Figure B-14). 
 
Figure B-14 | Concentration dependence of FRET ratio 
Dilution series of C-Y(tev) with the buffer TEV buffer (used for cleavage kinetics) 
A concentration of 1 μM substrate was therefore used in all further 
kinetics in line with the concentrations used in the original report of 
the FRET pair117. When thawed, purified C-Y(tev) variants did not 
exhibit their maximum FRET ratio (Figure B-15).  
 
Figure B-15 | Equilibration of C-Y FRET ratio 
Purified C-Y(tev) (1 μM) in TEV buffer at 25 °C after having been thawed from -80 °C at t= 
-0.6 hours. TEV (1 μM) added at t= 4 hours to half the sample (red). 
A >4 hour equilibration period at the assay temperature was therefore 
required in order to give a constant negative control. FRET ratio 
remained stable for several days after thawing. It is only the FRET ratio 
that equilibrates in this fashion, not the total fluorescence. I would 
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hypothesise that this is indicative of slow structural rearrangements of 
the relative orientations of the fluorophores. 
Cleavage of C-Y(tev) by purified TEV is specific (neither thrombin nor 
TEVAla showed substrate turnover) and concentration dependent 
(Figure B-16a). This indicates specific hydrolysis of the C-Y(tev) linker 
by TEV using the catalytic cysteine nucleophile. Kinetic traces could 
be globally fitted with the Michaelis Menten function (Methods eq. G-
2) in order to determine the composite kinetic activity parameter, 
kcat/KM (Figure B-16b). 
 
Figure B-16 | Concentration dependent cleavage of C-Y(tev) by TEV and kinetic fitting 
Activity of different 0.5, 1, 2, 4 μM TEV (red), 5 μM TEVAla (green) and 30 μM Thrombin 
(blue) on 1 μM C-Y(tev). FRET ratio used to determine product concentration by fitting to 
eq. C-1 (Methods) (b) Data for 1 μM TEV activity fitted with eq. C-2 (Methods) 
5.4 TEV PROTEOLYSIS OF C-Y(TEV) IS DETECTABLE IN INDIVIDUAL CELLS 
The lysate co-expression assay was modified to increase throughput 
from 102 to 106. To test the dynamic range of the assay in FACS, 
TOP10 E. coli containing pC-Y(tev) were transformed with either 
pMAA(TEV) or pMAA. After overnight co-expression the clonal 
populations were assayed by FACS. The populations were 
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distinguishable by the difference in FRET ratio (After excitation of 
CFP, the emission of YFP divided by emission of CFP - FL5/FL4) 
however there was significant overlap (Figure B-17a). YFP was used as 
a reporter for overall expression since the emission of YFP after its 
excitation (FL1) is independent of cleavage of the CFP-YFP fusion. 
When separated by FL1 it can be seen that cells with higher expression 
also have less signal variance due to higher signal:noise (Figure 
B-17b,c,d). 
 
Figure B-17 | Flow cytometric measurement of FRET in E. coli 
Flow cytometry plots showing FL1 (Emission from YFP after excitation of YFP) against 
FL5/FL4 (FRET ratio after excitation of CFP) for cells co-expressing C-Y(tev) and either MBP 
(blue) or TEV (red). Horizontal dashed lines indicate top and bottom FL1 deciles. The same 
data plotted as a histogram of FL5/FL4 (FRET ratio) for (b) cells with the top 10% FL1, (c) 
all cells, (d) cells with the bottom 10% FL1. 
Since the measurement of cleavage is ratiometric it is concentration 
independent, however high fluorescence gives higher signal:noise in 
the FRET ratio. Due to the small size of E. coli, achieving high enough 
substrate C-Y concentration required expression optimisation. It has 
previously been reported that low temperature expression improves 
fluorescence by reduced aggregation117. I found that overnight 
expression at 21 °C gave the highest signal. Additionally slow flow rate 
(<1000 cells s-1) to give longer laser beam passage time and high laser 
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power (>100mW) were necessary for high signal:noise ratio. Though 
these increase the signal:noise ratio and give a reduced variance in the 
FRET ratio, the median ratio remains the same. The ratio was also 
insensitive to the concentration of inducer (0.02%-1.00%) which is 
important for consistent library screening. 
A library of TEV variants generated by epPCR was co-expressed with 
C-Y(tev) and assayed by flow cytometry. The library showed two 
populations that correspond to the FRET ratios of populations co-
expressing TEV or expressing MBP (Figure B-18). The distribution of 
FRET ratios of cells in the top 10% of FL1 was roughly bimodal. 
Bimodality indicates that, in this assay, mutations are either effectively 
neutral or fully deleterious to TEV function (discussed in Chapter D). 
 
Figure B-18 | Sample flow cytometric of TEV mutant library 
Flow cytometry plots showing FL1 (Emission from YFP after excitation of YFP) against 
FL5/FL4 (FRET ratio after excitation of CFP) for (a) cells co-expressing C-Y(tev) and either 
MBP (blue) or TEV (red) (b) a density plot of a library of TEV mutants. 
The majority of noise in the system is biological rather than technical. 
If a specific subpopulation of cells are sorted and immediately re-
assayed, they show very little spread. If the sorted cells are grown and 
re-expressed, however, they produce a pattern identical to the original, 
unsorted population indicating that the re-expression has re-
introduced biological variation. 
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6 CONCLUSIONS 
6.1 SELECTION BY BLIP CLEAVAGE IS UNSUITABLE FOR DIRECTED EVOLUTION 
The plasmids and genes required to test the system were successfully 
constructed. Of the two loops targeted, only one allowed retention of 
inhibitory activity after insertion of the TEV cleavage sequence as 
demonstrated by the reduction in survival when iBLIP is expressed 
(Error! Reference source not found.). This demonstrates that loop 1 
tolerates the insertion of seven amino acids without disrupting 
function. Co-expression of TEV, however, fails to restore survival 
(Figure B-6) indicating that TEV fails to successfully inactivate BLIP 
and restore vitality. There could be a number of reasons for this failure: 
 TEV is not soluble or active in the periplasm 
 TEV is not exported to the periplasm by PelB export sequence 
 TEV does not cleave iBLIP because the loop is not exposed 
 Cleavage of iBLIP does not destroy the interaction with β-lactamase  
The main problem with the system is that it is difficult to isolate the 
point of failure in the multi-step pathway and the low expression of 
BLIP has made purification for in vitro analysis impractical. Since the 
main benefit of a cell survival selection system is its high throughput, 
the success of the high throughput FRET screening system in FACS 
system rendered this selection system obsolete. 
6.2 FRET SCREENING PROVIDES MULTIPLE PLATFORMS FOR DIRECTED EVOLUTION 
The CFP-YFP FRET-pair lends itself well to a variety of assay formats, 
each specialised for a different function. Purified proteins can be used 
to determine kinetic parameters by whole curve fitting (Figure B-16), 
cell lysate screening is a sensitive screen for medium throughput 
directed evolution (102) (Figure B-13) and flow cytometry allows for 
high throughput screening (106) (Figure B-18). Using the same 
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substrate for both screening and detailed characterisation avoids some 
artefacts common in directed evolution studies. In particular, directed 
evolution is rarely possible on the desired substrate and so one or more 
proxy colourmetric or fluorometric substrates are used. Improvements 
in turnover of the assayed substrate may not correlate to activity on the 
desired substrate as evolution optimises binding the colourmetric or 
fluorometric group232 or catalysis relies on their artificially high pKa 
values233. The FRET system is suitable for high and low throughput 
screening as well as subsequent kinetic characterisation. 
The substrate cleavage sequence can also be manipulated to create 
individual variant substrates or a whole class of related substrates by 
randomising one or more codons, allowing the study of specificity by 
measuring the set of cleaved substrates. 
The mutant library screened by lysate and FACS gives a good 
comparison between the assay formats. The overall agreement is good, 
both showing a bimodal distribution of mutant activities (Figure B-13 
& Figure B-18). The lysate screening system has higher dynamic range 
and greater sensitivity at discriminating between similar variants. 
Additionally the signal:noise ratio is high because the lysate screens the 
average FRET ratio of a large clonal population of E. coli. It is therefore 
well suited to the evolution from a low starting activity by isolating the 
single best variant from each round. The FACS system, conversely, was 
able to screen 4 orders of magnitude more variants and gives the ability 
to sort large populations. It is therefore better suited to experiments 
where an evolving population is generated. 
These FRET-based screening systems enabled the directed evolution 
of TEV and are used in the further experiments laid out in this 
dissertation. 
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Chapter C -  Handicap-recover evolution 
to accommodate a new nucleophile 
1 SUMMARY 
To understand the evolution of active sites, handicap-recover directed 
evolution was performed to convert Tobacco Etch Virus cysteine protease 
to a functional serine protease. Catalysis using serine was improved 
>103-fold but rather than re-specialise, the resulting enzyme was able to 
use either nucleophile. Description of the fitness landscape flanking the 
evolved trajectory revealed features that constrain and guide the 
evolution of active site architecture. In particular, high epistasis creates 
a rugged landscape but there are consistently several available uphill 
pathways at each step along the trajectory. Though mutations in the 
protein core are penalised, the active site second periphery is enriched in 
adaptive potential. 
 
 
 
 
 
Parts of this chapter have been submitted for publication: 
Shafee, T., Gatti-Lafranconi, P., Minter, R., Hollfelder, F. 
The evolvability of nucleophile exchange Nature Genetics. (2013) 
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2 INTRODUCTION 
2.1 THE EFFECT OF NUCLEOPHILE IDENTITY ON ENZYME MECHANISM 
As introduced in Chapter A, 2.2, nucleophilic enzymes use an 
interconnected set of active site residues to achieve catalysis. The 
sophistication of the active site network causes residues involved in 
catalysis, and residues in contact with these, to be the most 
evolutionarily conserved within their families58. In catalytic triads, the 
most common nucleophiles are serine (an alcohol) or cysteine (a thiol). 
Compared to oxygen, sulphur’s extra d orbital makes it larger (by 0.4 
Å234), softer, form longer bonds (dC-X and dX-H by 1.3-fold) and have 
lower pKa (by 5 units235). Here I concentrate on chemical differences 
between cysteine and serine proteases on catalytic chemistry, however 
similar issues affect hydrolases and transferases in general. 
The pKa of cysteine is low enough that some cysteine proteases (e.g. 
papain) have been shown to exist as an S- thiolate ion in the ground 
state enzyme236 (Figure C-1a) and many even lack the acidic triad 
member (Figure C-1b). Serine is also more dependent on other residues 
to reduce its pKa235 for concerted deprotonation with catalysis (Figure 
C-1c) by optimal orientation of the acid-base triad members (Figure 
C-1d)21. The low pKa of cysteine works to its disadvantage in the 
resolution of the first tetrahedral intermediate as unproductive 
reversal of the original nucleophilic attack is the more favourable 
breakdown product21. The triad base is therefore preferentially 
oriented to protonate the leaving group amide (Figure C-1e) to ensure 
that it is ejected to leave the enzyme sulphur covalently bound to the 
substrate N-terminus. Finally, resolution of the acyl-enzyme (to release 
the substrate C-terminus) requires serine to be re-protonated (Figure 
C-1f) whereas cysteine can leave as S-. 
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Sterically, the sulphur of cysteine also has longer bonds and a bulkier 
Van der Waals radius to fit in the active site237 and a mutated 
nucleophile can be trapped in unproductive orientations. For example 
the crystal structure of thio-trypsin indicates that cysteine points away 
from the substrate, instead forming interactions with the oxyanion 
hole234. 
The evolutionary specialisation of enzymes around the needs of their 
nucleophile makes it unsurprising that nucleophiles cannot be 
interconverted in extant proteases212,238–243 (nor in most other 
enzymes244–249) and the large activity reductions (>104) observed can be 
explained as a result of compromised reactivity or structural 
misalignment. 
2.2 NUCLEOPHILE EXCHANGE IN NATURAL EVOLUTION 
Although extant enzymes cannot switch nucleophiles, there are several 
superfamilies that show divergent evolution of serine and cysteine 
proteases from a common ancestor. I use the PA clan250 of 
chymotrypsin-like proteases as a model superfamily to study 
nucleophile switches in evolution. The PA clan contains a diverse array 
of proteases from eukaryotes, prokaryotes and viruses. It also 
encompasses varied functions including blood clotting (e.g. thrombin), 
digestion (e.g. trypsin), snake venoms (e.g. pit viper haemotoxin), 
bacterial toxins (e.g. exfoliative toxin) and viral polyprotein processing 
(e.g. polio, norovirus, and TEV proteases). 
Despite retaining as little as 10% sequence identity, PA clan members 
isolated from viruses, prokaryotes and eukaryotes show structural 
homology. Members were therefore aligned by structural similarity 
(with DALI251). The alignment was expanded by adding sequences 
without known structure by sequence homology (with BLASTp, see 
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methods Table G-5) and this final alignment used to generate a 
phylogeny (Figure C-2). My phylogeny suggests three independent 
nucleophile switching events (crossed circles), though nodes 1 and 2 are 
so deeply rooted that they may be a single event. Cellular proteases use 
serine as the nucleophile, but both cysteine and serine protease families 
are found in the viruses (indicated by red and black shading 
respectively in inner circle). Despite the fact that replacing the 
nucleophile has detrimental effects on the activity of extant 
proteases212,238–243, the PA clan shows that the distinct active sites of 
cysteine and serine proteases can arise from divergent as well as 
convergent evolution. There is currently, however, no model that 
explains evolution of such core components of the catalytic machinery. 
 
Figure C-2 | PA clan phylogeny 
The phylogeny of PA clan of proteases indicates that nucleophile changes have occurred 
in evolution (crossed circles). The colour of the branches and inner ring indicates the 
identity of the nucleophile (cysteine in red, serine in black), outer ring indicates organism 
(viral in white, prokaryote in light blue, eukaryote in blue). Proteases with known 
structure (marked by black dots) were aligned to TEVCys on the basis of structure using 
DALI, sequences of unknown structure were added by sequence alignment with BLASTp; 
the maximum likelihood phylogeny was generated using MEGA5.  
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3 RESULTS AND DISCUSSION 
For this chapter, Tobacco Etch Virus nuclear inclusion cysteine 
protease will be referred to as TEVCys. The nucleophile identity of all 
variants will also be indicated by the superscript. 
To investigate nucleophile switches in evolution I mutated the 
nucleophile of Tobacco Etch Virus nuclear inclusion cysteine protease 
(TEVCys) to serine (TEVSer). I performed 10 rounds of Directed 
Evolution (DE) and characterised the recovery of activity by two 
complementary methodologies. Firstly, I used biochemistry to 
investigate changes in catalytic activity and protein stability. Secondly 
I used High Throughput Screening and Sequencing (HT-SAS) to 
characterise the local fitness landscapes flanking the DE trajectory. 
3.1 REPLACEMENT OF NUCLEOPHILE DECREASES TEV ACTIVITY 104-FOLD  
Targeted mutagenesis was used to introduce the C151S mutation into 
TEVCys to create TEVSer (primers tevsF+tevsR). The C151S mutation 
causes a large reduction in kinetic activity of the purified enzyme 
(TEVSer) in line with other proteases212,238–243. Additionally, the 
replacement of the nucleophile with serine induces biphasic kinetics 
(Figure C-3), indicating a fast first step followed by a slower, rate-
limiting step. A standard steady-state interpolation (Equation C-1) can 
only accurately fit kcat/KM for TEVCys because the first step is rate-
limiting. For TEVSer and variants, the modified Equation C-2 was used, 
as it allows measurement of the rate of all steps before and after the 
rate-limiting step (kobs1 and kobs2) (Table C-1). Compared to the kcat/KM 
of TEVCys, the kobs1 and kobs2 of TEVSer were found to be 80 and 20,000-
fold lower, respectively, indicating that a strong handicap is associated 
with nucleophile replacement in TEVCys. Given the mechanism shown 
in section 2.1, it appears likely that the slow second step refers to de-
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acylation of the covalent intermediate. It could also be a slowed 
product-release step after catalysis, however this sems less likely given 
the nature of the mutation. 
[𝑷] = [𝑷]𝒎𝒂𝒙 − 𝒆−[𝑬]𝒌𝒄𝒂𝒕/𝑲𝑴𝒕 
Equation C-1 | Standard Michalis Menten interpolation 
[P] = concentration of product 
[P]max = final concentration of product (should be = starting substrate) 
[E] = concentration of enzyme 
kcat/KM = rate of overall reaction 
t = time  
[𝑷] = [𝑷]𝒎𝒂𝒙 − (𝑨𝟏𝒆
−[𝑬]𝒌𝒐𝒃𝒔𝟏𝒕 + 𝑨𝟐𝒆
−[𝑬]𝒌𝒐𝒃𝒔𝟐𝒕) 
Equation C-2 | Modification of Eq 1 for biphasic reaction  
[P] = concentration of product 
[P]max = final concentration of product (should be = starting substrate) 
A1 = Jump amplitude (ie. how much turnover is performed in first kinetic step) 
A2 = Second jump amplitude (should = [P]max-A1) 
[E] = concentration of enzyme 
kobs1 = rate of first kinetic step 
kobs2 = rate of second kinetic step 
t = time 
 
 
Figure C-3 | Monophasic and biphasic curve fitting of TEVCys and TEVSer 
Kinetic data for cleavage of 1 µM substrate by (a) 4 µM TEVCys and (b) 20 µM TEVSer fit with 
single exponential (Eq. C-1) or double exponential (Eq. C-2).  
Table C-1 | Regression of curve fitting of TEVCys and TEVSer 
Summary of kinetic parameters and R2 values for fits to single or double exponential 
model. 
SINGLE EXPONENTIAL DOUBLE EXPONENTIAL
kcat/KM R
2 Kobs1 Kobs2 R
2
TEVCys 2.4 x 10-2 0.99 2.4 x 10-2 0.00 0.99
TEVSer 7.6 x 101 0.92 2.3 x 102 8.9E-01 0.98
Time /min
[P
] 
/ 
u
M
[P
] 
/ 
u
M
Time /min
a
b
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3.2 NUCLEOPHILE MUTATION HAS MINIMAL EFFECT ON CATALYTIC PROMISCUITY 
Trypsin shows a range of catalytic promiscuity39. I therefore checked 
for promiscuous hydrolysis of a range of substrates: phosphate, 
phosphonate, phospho-diester, sulphate, sulphonate, acetate, 
phosphoryl-choline and xylopyranoside. Of these, only activity on 
phosphonates was detectable (Figure C-4) and found to be 2.7 min-1M-
1, 104 worse than the native protease activity. Surprisingly, the activity 
of TEVSer was 0.8 min-1M-1 indicating that this promiscuous activity is 
less sensitive to the nucleophile mutation than the native activity. 
 
Figure C-4 | Promiscuous phosphonatase activity of TEVCys and TEVSer 
Hydrolysis of different concentration of pNp-phenolphosphonate by 10 µM enzyme in 
TEV activity buffer at 25 °C. 
3.3 DIRECTED EVOLUTION RESTORES PROTEOLYTIC FUNCTION USING SERINE 
In order to investigate how the enzyme can compensate for the 
handicap of using a non-native nucleophile, 10 rounds of directed 
evolution (DE) were performed on TEVSer by selecting for activity 
recovery in the presence of the mutated nucleophile. 
Libraries of variant genes were generated by error prone PCR (epPCR), 
such that on average each resulting gene contained 1.3±0.4 amino acid 
mutations. Libraries were screened by the lysate assay detailed in 
0.E+00
1.E-03
2.E-03
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 /
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Chapter B, 5.2. Briefly, libraries were transformed into E. coli Top10 
cells bearing the CFP-YFP substrate plasmid and the lysates from 350 
individual colonies co-expressing protease and substrate were 
screened in each round. The single most active variant was used as the 
template for the next epPCR library and any S151C revertant rejected 
to force the recovery to follow a ‘forward’ evolutionary pathway. 
Revertants were predicted to occur once per thousand variants and 
results agreed with a revertant found in every second round (on 
average). 
In this ratiometric, co-expression assay, the effect of the handicapped 
nucleophile caused a more moderate 6-fold cleavage reduction. Due to 
the sensitivity of the lysate assay, this was enough to allow directed 
evolution. A co-expression time of 4 hours gave good signal strength 
(high enough substrate concentration) whilst also giving good dynamic 
range (no saturation). 
Over 10 rounds of evolution (TEVSer→TEVSerX), the in vivo activity 
was recovered from 17 to 75% of TEVCys in the cell lysate assay (Figure 
C-5a & Table C-2). To determine which enzyme properties were 
responsible for the improvement, I purified each enzyme variant for 
kinetic characterisation. In vitro kinetics indicated that the in vivo 
activity increase is due to a larger burst amplitude and an improvement 
in both kobs1 (2x103-fold) and kobs2 (3x103-fold) (Figure C-5b), with 
diminishing increments in later rounds, typical of DE trajectories53. 
Despite the recovery, kinetics of all isolated variants were still best fit 
to the biphasic model (Table C-3). Conversely, S151C revertants could 
be fit to monophasic kinetics.
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The process of transcribing and translating a gene to make an enzyme 
is not perfect with an error made every 104 residues. It is possible that 
the apparent activity of TEVSer (and variants) is due contamination by 
enzymes with the original cysteine nucleophile. To rule this out, the 
identity of the nucleophile was confirmed in the proteins TEVSer and 
TEVSerIV by mass spectrometry and sensitivity to PMSF (a serine 
protease inhibitor) but not Io-Ac (a cysteine protease inhibitor). 
 
Figure C-5 | Evolutionary recovery of TEVSer→TEVSerX lineage 
(a) Activity of TEVSer→TEVSerX (black) and TEVCys back-mutants (white) along evolution 
lineage by cell lysate screening assay normalised to wtTEV. (b) In vitro kcat/KM for TEVCys 
variants (white circles) and kobs1 and kobs2 for TEVSer variants (black and grey circles 
respectively). The red dashed arrow indicates the effect of the initially introduced 
handicap nucleophile mutation (C151S). Error bars represent standard deviation of: 8 
biological repeats of lysate activity, 3-4 kinetics technical repeats of kinetic activity. 
Table C-3 | Regression of curve fitting of evolved variants 
Summary of R2 values for fits to single exponential (Eq. 1) or double exponential (Eq. 2) 
model for all variants. Kinetic data for cleavage of 1 µM substrate 20 µM TEVSer and 4 µM 
of all other variants. 
R2 FIT
VARIANT EQN. 1 EQN. 2
TEVSer 0.92 0.98
TEVSerI 0.92 0.96
TEVSerII 0.91 0.98
TEVSerIII 0.86 0.98
TEVSerIV 0.90 0.96
TEVSerV 0.73 0.98
TEVSerVI 0.31 0.97
TEVSerVII 0.26 0.98
TEVSerVIII 0.83 0.95
TEVSerIX 0.81 0.94
TEVSerX 0.54 0.97
TEVCys 0.99 0.99
TEVCysI 0.98 0.99
TEVCysII 0.98 0.98
TEVCysIII 0.99 0.99
TEVCysIV 0.99 0.99
TEVCysV 0.99 0.99
TEVCysVI 0.99 0.99
TEVCysVII 0.99 0.99
TEVCysVIII 0.95 0.98
TEVCysIX 0.95 0.99
TEVCysX 0.93 0.99
a
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3.4 THE EVOLVED PROTEASE CAN USE EITHER NUCLEOPHILE 
Natural enzymes are sensitive to nucleophile mutations because of the 
evolutionary specialisation of their active site244–249. Therefore, DE 
mutations were expected to re-specialise the enzyme for the serine 
nucleophile. However, nucleophile S151C back-mutants of all 
TEVSer→TEVSerX variants (TEVCys→TEVCysX) retained in vivo 
activity levels similar to TEVCys in the lysate assay (Figure C-5a). The 
kinetics of purified enzyme variants show that the modifications to the 
enzyme active site architecture prove nearly-neutral to activity with the 
original cysteine nucleophile. Consequently while the kobs1 and kobs2 of 
TEVSerX are 103-fold improved over TEVSer, the kcat/KM of 
TEVCys→TEVCysX variants fluctuated by less than 4-fold (Figure 
C-5b), giving a trajectory that lacks a strong trade-off in nucleophile 
use (Figure C-6).  
 
Figure C-6 | Nucleophile activity tradeoff 
Plot of kcat/KM activity using the original cysteine nucleophile versus (a) kobs1 and (b) kobs2 
with a serine nucleophile for lineage. 
This neutrality may be because the mutations that accumulate to 
improve serine’s nucleophilicity have little effect on cysteine catalysis 
due to its higher intrinsic nucleophilicity22. Mutations did not occur 
that fully specialise the active site towards serine (by failing to create a 
thiolate zwitterion239, sterically clashing237, or causing hyper-reactive 
oxidisation to sulphinic acid252). 
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3.5 CATALYTIC ACTIVITY IS RESTORED AT THE EXPENSE OF STRUCTURAL INTEGRITY 
Previous works have observed trade-offs between improved activity 
and structure destabilisation61,176,253. Function-altering mutations 
close to the active site also tend to be in the core, which does not 
tolerate mutations well. Since the total amount of active protein 
present in a cell is a complex function of expression, folding, unfolding 
and aggregation, I used a set of techniques to characterise the stability 
of variants.  
Differential scanning fluorimetry measures protein melting 
temperature (TM). For this, enzyme variants had to be expressed and 
purified without the MBP fusion partner since this would mask the 
signal from thermal unfolding of TEV. Secondly, the soluble 
expression of variants still fused to MBP was measured by gel band 
densitometry and indicates the total amount of active protein present 
in the cell. Finally an in silico folding energy estimate could be evaluated 
by FoldX which calculates the total energy difference between the 
folded and unfolded states (ΔG of folding) as well as the change in this 
difference upon individually mutating of each residue to alanine (ΔΔG 
of alanine mutation). 
The nucleophile mutation did not affect melting temperature (TM) of 
purified protein (Figure C-7a) and quantification of soluble expression 
in E. coli showed only a 10% decrease in TEVSer (Figure C-7b). FoldX 
also only predicted a minor destabilisation of the folded state (Figure 
C-7c). In contrast, during the evolution, there was a negative trade-off 
between activity and soluble expression (Figure C-7b), a frequently 
reported compromise61,253. FoldX calculations agreed with this by 
predicting increasing destabilisation of the folded state along the DE 
trajectory (Figure C-7c).  By the tenth round (TEVSerX), the >1000-fold 
increase of kobs1 and kobs2 was accompanied by a 6-fold drop in soluble 
expression. In rounds where solubility decreased, mutations were in 
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residues with low solvent accessibility (0.1) whereas the average solvent 
accessibility of mutations in rounds where solubility increased was 
higher (0.6). 
This negative pleiotropy was temporarily broken in rounds V and VI 
by two surface mutations (W130C and E194D) and a C-terminal 
truncation (due to a frameshift), which allowed the increase of both 
activity and solubility. 
 
Figure C-7 | Stability losses during recovery of TEVSer lineage 
(a) Soluble expression (gel band quantification) and (b) thermal denaturation 
temperature of selected variants (Differential scanning fluorimetry without MBP 
fusion partner). (c) Energy difference between the folded and unfolded states (ΔG) 
for all evolved variants (grey) and S151C revertants (white). Values are normalised to 
TEVCys, higher values indicate lower stability. (d) Distribution of the destabilisation 
effects of alanine mutations to all residues in TEVCys. Higher values indicate greater 
destabilisation by mutation to alanine. All variants show similar profiles. Error bars 
represent standard deviation of: 2 biological repeats of soluble expression, 3 
technical repeats of DSF, 2 technical repeats of FoldX. 
3.6 MUTATIONS THAT RECOVER ACTIVITY CLUSTER AROUND THE ACTIVE SITE 
To examine the distribution of mutations within the protein structure 
I used the published structure211 (PDB code 1lvm) to separate the 
enzyme into concentric shells emanating outwards from the catalytic 
triad. The first shell includes all residues within 4 Å of His46, Asp81 
and Ser151. The second shell is all residues 4 Å from the first shell, and 
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so on. Mutations accumulated in the DE lineage (Table C-2) were not 
evenly distributed through the structure (p=0.005). The triad first shell 
did not accumulate any mutations. The triad second shell, however, 
contained 54% of mutations despite comprising only 23% of the 
protein (Figure C-8). Shells further than the second, conversely, were 
depleted in mutations. These observations suggest a strong selective 
pressure for the improvement of amino acid interactions around the 
active site254, consistent with the idea that the non-native nucleophile 
had to be re-tuned. 
  
Figure C-8 | Mutations positions 
Structure of TEV protease (1lvm) with 2nd shell (dark blue) and ≥3rd shell (light blue) 
mutations from directed evolution trajectory. Triad in red, substrate in black. The triad 
first shell is defined as residues 4A away from H48, D81 or S151. The second shell is any 
residues 4A from the first shell. 
Given that more than one mutation accumulated in each round, I 
performed a back-shuffle of the round II, V and VIII variants with 
TEVSer to see which mutations could be neutrally reverted to wild type 
at different rounds. This involved digesting the variant genes into 50 
nt fragments, mixing them together with the similarly digested TEVSer 
gene and using PCR to reassemble the shuffled products. For 
reassembly, each evolved variant was mixed with TEVSer in a ratio such 
that 2-3 of the evolved mutations would be randomly reverted in each 
member of the shuffled library. Sequencing of 10 active variants from 
each shuffled library was expected to reveal some mutations that are 
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universally required for improved function (and so active variants 
never show reversion) whereas others would be neutral (and so would 
be reverted in variants retaining high activity). Mutations close 
together, however, rarely recombined and so the effects of some 
mutations could not be separated (e.g. A206T & L210M). 
What was actually found was evidence of epistasis between the 
mutations accumulated in the lineage (Table C-4). This is consistent 
with other previous work on evolution of active site residues which 
looked in detail at the epistatic interactions between three residues255. 
Reversions of H28L, L210M and K215R were tolerated from TEVSerV 
but not from TEVSerVIII. Similarly, reversion of E224G in TEVSerII 
did not reduce in vivo activity but its removal from TEVSerVIII does. 
There are therefore no mutations that remain completely neutral. The 
finding that some mutations are nearly-neutral in early rounds yet 
adaptive in later rounds suggests epistatic dependence of later adaptive 
mutations on these early nearly-neutral substitutions. This makes 
sense as the mutations are tightly clustered, with many contacting each 
other in the structure. Unfortunately, multiple attempts to crystalise 
variants along the DE trajectory were unsuccessful. Even the wild type 
protease TEVCys is reportedly hard to crystallise due to poor 
reproducibility211. 
 
Table C-4 | Back-shuffle mutation retention 
Selection of 10 variants that retain activity after back-shuffle with TEVSer. Shown are the 
proportion of active variants that retain each mutation. Back-shuffles were performed by 
shuffling TEVSer with each of TEVSerII, TEVSerV and TEVSerVIII such that 2-3 reversions 
occurred on average per variant. Mutations K229R, E230K and Δ231-236 are all caused by 
a 1nt frameshift and so are included in the table as ‘STOP’. 
The >103 increase in activity using serine was achieved by relatively few 
mutations (TEVSerX has 92.4% sequence identity to TEVCys) even 
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though the most closely related natural serine proteases have only 15% 
identity.  
The closeness in protein sequence space of this nucleophile-
permissiveness to an extant enzyme explains how divergent evolution 
of core catalytic machinery can occur within evolutionary 
superfamilies (such as the PA clan, Figure C-2). The ancestral gene 
basal to the divergent serine and cysteine branches of the PA clan could 
have been nucleophile-permissive despite modern members being 
unable to tolerate the switch.  
3.7 MEASUREMENT OF LOCAL FITNESS LANDSCAPES ALONG THE TRAJECTORY 
Directed evolution follows a single pathway through a fitness 
landscape and is a useful tool to understand how a protein can evolve, 
and what properties the evolving enzyme gains and loses62. The focus 
on detailed characterisation of a single trajectory, however, misses the 
broader context of the surrounding fitness landscape. In particular, it 
would be useful to know which properties of the evolved trajectory are 
general, and which occurred by chance in that specific lineage. I 
therefore used the Fluorescence Activated Cell Sorting (FACS) assay 
(Chapter B, 5.4) for High Throughput Screening and Sequencing (HT-
SAS) to characterise the local fitness landscapes flanking the 
trajectory. I aimed to address to what extent the following observations 
were stochastic events, or reflective of features of the fitness landscape: 
 Rapid evolutionary recovery of activity using the new nucleophile 
 Clustering of adaptive mutations around the active site periphery 
 Trade-offs between improved activity and protein stability 
 Epistatic interactions between the accumulated mutations  
For each of the mutagenised libraries generated in rounds I to X of the 
evolutionary trajectory, ≈106 members were re-screened by flow 
cytometry. The library members exhibiting the top 1% activities were 
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isolated and a representative sample of ≈103 mutants subjected to 454 
sequencing. Frequency of mutations before and after selection was 
measured and used to calculate the enrichment factor (for each 
position of the sequence). Mutations that are enriched are beneficial 
under the selection pressures applied, those that are purged are 
deleterious. Linking sequence and function79,126 provides insight into 
the series of local fitness landscapes flanking the DE trajectory(Figure 
C-9). Furthermore, mapping functional effects on the protein 
structure121 indicates which regions of the structure are constrained 
and which are enriched in adaptive potential. 
 
Figure C-9 | Schematic of sequence space flanking trajectory 
A 2D simplification of the multi-dimensional space of all possible protein sequences. 
Similar sequences are closer together in this space. (a) The TEVSer→TEVSerX trajectory 
generated by directed evolution. Only the trajectory members (large circles) are 
characterised. (b) Many related sequences (small circles) surround members of the 
directed evolution trajectory. High throughput selection and sequencing allows some of 
their properties to be characterised. 
After HT-SAS, 29% of TEVSer residues showed greater than 2-fold 
enrichment of mutations (Error! Reference source not found.). The 
protein surface and regions away from the active site were particularly 
enriched (52% and 36% respectively). The same analysis was performed 
for all variants along the DE lineage up to TEVSerIX (Figure C-11) to 
build an overlapping series of local fitness landscapes. 
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Figure C-10 | Mutation enrichments for TEVSer 
Enrichment for each mutation shown (a) for each residue in the sequence and (b) as a 
distribution. 
3.8 MUTATIONS HAVE STRONG EPISTATIC DEPENDENCE ON THEIR PREDECESSORS 
Due to differences between the lysate and FACS screening techniques, 
the selection pressures in HT-SAS are not identical to those in DE 
(Chapter B 6.2). 
 
Figure C-11 | Mutation enrichments for the TEVSer→TEVSerX lineage libraries 
Heatmap (blue=purged, red=enriched) of mutation enrichment after selection from each 
round of TEVSer lineage mapped on primary sequence. Residues are marked (+) to show 
consistent enrichment ≥0 and (-) for enrichment ≤0. Nucleophile reversion S151C always 
enriched so all variants with S151C separated from other analyses. (Terminal half of 
TEVSerII shown only due to failed forward sequencing read). 
Despite the lower sensitivity of the HT-SAS analysis at the single 
residue level, some striking correlations were evident (Figure C-12): the 
H28L mutation, introduced in TEVSerIV, showed enrichment of 
alternative residues in the two subsequent rounds but is increasingly 
selected for retention in later rounds. The back mutation of W130C in 
TEVSerV also coincided with its purge from the library. Finally the 
N174K of TEVSerVIII showed enrichment (both N174K and N174Y) 
before it is selected in the lineage, after which further mutations were 
no longer enriched. The previous observation, that nearly-neutral 
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mutations can become adaptive for later evolution, appears to 
represent a more general property of the local fitness landscapes. 
 
Figure C-12 | Enrichments of notable mutations 
Mutation enrichment after selection from each round of TEVSer lineage of nucleophile 
mutations to cysteine (S151C) or any non-cysteine residue (S151X). Also shown are three 
residues which mutated during the DE lineage (new residue in grey boxes). 
The real power of HT-SAS is not in analysing individual residues, but 
rather analysing trends in large sets of residues90. Results in section 3.6 
suggested that there are epistatic interactions between the mutations 
accumulated in the DE lineage in line with some previous work255. To 
see if this was a general effect, I looked at whether the mutations 
accumulated in the DE lineage affected which residues subsequently 
showed adaptive mutations. The enrichment profiles (Figure C-11c) 
indicated that mutations at very few positions are universally enriched 
or universally purged throughout the DE lineage. The S151C 
nucleophile reversion was always enriched (average 9.8-fold, p=0.0004) 
and any other S151X mutation was selected against (average 43-fold, 
p<0.0001) (Figure C-11c & Figure C-12). Only 9 other residues (4%) 
showed consistent mutation enrichment, on the surface (L98, T191), 
in the binding pocket (N177, S208, V209, V216) and in the 
unstructured C-terminus (V228, E230, L235). Similarly, only 29 (12%) 
positions are so constrained that they were consistently purged of any 
variation, mostly buried, hydrophobes (Figure C-13). The mutations 
accumulated in the DE lineage, therefore, had large effects on the 
adaptiveness of other possible mutations in the protein. At each round, 
the set of mutations that are adaptive appeared to change. The shifting 
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spectrum of adaptive mutations is consistent with a rugged fitness 
landscape in which the mutations accepted along the DE trajectory 
drastically influence the possible uphill routes by epistasis. 
 
Figure C-13 | Locations of beneficial or deleterious mutations 
(a) Structure of TEVCys (PDB 1lvm) showing enrichment of non-wt amino acids for each 
residue averaged over whole TEVSer→TEVSerX lineage. Thick, blue regions indicate positive 
enrichment of non-wt amino acids, thin red region indicate purging of non-wt amino 
acids. (b) Structure of TEV (PDB code 1lvm) overlaid with 29 consistently purged 
mutations (red), 6 consistently enriched mutations (blue). Also shown are catalytic triad 
(red sticks) and N-terminal product (black sticks). 
3.9 ADAPTIVE MUTATIONS ARE COMMON AT ALL STEPS OF THE TRAJECTORY 
Epistasis is usually considered a constraining factor on evolution as the 
lack of a smooth landscape makes it harder for evolution to access 
fitness peaks172. Despite this, at all steps along the adaptive trajectory 
there were residues (average 22% of 236) that display beneficial 
mutations (Figure C-14), indicating multiple uphill pathways in the 
flanking fitness landscape.  
 
Figure C-14 | Adaptive potential along the TEVSer→TEVSerX lineage 
Proportion of residues that show >2-fold enrichment for mutation in each library along 
evolutionary lineage. 
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That many alternatives to improve activity exist is consistent with the 
rapid evolutionary compensation of the mutated nucleophile 
handicap. It indicates that the abundance of adaptive mutations was 
sufficient to overcome the small number of variants screened at each 
round of DE. 
3.10 SOME PROTEIN REGIONS ARE HOTSPOTS FOR ADAPTIVE MUTATIONS 
The mutations accumulated in the DE lineage were overrepresented in 
the triad second shell. However, the available adaptive mutations vary 
from round to round. To resolve this apparent conflict, I looked at 
whether different regions of the protein were more or less likely to 
contain adaptive mutations. 
As stated previously, the 12% of positions that were consistently 
constrained to the wild type residue are mostly located in the protein 
core. In fact, mutations in buried residues tended to be more 
deleterious on average (p=0.01 Figure C-15), supporting the previous 
observations of a trade-off between activity and solubility (Figure C-7). 
 
Figure C-15 | The effect of mutations in the protein core 
The average enrichments for residues with solvent accessibility <0.02 compared to the 
average for each round. 
Additionally, adaptive mutations are disproportionately located in the 
active site periphery (triad second shell). Firstly beneficial mutations 
were more common in this region (average 28% of 53, p<0.0001, Figure 
C-16a). Secondly, the average enrichment of triad second shell 
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mutations was higher than for the protein as a whole (p=0.04, Figure 
C-16b & Figure C-13b). The second shell encompasses some core 
residues which, if removed from the analysis, enhance this trend 
(p=0.01). Conversely, residues contacting the nucleophile (nucleophile 
first shell) were strongly constrained showing few beneficial mutations 
(average 16% of 11, p<0.0001) and certainly more detrimental on 
average (p<0.0001). The triad’s first shell showed the largest 
fluctuations, indicative of the strong effects the interactions have on 
the core catalytic machinery. Finally, mutations in shells further away 
(triad ≥third shell) showed no more beneficial mutations than the 
protein on average (p=0.18). 
 
Figure C-16 | Beneficial mutations more common in triad second shell 
(a) Proportion of residues that show >2-fold enrichment and (b) the enrichment of 
mutations in each shell normalised to the average per round. Nucleophile 1st shell: 
residues 4 Å from S151. Triad 1st shell: residues 4 Å from H48, D81 or S151. Triad 2nd shell: 
residues 4 Å from the first shell. Triad ≥3rd shell: remaining residues. 
Together, these results indicate that even though the set of adaptive 
residues available changes from round to round, there are some 
underlying trends in their locations. 
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Underlying trends in the adaptive potential of different regions of the 
enzyme explain the biased accumulation of mutations in this region 
during the adaptive DE trajectory (Figure C-8). Although few 
individual residues show consistent effect upon mutation, several 
regions of the protein do. Therefore, despite high epistasis, the active 
site second shell is repeatedly enriched in adaptive mutations. This is 
consistent with meta-analysis of directed evolution experiments which 
show that the largest catalytic changes are often caused by mutations 
4-8Å from the catalytic centre254. 
Conversely, residues that showed improvement in activity using serine 
do not correlate to those found in natural serine proteases in the PA 
clan. In the PA clan, therefore, the adaptive differences between serine 
and cysteine proteases are buried by drift, consistent with their ancient 
divergence. 
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4 CONCLUSIONS 
The handicap-recover directed evolution demonstrated that it is 
possible to convert TEVCys into a functional serine protease TEVSerX. 
In addition to biochemically characterising this specific uphill 
trajectory (TEVSer→TEVSerX), I generate complementary data on the 
flanking fitness landscape by HT-SAS. These combined methods 
reveal how local fitness landscape topology guides the evolutionary 
trajectory. 
4.1 EVOLUTIONARY CONSTRAINTS ON THE EVOLVED TRAJECTORY 
The trajectory highlights several evolutionary constraints. The activity 
improvement negatively trades-off with structural integrity. The 
adaptive mutations accumulated along the evolutionary trajectory to 
TEVSerX destabilise the structure and promote aggregation. 
Characterising local fitness landscapes throughout the trajectory 
reveals that buried residues rarely contain adaptive mutations. 
Likewise, the 12% of residues consistently purged of mutations are 
mostly in the protein core. These biophysical constraints bias 
evolution away from these regions of sequence space. 
Previous work on active site evolution found two supporting mutations 
that enabled exchange of an active site residue in phosphoglycerate 
kinase255 but that their effects were contingent on their order of 
introduction. Of eight possible routes to the three mutation variant, 
only one did not pass through a fitness valley, suggesting that rare 
mutation combinations dominate and constrain the evolutionary 
trajectory. Similarly my results are consistent with high epistasis 
between mutations within the trajectory and between trajectory 
mutations and the spectrum of possible mutations. This creates a 
rugged fitness landscape where the acceptance of each mutation 
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drastically alters which subsequent mutations are adaptive. This 
ruggedness reduces repeatability of evolution such that replicate 
trajectories would widely deviate. 
4.2 HIGH ADAPTIVE POTENTIAL GENERATES A VERSATILE ACTIVE SITE 
Despite these constraints, the 104-fold drop in activity was 
compensated for remarkably easily. In only 10 rounds, screening 350 
variants per round, activity was recovered by >103 to improve the 
activity of TEVSerX to within an order of magnitude of the original 
TEVCys. The results indicate that the proportion of adaptive mutations 
is of the order of 10-1-10-2, at the high end of previous evolvability 
measurements (Chapter A, 5.1) and therefore that extra rounds of 
evolution might further increase activity. Additionally, this increase 
does not trade-off with the ability to use the original nucleophile, 
cysteine, generating an enzyme that efficiently uses either. This was 
achieved through very few mutations compared to the sequence 
difference between natural serine and cysteine proteases. These 
mutations cluster around the active site periphery and is representative 
of an underlying trend for triad second shell mutations to be rich in 
adaptive potential. 
Indeed analysis of the flanking fitness landscape shows that the ease of 
this evolution reflects the large number of possible adaptive pathways 
at each step. By HT-SAS, we show that there are many possible 
beneficial mutations available at each round. Hence, whilst routes to 
any given solution may be rare255, the abundance of solutions results in 
high overall evolvability of nucleophile exchange. Thus the easily 
evolved enzyme TEVSerX is likely one of a great many similar solutions. 
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Chapter D -  Neutral evolution and 
emergent robustness 
1 SUMMARY 
Populations of TEV protease genes were neutrally evolved in order to 
investigate how they spread through the local neutral network. Next 
generation sequencing revealed that evolution generated a number of 
highly robust variants whose descendants come to dominate the later 
populations due to their increased tolerance to mutations. These 
variants show improved structural robustness that correlates with a 
preferential distribution of mutations in exposed, disordered structural 
regions away from the active site that have minor impacts on protein 
stability. This shows how long-term neutral evolution contains implicit 
selection for robustness as genes diffuse though the local neutral 
network to extinction-resistant regions with more neutral neighbours.  
 
 
 
 
 
Parts of this chapter and Chapter E have been combined and prepared for publication: 
Shafee, T., Gatti-Lafranconi, P., Minter, R., Hollfelder, F. 
Neutral evolution – two combined mechanisms generate robust and evolvable enzymes. MBE. (2013)  
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2 INTRODUCTION 
2.1 PROTEIN ROBUSTNESS AND TOLERANCE TO MUTATIONS 
As introduced in more detail in Chapter A, 4.1, proteins achieve 
stability through an internal network of interactions. Measurements of 
protein tolerance to random amino acid substitution (τsub) have found  
an average τsub=0.65±0.0250,79,144,256. This indicates that only a third of 
random mutations destroy function in proteins so far studied. 
In this robustness there is an apparent contradiction: proteins are 
apparently stable enough to tolerate most mutations, yet they are only 
marginally stable before mutation, with ΔGfolding of around -10 
kcal/mol257–259. This marginal stability has been explained by both 
adaptive and neutral mechanisms (Figure D-1). Firstly by selection to 
avoid accumulation of aggregates and be protease resistant139,259. 
Secondly there is evidence that excess stability can reduce the 
flexibility necessary for protein activity14,17,18,61. Finally excess 
stability above what can be selected for can be eroded by genetic 
drift8,260 since mutations are more likely to reduce than increase 
stability. 
 
Figure D-1 | Protein stability effects on fitness 
Selection pressure on the left hand side of the curve increases stability to avoid 
aggregation, degradation and unfolding. Selection on the right hand side reduces stability 
to maintain activity and avoid uncontrolled and toxic accumulation of protein. Drift in the 
centre reduces stability down to the minimum viable threshold as random mutations 
erode stability. 
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The probability that an 
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like function after random 
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perturbation, in this case 
after mutation 
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A deeper understanding of the evolution of robustness may be able to 
resolve the apparent paradox that proteins tolerate mutations 
surprisingly well despite being perpetually on the edge of unfolding 
even before those mutations. 
2.2 THEORETICAL PREDICTIONS OF ROBUSTNESS EVOLUTION 
Mathematical modelling in silico has been used to investigate neutral 
network structure and its evolutionary consequences and predicts that 
neutral networks of equivalent proteins are not 
homogeneous133,149,150,261–265. Some sequences in the network are 
more highly connected (have more neutral neighbours) and form 
central nodes in the network, whilst others form sparsely connected 
edge regions. Both abstract mathematics149,265 and explicit 
models133,263,264 predict that large, neutrally-evolving populations can 
evolve towards regions of the network with more neutral neighbours, 
i.e. with increased robustness. This can be understood in terms of the 
disproportionate extinction of variants that, though perfectly fit, have 
fewer neutral neighbours and so are more likely to be deactivated by 
mutation. As a counterpoint, models of lethal mutagenesis therapy in 
viruses indicate that, although robustness can increase as an adaptation 
to high mutation rates266, it may not be high enough to prevent 
extinction267. 
Classical population genetics also makes a number of predictions on 
the conditions under which robustness could evolve. For example, 
population size (N=total number of variants) and effective population 
size (Ne=total number of breeding variants) have a strong effect on the 
balance of selection versus genetic drift in an evolving population. 
Small populations (low N) have a smaller pool of variation, important 
when beneficial mutations are rare and the rate limiting step of 
evolution is the generation of adaptive variation, not its fixation by 
 
Neutral neighbour 
Two enzyme variants 
related by a single mutation 
that retain the same 
function 
 
Effective population size (Ne) 
The number of variants in a 
population that genetically 
contribute to the next 
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selection. In small effective populations (low Ne), the stochastic effect of 
random chance has a larger impact on the differential survival of 
mutants and can overwhelm selection. Consequently, the small 
selection coefficients hypothesised to be important in the evolution of 
robustness likely require large populations149. 
2.3 EMPIRICAL EVIDENCE FOR THE EVOLUTION OF ROBUSTNESS 
Although the theoretical foundations of the evolution of robustness 
have been in place for some time, experimental and empirical evidence 
is currently limited. 
Bioinformatic analysis indicates that eukaryote miRNA hairpins are 
more robust to mutations (Figure D-2a) than random sequences which 
fold into the same secondary structure268 (Figure D-2b). This indicates 
that natural RNA structures have evolved to be tolerant to mutations. 
 
Figure D-2 | Robustness of a miRNA fold 
Around a central starting structure, all point mutants are arranged. Greater distance from 
the central circle indicates greater structural divergence after mutation. (a) An example 
of a natural miRNA. (b) An example of the same starting structure but produced using 
randomised nucleotides to produce correct starting base pairing. The resulting mutant 
structures are more dissimilar to the parent structure. (Adapted from reference268) 
Additionally, experimental evolution of an RNA virus (phage φ6) has 
looked at the erosion of robustness under reduced selection pressure. 
Populations were either evolved under co-infection conditions (when 
complementation is expected to buffer deleterious mutations), or 
under single-infection conditions. Populations evolved with high co-
infection were sensitive to mutagenesis which caused greater 
a b
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reductions in fitness than mutation of the control populations (Figure 
D-3). This was interpreted to suggest that buffering by co-infection 
weakened selection for robustness.  
 
Figure D-3 | Viral robustness after evolution at different co-infection rates 
After evolution with low co-infection, populations retain wild type robustness levels when 
mutagenised. When evolved at high co-infection, the resulting viruses show greater 
variance and lower average fitnesses after mutation. 
Two experimental protein evolution works have addressed how the 
accumulation of neutral mutations can increase robustness during 
neutral evolution187,188. This process is sometimes called ‘neutral drift’ 
although I will avoid this term for now, since it implies that the process 
is completely non-directional which is not necessarily the case. 
Firstly, an experiment on P450 oxidase confirmed that robustness can 
be generated as an emergent property of a neutrally evolving 
population187. A lysate activity endpoint screening system was used to 
assay either 1 or 435 variants and sort all variants with >75% activity. It 
was found that when only 1 variant was selected from round to round 
the mutation tolerance fell from 48% to 39% (Figure D-4). 
The larger evolving population became highly polymorphic with few 
mutations shared in multiple variants. In this case, the tolerance to 
mutations increased very slightly from 48% to 50% and the enzymes 
were found to be more thermostable and resistant to urea degradation. 
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Figure D-4 | Mutation tolerance over neutral evolution of P450 oxygenase 
The fraction of variants that retain function after mutagenesis of µ=0.3 non-synonymous 
changes per codon i.e. roughly one mutation per 460a.a gene. The N=1 lineage (white) 
had a single mutant screened at each round, if it retained >75% activity, it was selected 
for the next. The N=102 lineage (grey) had 435 variants screened at each round and all 
variants retaining >75% activity were selected for the next. (Data from reference187) 
Secondly, an experiment on β-lactamase concentrated on altering the 
strength of selection pressure188. A cell survival selection system was 
used to evolve the gene on either 250 or 12.5 µg/ml of ampicillin. At 
each round >106 variants were selected, however tolerance to 
mutations was not quantified and merely reported to be in general 
>50%. Several mutations were enriched (Figure D-5a) which were 
predicted to be stabilising. Some of these mutations were characterised 
and indeed increased thermostability (Figure D-5b) and some were able 
to compensate for an introduced destabilising mutation. 
   
Figure D-5 | Enriched mutations after neutral evolution of TEM1 β-lactamase 
(a) After neutral evolution for 18 rounds, the most enriched mutations (χ2 p<0.05) are 
shown here. Selection on 0 µg/ml (black bars), 12.5 µg/ml (blue bars), 250 µg/ml (red 
bars), * indicates variants chosen for biophysical characterisation. (b) Thermal 
denaturation temperatures of the chosen variants are higher than the wild type TEM 
starting enzyme. ((a) Adapted from reference188 and (b) data from reference188) 
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Together, these two evolution experiments support the core 
theoretical prediction that mutations which increase robustness can be 
accumulated in neutral evolution.  
In my work I have added to this body of results by providing evidence 
of how robust variants appear, some of their biochemical and 
biophysical properties, and how their descendants take over the 
population. Using a high throughput screening system I was able to 
generate disaggregated data on the distribution of activities after 
mutation (as with the P450 evolution), in addition to assaying large 
populations (as with the TEM1 evolution). This has enabled 
observation of the accumulation of mutation diversity in greater 
breadth and detail than previously possible. Use of phylogenetic 
methods and ancestor reconstruction allowed confirmation of the 
hypothesis that the ancestors of late round populations genuinely were 
more robust and mutation tolerant than the wild type starting point. 
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3 RESULTS AND DISCUSSION 
For this chapter, Tobacco Etch Virus nuclear inclusion cysteine 
protease will be referred to as wtTEV and derived populations will be 
denoted by the number of rounds of evolution. 
In Chapter C, I performed DE via small libraries using the lysate assay 
developed in Chapter B, 5.2. Local fitness landscapes flanking the 
trajectory were assessed by HT-SAS using a higher throughput, flow 
cytometric assay, described in Chapter B, 5.4. In this chapter, I have 
used the flow cytometric assay to perform DE by screening large 
libraries and selecting a pool of variants at each round that maintain 
wild type function.  
3.1 THE DISTRIBUTION OF FITNESS EFFECTS OF TEV MUTANTS 
The wtTEV gene was randomly mutagenised by epPCR, the library of 
mutants was cloned into pMAA and co-expressed with the C-Y(tev) 
substrate in E. coli. When assayed by FACS, the distribution of 
phenotypes was bimodal. This corresponds to a DFE where mutant 
enzymes either have activity similar to wild-type TEV, or are inactive 
(Figure D-6a). This agrees with previous findings that mutations in 
whole organisms153,154 and individual enzymes79 often show a bimodal 
distribution. The rate at which mutations were introduced did not alter 
the bimodality of the distribution, but affected the relative ratio 
between the two sub-populations. 
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Figure D-6 | Bimodal distribution of fitness effects and purified mutant characterisation 
(a) FRET ratios as measured in FACS of cells expressing: wtTEV, no protease or library of 
protease variants after random mutagenesis at µ=0.5% (1 amino acid per gene) and 
µ=1.5% (3 amino acids per gene). For 96 purified variants, (b) the initial rate activity on 
purified substrate, and (c) total soluble protein in 300μl lysate from 1ml expression 
culture (measured by Bradford test). (d) Soluble expression vs specific activity for 92 
members of a library of variants (wtTEV after mutagenesis at µ=1.5%) 
Mutation tolerance of an enzyme or enzyme population can be 
calculated by the relative abundance of wt-like enzymes after error 
prone PCR (epPCR). Since epPCR generates some variants with 1 
mutation, some 2, some 3 etc. the mutation range follows a Gaussian 
distribution. This spread can be used to calculate what proportion of 
random mutations are neutral (τsub) using Equation D-1 (adapted from 
reference144). The equation makes a number of assumptions: 
Mutations are either neutral or lethal, and their effects are additive (i.e. 
two neutral mutations are always neutral together). 
𝑆 = ∑ 𝑓𝑛
𝑛=0
(𝜏𝑠𝑢𝑏)
𝑛 =  𝑓0(𝜏𝑠𝑢𝑏)
0 + 𝑓1(𝜏𝑠𝑢𝑏)
1 + 𝑓2(𝜏𝑠𝑢𝑏)
2 … +𝑓𝑛(𝜏𝑠𝑢𝑏)
𝑛 
Equation D-1 | The probability of enzyme activity retention after random mutation 
S = the fraction of enzyme variants displaying wt-like activity 
n = number of mutations 
fn = the fraction of enzyme variants with n mutations  
τsub = the probability that a random mutation will be neutral 
Nb. Frameshift mutations will cause underestimation τsub, however, these were rare 
enough that they made no difference to these estimates 
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When mutations were introduced at either µ=0.5% or µ=1.5% non-
synonymous changes per codon (≈1 or 3 amino acid mutations per 
enzyme) in wtTEV, the probability of activity retention after a random 
amino acid substitution (τsub) was 0.78 and 0.74, respectively. This is 
higher than reported previously for other proteins (average 
τsub=0.65±0.02)50,79,144,256 meaning that in wtTEV only a quarter of 
random amino acid changes destroy activity. This may be because viral 
proteins are hypothesised to have higher structural robustness269 to 
compensate for the lack of genomic robustness, high mutation rates 
and strong selection pressures inherent to the viral life cycle266,270,271. 
I attempted to investigate the underlying protein properties by 
purifying 92 members of the µ=1.5% mutant library. Poor expression of 
the protease lead to a high degree of noise in the data. However, some 
broad observations could be made. The underlying distribution of 
purified enzyme specific activities appeared less defined (Figure D-6b) 
and the range of expression showed no bimodality (Figure D-6c). The 
lack of obvious bimodality in the activity of purified enzyme variants 
may indicate that the bimodal distribution of phenotypes was partly 
the effect of the ‘end-point’ style phenotype assay. This  is consistent 
with the observation that changes in enzyme kcat/KM have non-linear 
effects on pathway flux130 and fitness272. There also appeared to be a 
negative trade-off between activity and soluble expression in the 
library (Figure D-6d) in line with results in Chapter C. 
3.2 GENERATING NEUTRAL EVOLUTION LINEAGES 
To investigate how mutation tolerance can change during evolution, I 
performed several neutral evolution experiments. For each generation, 
a population of 106 mutant enzymes was expressed, assayed, and a 
homogeneous sub-population of functionally neutral mutants isolated 
by FACS (with >99% of selected clones retaining activity on the native 
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cleavage sequence). In this way, mutations that were neutral were 
accepted for the next round of evolution. Better-than-wt cleavage was 
not preferentially selected, and so mutations that increase activity were 
not preferentially selected. 
Population size was controlled at N=106 by screening 106 variants at 
each round. Similarly I controlled effective population size at 2x104 by 
limiting the number of neutral variants selected for the next round of 
mutagenesis. Parallel neutral evolution lineages compared the effect of 
mutation rate (µ=0.5% or µ=1.5% non-synonymous changes per codon 
per round). As mentioned in Chapter B, 5.2, mutations were evenly 
distributed through the gene with very few frameshifts. Keeping 
population and effective population sizes, mutation rate and selection 
pressure constant ensured that changes seen were due to the duration 
of neutral evolution, not changing conditions. 
Since not all mutations are neutral, they were accumulated at a slightly 
lower rate than they were introduced (i.e. some mutations are 
deleterious and purged from the evolving populations). The Ne=104 
lineages accumulated mutations at roughly linear rates of 0.4% and 
0.7% amino acid variation per round (at µ=0.5% and 1.5% respectively 
Figure D-7a) although the rate lowered after round 7. These rates were 
slightly higher than in the equivalent Ne=102 lineages (0.3% and 0.7% 
Figure D-7b). 
 
Figure D-7 | Mutation accumulation rate 
Accumulation of sequence diversity over course of experimental evolution at µ=0.5% 
(white) or µ=1.5% (grey) non-synonymous mutations per codon per round with effective 
population size of (a) Ne=104 or (b) Ne=102. Dashed lines indicate average trend rate. 
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Initially, as the populations accumulate mutations, their tolerance to 
further mutations (defined as τ0.5% and τ1.5% for µ=0.5% and µ=1.5%, 
respectively) decreased (Figure D-8). By the time populations had 
accumulated ≈2% sequence diversity, mutation tolerance fell from 
τ0.5%=0.60 to 0.08 and from τ1.5%=0.28 to 0.06. This indicates that these 
populations contain variants that, though neutral in function, are less 
robust. This would be expected by a model in which proteins have 
stability in excess of some threshold134,273. Mutations, on average, 
erode this excess stability such that a greater proportion of the 
population sits on the stability threshold and is affected by mutations 
(less robust)91,134. 
 
Figure D-8 | Population mutation tolerance 
Change in mutational tolerance over evolution at mutation rates µ=0.5% (white) or 
µ=1.5% (grey) non synonymous mutations per codon per round. Tolerance measured by 
proportion of variants retaining wt-like activity after mutagenesis (i.e. τ0.5% for µ=0.5% of 
codons per gene and τ1.5% for µ=1.5%). 
From this low point in mutation tolerance, the decline halted. In the 
µ=0.5% lineage, tolerance initially fluctuated and then recovered to 
near wild type levels by later rounds. The trend in the µ=1.5% lineage 
was more pronounced and showed a general increase in the tolerance 
to mutations that begins at round 3 and reached τ1.5%>0.50 at rounds 
9-11. 
Consistent with the threshold hypothesis discussed above, once the 
population reaches a critical stability level, selective pressure to 
improve robustness sets in. In the case of wtTEV, this leads to the 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0 1 2 3 4 5 6 7 8 9 10 11
M
u
ta
ti
o
n
 t
o
le
ra
n
ce
 /
 τ
x
Evolution round
Chapter D - Neutral evolution and emergent robustness 
99 
recovery and stabilisation of mutation tolerance with efficiency that is 
relative to the rate at which mutations are introduced. The stronger 
increase in mutation tolerance in the µ=1.5% lineage is consistent with 
a greater selection pressure for robustness under higher mutation rate. 
It may also explain why this tolerance increase is greater than that seen 
in previous work on P450 oxidase187 (Figure D-4). 
3.3 ENRICHED MUTATIONS CONFER POPULATION ROBUSTNESS 
In order to investigate which mutations were accumulating in the 
evolving lineages, the populations of TEV variant genes were deep 
sequenced (1200±500 sequences per population). In early rounds, most 
residues accumulated diversity at rates at or below the mutation rate: 
increased diversity at individual positions in the sequence indicates the 
accumulation of neutral mutations is favoured. 
Conversely, positions where non-wt mutations were purged indicates 
that those mutations are deleterious and under negative selection. In 
both lineages, after diversity accumulated to 2% (5 rounds at µ=0.5% or 
3 rounds at µ=1.5% (Figure D-9a,g), previously neutral mutations 
started to be strongly enriched, indicative of positive selection. 
Residues in shells further from the active site triad accumulated more 
mutations (Figure D-9b,h). This is in sharp contrast to results in 
Chapter C, 3.10 where mutations in the triad second shell were 
enriched in variants more active with an alternative nucleophile. 
Additionally, residues predicted by FoldX to be minimally destabilised 
by alanine mutation (indicating their importance in stable folding) 
accumulate fewer mutations (Figure D-9c,i). Later rounds also showed 
a bias towards mutation accumulation outside of the enzyme core and 
in disordered regions (Figure D-9d,j).  
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Figure D-9 | Mutation accumulation by structural region (Ne=104 lineages) 
(a) Changes in frequency of non-wt residues in the µ=0.5% lineage plotted by sequence. 
(b) Mutation accumulation separated by triad interaction shell with residues <4Å from 
the catalytic triad (light red), 4-8Å from the catalytic triad (red) and >8Å from the catalytic 
triad (dark red). (c) Mutation accumulation separated by alanine mutation sensitivity 
(FoldX prediction) with residues predicted to give >3kJmol-1 destabilisation (dark blue) 
and <1kJmol-1 destabilisation (light blue). (d) Mutation accumulation separated by 
disorder prediction (IUPred) with residues with disorder prediction >0.6 (light purple) and 
<0.2 (dark purple). (e) Mutation accumulation separated by residues with sequence 
conservation within the viral C4 proteases of >0.9 (green) and all residues (black) (f) 
Round 11 non-wt residue frequency mapped onto structure (residues purged of variation 
in red, enriched in blue). (g-l) Same data for µ=1.5%. 
Chapter D - Neutral evolution and emergent robustness 
101 
However, there was no correlation between the accumulated mutations 
and sequence conservation in an alignment of naturally occurring viral 
proteases (Figure D-9e,k). This disagrees with previous experiments 
that suggested that back-to-ancestor mutations were key to the 
emergent robustness in an experimentally evolving population188,274s. 
These trends could also be seen when mutation accumulation was 
plotted on the structure as mutations were purged in the core, whereas 
the surface contained neutrally accepted and actively enriched 
mutations (Figure D-9f,l). 
Although neutral to the selected phenotype, mutations did affect the 
underlying properties that give rise to that phenotype. To analyse this 
in more detail, I focused on the µ=1.5%, Ne=104 lineage. The average 
kcat/KM activity of the population fell to 16% of wtTEV by round 3 after 
which it was never above 30% (Figure D-10). Average soluble 
expression of the populations was always lower than wtTEV (Figure 
D-11a) and showed increasing dependence on the MBP fusion partner 
(Figure D-11c).  
 
Figure D-10 | Population average activity (µ=1.5%, Ne=104 lineage) 
Averaged Activity (kcat/KM) of populations in the µ=1.5% lineage. The whole population of 
enzyme variants was expressed and purified. Activity assays of the purified mixed enzyme 
reflects average activity. 
This indicates that (at least at the whole-population level) selection for 
increased activity or concentration of active enzyme has not occurred 
and in fact both properties have fallen slightly, likely reflective of 
permissive selection for neutral function. A similar phenomenon has 
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been seen in other neutral evolution experiments where the activity of 
populations falls slightly to match the selection threshold187,188.  
While the soluble expression of the evolving populations was always 
less than the wtTEV starting level (Figure D-11a), their soluble 
expression after mutagenesis is higher than wtTEV in later rounds 
(Figure D-11b). This indicates that later populations retain soluble 
expression after mutagenesis better than wtTEV. Therefore, despite 
the fall in average soluble expression in later populations, these 
suffered a smaller loss in solubility upon mutation. This suggested that 
the enriched mutations (Figure D-9a) were likely selected for their 
effect on improving enzyme robustness that increased mutation 
tolerance and extinction-resistance (Figure D-8). 
  
Figure D-11 | Population average soluble expression (µ=1.5%, Ne=104 lineage) 
Population average soluble expression for (a) evolved populations, (normalised to wtTEV) 
(b) evolved populations after mutagenesis (normalised to wtTEV) (c) evolved populations 
after mutagenesis without MBP fusion (normalised to wtTEV after mutagenesis without 
sMBP fusion). 
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3.4 LATER POPULATIONS ARE DESCENDED FROM ROBUST NODE SEQUENCES 
High-throughput sequencing allowed phylogenies of the evolving 
lineages to be generated. A standard phylogeny only shows the 
sequences of contemporary, extant sequences (in this case, the final 
round of the experimental evolution). Since lineages in this work were 
sequenced throughout evolution, it is possible to use these ‘fossil’ 
DNA sequences to view evolutionary dynamics on a phylogeny. 
When viewed as a phylogeny it can be seen that early populations have 
wtTEV as last common ancestor (Figure D-12) in agreement with 
mutations being accumulated across the gene. Later populations, 
however, are descended from non-wt nodes, consistent with the 
enrichment of mutation cohorts in Figure D-9. The co-enrichment of 
mutation cohorts is common in situations of high mutation rate and 
strong selection275. 
The phylogeny shows that these mutation cohorts were enriched, not 
as the result of a single sequence becoming more common, but due to 
the descendants of a particular sequence being more common. 
In the case of the µ=1.5% lineage (Figure D-12b), node sequence TEV-
β1 appears in round 3 and its descendants proliferate until they are 
outcompeted by descendants of TEV-β2 in rounds 9-11. A similar 
trend is seen for the µ=0.5% lineage (Figure D-12a) but with TEV-α1 
and TEV-α2 cofounding later populations, i.e. neither are extinct by 
round 11. These phylogenetic topologies suggests that the node 
sequences (α1, α2, β1 & β2) are more extinction-resistant than wtTEV 
and other members of their population.  
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Figure D-12 | Ne=104 Lineage phylogenies 
Phylogenetic trees of (a) the µ=0.5% lineage and (b) the µ=1.5% lineage. Small circles 
indicate 100 sequences from each of rounds 1,3,5,7,9,11 that were aligned and used to 
generate each phylogeny. Large circles indicate wtTEV (red) and reconstructed nodes 
(grey). 
The observation that these node sequences appeared to be more 
evolvable could be confirmed by reconstructing and characterising the 
node enzymes. Ancestral gene reconstruction is increasingly used to 
check predictions about the properties of ancient enzymes276,277. 
Phylogenetic methods implicitly generate the most likely sequence of 
each node anyway and whole gene synthesis is becoming economical. 
The same technique is even more applicable to the phylogenies 
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generated here. The deep sequencing of very similar genes gives a high 
degree of certainty when inferring node sequences. 
I therefore did this for the genes of four ‘ancestral’ node genes, two 
from each of the µ=0.5% and µ=1.5% lineages (Table D-1 & Figure 
D-13). The ancestral node sequences were inferred by the phylogenetic 
trees of late round populations (7, 9 & 11). I was able to observe all 
predicted node sequences in the sequencing results of earlier rounds, 
confirming that they genuinely existed. Since the forward and reverse 
halves of the gene were sequenced separately, the two half-reads were 
stitched together based on tree topology. Finally, the correct pairing of 
the two gene halves was confirmed by full length Sanger sequencing of 
individual descendants from later rounds. 
 
Table D-1 | Reconstructed node summary (Ne=104 lineages) 
List of the mutations in each reconstructed node sequences relative to wtTEV 
Figure D-13 | Reconstructed node mutation locations (Ne=104 lineages) 
Amino acid mutation locations in α1, α2, β1 and β2 (a-d) mapped onto the structure of 
wtTEV (PDB 1lvm). Substrate in black, catalytic triad in red, mutations in grey. 
The reconstructed nodes each contained 9-10 nucleotide mutations 
compared to wtTEV, only 3 to 7 of which were non-synonymous (Table 
NAME FIRST SEEN
IN ROUND
AMINO ACID MUTATIONS
α1 7 P8Q, P13T, Q58R, N68T, F139L, S153N, R203G, 
α2 9 K6M, P8S, H61Q, F132S, D136E, F162L, T191R
β1 3 Q58R, S123N, W202R
β2 5 S15A, T29S, K67R, D148V, S200R, E223STOP
a b
c d
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D-1). The only recurring mutation was Q58R independently evolved 
in α1 and β1 (using different codons). P8 was also mutated to polar 
residues in α1 and α2. The C-terminal truncation at residue 223 in β2 
is interesting as a similar truncation was also observed in the TEV 
evolution experiment for increased activity using a mutant nucleophile 
reported in Chapter C. This convergence suggests that the C-terminal 
truncation in TEVSerVI may have been an adaptation to increase 
robustness in that system as well. 
As hypothesised, the enzymes that these genes encode displayed 
higher tolerance to mutations (Figure D-14a). At low mutation rates 
(µ=0.5%) all reconstructed nodes showed >90% of variants that still 
retained wt-like activity upon mutation. Even at high mutation rates 
(µ=2.0%) which leave only 10% of wtTEV variants active, 
reconstructed nodes displayed >50% active mutants. Using the µ=2.0% 
mutation rate, I calculate τsub=0.89 for β1, τsub=0.95 for α1 and 
τsub=0.96 for α2 and β2 (for wtTEV τsub=0.74). This validates the 
hypothesis that these node sequences encode particularly mutation 
tolerant enzymes. 
 
Figure D-14 | Robustness of reconstructed node sequences 
(a) Mutational tolerance to µ=0.5% (white) µ=1.0% (grey) and µ=2.0% (black) amino acid 
mutations per protein, (b) kcat/KM activity in M-1 min-1 and (c) soluble expression after 4 
hours (black) and 16 hours (grey). 
Indeed, the smaller improvement in mutation tolerance of β1 over 
wtTEV may explain why it was outcompeted by β2. Conversely, α1 and 
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α2 have almost the same mutation tolerance in agreement with the 
persistence of descendants of both variants in later rounds. 
In order to assess the underlying biophysical and biochemical 
determinants of the observed robustness, I purified the enzymes for 
characterisation. All reconstructed nodes had reduced kcat/KM relative 
to wtTEV (Figure D-14b) in line with the generally reduced population 
average activity (Figure D-10). However, they showed increased soluble 
expression levels (Figure D-14c). The variants with the highest 
mutation tolerance (α2 and β2) showed both the highest activity and 
soluble expression among reconstructed nodes. This agrees with the 
high retention of solubility after mutation (Figure D-11b) in the 
populations descended from these nodes. 
Mutations frequently reduce the stability of enzymes169,278 and it is 
known that wtTEV is poorly soluble and prone to aggregation216–218.  
Together, these results imply that structure robustness, particularly 
resistance to aggregation, is a key aspect of the extreme mutation 
tolerance observed in the reconstructed enzymes. 
3.5 EMERGENCE OF ROBUSTNESS REQUIRES LARGE EFFECTIVE POPULATION SIZE 
By way of comparison, analogous experiments were performed in 
which a smaller effective population of only 2x102 variants (Ne=102) 
were selected at each round. As mutation rates (µ=0.5% or 1.5%) and 
screened library size (N=106) were kept constant, these parallel lineages 
report on the effects of bottlenecks in the effective population size 
only. In this way it is possible to disentangle the two effects of a smaller 
variation pool (N kept constant) and the effect of drift (Ne varied by 
two orders of magnitude) and address the theoretical predictions 
introduced in section 2.2. 
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Under these conditions, neither of the lineages recovered tolerance 
(Figure D-15Error! Reference source not found.). At µ=0.5%, tolerance 
remained constantly below τ1.5<0.15. When µ=1.5%, tolerance only 
transiently increased, peaking at τ1.5=0.75 in round 8 (≈4% amino acid 
variation) but quickly fell to τ1.5=0.00 causing lineage extinction. This 
contrasts with the results of the Ne=104 lineages (Figure D-8) and 
indicates that restriction in the number of variants used leads to, in the 
best scenario, stochastic variations in robustness and does not allow 
the fixation extinction-resistant populations. 
 
Figure D-15 | Mutation tolerance (Ne=102 lineages) 
Change in mutational tolerance over evolution at mutation rates µ=0.5% (white circles) 
or µ=1.5% (grey circles) non synonymous mutations per codon per round in lineages with 
Ne=102. Tolerance measured as the proportion of variants retaining wt-like activity after 
mutagenesis (i.e. τ0.5% for µ=0.5% of codons per gene and τ1.5% for µ=1.5%) 
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The restricted effective population size (Ne=102) had effects on the 
efficacy of selection for both populations. The lack of highly robust 
variants generated in the µ=0.5% lineage may be due to the low 
accepted mutation rate (total amino acid diversity is never >2%) and 
therefore insufficient sequences were sampled to find effective, 
robust variants. Alternatively it may be due to the stochastic purging 
of otherwise robust variants by genetic drift in the small effective 
populations.
 
Figure D-16 | Mutation accumulation by structural region (Ne=102 lineages) 
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(a) Changes in frequency of non-wt residues in the µ=0.5% lineage plotted by sequence. 
(b) Mutation accumulation separated by triad interaction shell with residues <4Å from 
the catalytic triad (light red), 4-8Å from the catalytic triad (red) and >8Å from the catalytic 
triad (dark red). (c) Mutation accumulation separated by alanine mutation sensitivity 
(FoldX prediction) with residues predicted to give >3kJmol-1 destabilisation (dark blue) 
and <1kJmol-1 destabilisation (light blue). (d) Mutation accumulation separated by 
disorder prediction (IUPred) with residues with disorder prediction >0.6 (light purple) and 
<0.2 (dark purple). (e) Mutation accumulation separated by residues with sequence 
conservation within the viral C4 proteases of >0.9 (green) and all residues (black) (f) 
Round 11 non-wt residue frequency mapped onto structure (residues purged of variation 
in red, enriched in blue). (g-l) Same data for µ=1.5%. 
Mutations were tolerated in regions similar to those seen in in the 
Ne=104 lineages. These regions were away from the catalytic triad 
(Figure D-16b), in residues predicted to be only marginally destabilised 
by alanine mutation (FoldX) (Figure D-16c), and in disordered regions 
(Figure D-16d). However, for the µ=1.5% lineage, the trend was weak 
and mutations were accumulated more evenly through the structure 
(Figure D-16h-l). In particular mutations close to the triad were not 
purged as they were in other lineages. It is tempting to speculate that 
the lack of confinement of mutations to certain structural regions was 
the cause of the extinction of this lineage. 
I also constructed phylogenies for the Ne=102 lineages. The phylogeny 
indicates that the µ=0.5% lineage is dominated by the descendants of a 
variant (TEV-α3) that contains a single mutation V199D (Figure D-17a 
& Table D-2). This did not particularly increase the population’s 
mutation tolerance (Figure D-15Error! Reference source not found.) 
and therefore is likely a chance fixation by genetic drift. 
Conversely, the phylogeny of the µ=1.5% lineage shows dominance of 
round 7 by descendants of TEV-β3, a variant with 3 amino acid 
substitutions (Table D-2b). Later rounds are dominated by the 
descendants of TEV-β4, a direct descendant of β3 with 9 extra 
substitutions and a truncation. The truncation is in fact a convergence 
with the truncation observed in β2. Radiation from β4 is limited in the 
final rounds due to the extinction of the whole lineage when no 
variants remained active after epPCR.  
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Therefore the phylogeny topologies for the Ne=102 lineages reflects 
their failure to evolve increased robustness, in line with predictions 
that large populations are required. Since the number of mutants 
screened at each round was the same (N=106), this is likely not due to a 
smaller pool of variation, but due to the greater stochastic effects of 
drift in agreement with the reduced purging of mutations in the active 
site and regions vital to structure (particularly when µ=1.5%). It is 
worth noting, however, that previous work performed on a P450 
oxidase compared Ne=1 versus Ne=102 found that 102 was sufficient 
for the evolution of robustness187. Theoretical work suggest that 103 is 
roughly the threshold where emergent robustness is expected in 
populations of these mutation rates149. 
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Table D-2 | Reconstructed node summary (Ne=102 lineages) 
List of the mutations in each reconstructed node sequences relative to wtTEV 
Figure D-17 | Ne=102 lineage phylogenies and node mutation locations 
Phylogenetic trees of (a) the µ=0.5% lineage and (b) the µ=1.5% lineage. Small circles 
indicate 100 sequences from each of rounds 1,3,5,7,9,11 that were aligned and used to 
generate each phylogeny. Large circles indicate wtTEV (red) and reconstructed nodes 
(grey). Amino acid mutation locations in α3, β3 and β4 (c-e) mapped onto the structure 
of wtTEV (PDB 1lvm). Substrate in black, catalytic triad in red, mutations in grey.  
NAME FIRST SEEN
IN ROUND
AMINO ACID MUTATIONS
α3 9 V199D
β3 3 D78E, S120N, D127E
β4 7 K3R, T22M, D78E, K119E, S120N, D127E, S153C, 
T175S, K184E, F186L, S208P, W211R, E223STOP
5 nt mutations
wtTEV
Round 1
Round 3
Round 5
Round 7
Round 9
Round 11
a
b
c
d
eβ3
β4
α3
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4 CONCLUSIONS 
By coupling high-throughput experimental evolution and deep 
sequencing I was able to reconstruct a complex sequence of 
evolutionary events. The results presented here indicate that neutrally 
evolving populations of enzymes can find robust enzyme variants in 
the local neutral network around wtTEV. These robust variants have 
higher mutation tolerance and hence their descendants are 
overrepresented in later populations. In this way robustness can evolve 
by simply selecting for preservation of wild-type function in the face of 
mutations. The robustness of natural enzyme folds may, in part, be an 
emergent property of such forces. Additionally, these results also 
indicate that mimicking neutral processes can be used as an enzyme 
engineering method to accumulate mutations to increase robustness 
and so manipulate evolvability. 
wtTEV already has higher mutation tolerance (τsub=0.76) than 
previously measured proteins50,79,144,256 (average τsub=0.65±0.02), 
possibly an adaptation to the high mutation rate of viral 
geneomes267,269,279. Viruses are known to have lower tolerance to 
random nucleotide mutations than cellular organisms154. In the 
absence of robustness mechanisms such as genetic redundancy and 
alternative metabolic pathways, higher protein structure robustness 
may be an adaptation to achieve viable mutation tolerance. 
Deep-sequencing allowed me to follow the populations’ evolution in 
molecular detail. This showed how mutations were purged from 
enzyme regions essential for its function254 (close to the catalytic triad) 
and its stability (those predicted to have high order propensity and to 
be key to fold stability). It also revealed how some mutations were 
enriched above the background rate of mutagenesis, indicating positive 
selection. 
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In both high and low mutation rate lineages, selection for neutrality 
lead to the erosion of mutation tolerance until amino acid diversity of 
≈2% accumulated. Once this point was reached most variants, 
although functional, were sensitive to mutation (average τ0.5%=0.08 
and τ1.5%=0.06) and those variants eventually went extinct. However, 
when the effective population size is large (Ne=104), populations 
contain a small number of variants with increased robustness. 
Deep-sequencing also allowed the phylogenies of the evolving lineages 
to be built. Using the lineage phylogenies, I reconstructed four node 
enzymes. Only a single mutation convergently evolved in two, 
highlighting the diverse set of solutions to the problem of mutation 
tolerance. Despite the lack of common mutations, there are common 
properties. All have reduced kcat/KM activities but increased soluble 
expression compared to wtTEV. Additionally their descendants retain 
solubility after mutation better than wtTEV. The wtTEV enzyme is 
known to be highly insoluble and this resistance to aggregation both 
before and after mutation indicates greater protein structure 
robustness. 
This structural robustness drastically increases mutation tolerance of 
the reconstructed enzymes. Three of these (α1, α2, β2) have tolerance 
to random amino acid mutation of τsub>0.95 (compared to τsub=0.76 for 
wtTEV and τsub≈0.66 for an average protein144). This mutation 
tolerance indicates that they have a high proportion of neutral 
neighbours and are therefore in a more interconnected region of the 
neutral network. Though these robust variants exist in the population 
only transiently, the high retention of fitness by their mutant 
descendants causes disproportionate neutral sequence radiation. This 
sequence radiation demonstrates how second order selection for 
robustness can result from direct selection for maintenance of wild 
type activity. 
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Chapter E -  Adaptive evolvability and 
changing cleavage specificity 
1 SUMMARY 
Building on the results of Chapter D, I demonstrate how the 
accumulation of mutations neutral to activity on the native substrate 
can increase evolvability for sequence specificity changes. During 
neutral evolution, the frequency of fortuitous adaptive mutations 
fluctuated stochastically, with pronounced effects on the ‘immediate 
evolvability’ in response to selection. Additionally, later, robust 
populations had increased ‘long-term evolvability’ enabling higher 
activity after several rounds of adaptive evolution. In addition to 
shedding light on the evolution of evolvability, these results suggest ways 
of manipulating the sequence specificity of proteases for therapeutic and 
biotechnological applications. 
 
 
  
 
 
Parts of this chapter and Chapter D have been combined and prepared for publication: 
Shafee, T., Gatti-Lafranconi, P., Minter, R., Hollfelder, F. 
Neutral evolution – two combined mechanisms generate robust and evolvable enzymes. MBE. (2013) 
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2 INTRODUCTION 
2.1 EVOLVABILITY OF ENZYMES 
Enzyme evolvability is the propensity of an enzyme (or population of 
enzyme variants) to acquire new functions by mutation and selection. 
The generation and improvement of, promiscuous functions provides 
a starting source of adaptive variation for evolution. In experimental 
measurements of adaptive evolvability of enzymes, several outcomes 
affect the response to a novel selection pressure. Even if the whole 
population does not display a promiscuous activity, some individual 
variants may be adapted, or have high potential for adaptive evolution. 
I will therefore separate ‘immediate’ and ‘long-term’ evolvability.  
Immediate evolvability is how well a population can adapt by selection 
from standing variation alone. It is dependent on the population size 
(number of variants), the number of those variants that are unique 
(heterogeneity), and whether any variants have new promiscuous 
activities that do not compromise the native activity. Immediate 
evolvability, therefore, dictates the maximum promiscuous activity 
that can be selected from that population without further mutations. 
Long-term evolvability determines the maximum activity after several, 
iterative rounds of mutagenesis and selection. It partly depends on 
adaptive standing (as with immediate evolvability) variation but also on 
the frequency and magnitude of beneficial, de novo mutations. For 
example, robustness could increase evolvability if a stable scaffold can 
compensate for destabilising adaptive mutations in the active 
site273,280–282. Experiments suggest that this is the case if the active site 
and scaffold are separated in the structure72,273,283 allowing ‘global 
suppressor’ mutations. 
 
Standing variation 
Genetic variation present in 
a heterogeneous 
population 
 
Immediate evolvability 
The potential for adaptive 
evolution provided by 
standing variation by 
selection but no further 
mutation 
 
Long-term evolvability 
The for adaptive evolution 
provided by both standing 
variation and new 
mutations 
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2.2 NEUTRAL MUTATIONS AND CRYPTIC VARIATION 
Interest in the interplay between drift and selection started in the 1930s 
when the shifting-balance theory proposed that, in some situations, 
genetic drift could facilitate later adaptive evolution284. Although this 
theory was largely discredited285 it drew attention to possibility that 
drift can generate cryptic variation that, though neutral to current 
function, may affect selection for new functions127,189,286,287. 
In terms of sequence space, current theories predict that if the neutral 
networks for two activities overlap, a neutrally evolving population 
may diffuse to regions of the neutral network of the first activity that 
allow it to access a second146,148,288,289 (Figure E-1). This would only be 
the case when the distance between activities is smaller than the 
distance that a neutrally evolving population can cover. The degree of 
inter-penetration of the two networks will determine how common 
cryptic variation for the promiscuous activity is in sequence space. 
 
Figure E-1 | Two overlapping neutral networks 
A large set of ‘lattice model’ protein genes generated in silico (top) contain two neutral 
networks of Structure A (blue) and Structure B (red). Each black dash represents a 
sequence, the lines connecting them represent mutations. When viewed as a fitness 
landscape (bottom), they form two overlapping peaks. It is possible for a neutrally 
evolving sequence to mutate to the edge of network A (a1⟶a2⟶a/b) and arrive at a 
promiscuous sequence that exists in both neutral networks. From there is this possible to 
evolve to new structure B specialist (a/b⟶b1). (Adapted from reference288) 
Sequence space
Sequence space
 
Cryptic variation 
Genetic variation that 
introduces promiscuous 
activities to some members 
of a population 
 
 
Chapter E - Adaptive evolvability and changing cleavage specificity 
119 
Evidence is accumulating that mutations neutral to native function can 
be rich in cryptic variation that though unselected, may affect 
immediate evolvability188,290,291. For example, accumulation of neutral 
mutations in P450s, caused up to 4-fold changes in six measured 
promiscuous activities290 (Table E-1). Similarly, in β-lactamase, 
neutrally evolved populations contained slightly more variants that 
conferred resistance to cefotaxime than the mutagenised wild type188. 
Conversely, experiments on immediate evolvability of β-glucuronidase 
indicate that pools of neutral mutants can be less rich in adaptive 
mutations than random mutants. In this case, the most adaptive 
mutations and mutation combinations trade-off with the original 
activity and so are not present in neutrally evolved 
populations26,53,292,293. 
ENZYME 
ROUNDS OF 
NEUTRAL 
EVOLUTION TARGET SUBSTRATE 
MOST 
IMPROVED 
VARIANT 
P450 oxidase 15 propranolol 1.6 - fold 
  11-phenoxyundecanoic acid 2.2 - fold 
  2-amino-5-chlorobenzoxazole 3.2 - fold 
  1,2-methylenedioxybenzene 2.6 - fold 
  2- phenoxyethanol 4.1 - fold 
β-glucuronidase 4 β-galactose 3.9 - fold 
paraoxonase 1 1-3 mixed paraoxon 2.2 - fold 
  2-naphtylacetate 5.0 - fold 
  dihydrocoumarin 1.8 - fold 
  O-acetoxy-7-hydroxycoumarin 2.1 - fold 
  5-thiobutyl butyrolactone 1.9 - fold 
  
7-O-diethylphosphoryl-3-cyano-
7-hydroxycoumarin 
2.4 - fold 
   
FREQUENCY 
INCREASE 
β-lactamase 18 0.5 µM cefotaxime 1.7 - fold 
  0.8 µM cefotaxime 1.8 - fold 
  1.0 µM cefotaxime 1.1 - fold 
  2.0 µM cefotaxime 1.1 - fold 
  5.0 µM cefotaxime * 
Table E-1 | Previously measured immediate evolvabilities 
Improvement in a promiscuous activity in the best variant isolated from neutrally evolved 
populations. Fold improvements calculated from reported kcat/KM activities for P450 
oxidase and β-glucuronidase, calculated from ‘specific activity’ for paraoxonase 1. Since 
activities of individual variants were not reported for β-lactamase, the frequency of 
variants surviving a particular antibiotic concentration (normalised to an error prone PCR 
library) was used. * indicates that the wt enzyme library had no surviving colonies, the 
neutrally evolved population had 1.5% survival. (Data from references188,290,291,293) 
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Observations that neutral evolution can increase enzyme robustness187 
(see Chapter D) indicate that long-term evolvability might also be 
affected as more mutation-tolerant enzymes may better tolerate the 
introduction of adaptive, but destabilising mutations180,273,281. Long-
term evolvability has been described for organisms including 
bacteria186 and algae294 but comparative studies of protein long-term 
evolvability are largely theoretical72,295,296. Substrate specificity is 
therefore a good model to study evolvability, although available studies 
have not, so far, addressed immediate and long term evolvability 
independently. 
2.3 PROTEASE SPECIFICITY ENGINEERING 
Directed evolution has proven to be a successful method for altering 
protease specificity297. In the last two years, three publications on TEV 
protease have shown changes in specificity for the residue before224 
and after114,214 the cleaved peptide bond at the P1 and P1’ positions 
(Table E-2). 
A cell survival selection system was created based on cleavage of a 
modular transcription repressor allowing expression of a kanamycin 
resistance gene. This system isolated a TEV variant active on a 
substrate with aspartate at the P1’ position114 after 3 rounds of 
selection. The final variant had 14 mutations and was 3-fold more 
active on the target substrate and 92-fold less active on the native. 
A GFP-RFP fluorescence assay has been used to select for activity on a 
substrate with arginine at the P1’ position214. Though never kinetically 
quantified, the isolated variant after 4 rounds had almost 2-fold higher 
specific activity on the target sequence and showed general broadening 
of sequence preference at the P1’ position.  This was achieved through 
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a mutation that may increase flexibility of the loop forming the 
substrate binding tunnel. 
Finally, altered specificity at the P1 position has been attempted224. 
This was a much greater challenge than the previous two works listed 
as the specificity at this position is strict and evolutionarily conserved. 
The Yeast Endoplasmic reticulum Screening System (YESS) couples 
protease activity to display of affinity tags on the surface of the yeast 
cell are then fluorescently labelled. A library of substrates randomised 
at the P1 position was screened against a library of proteases 
randomised around the P1 pocket whilst also counter-selecting against 
cleavage of the native sequence. The system isolated variants active on 
either P1 glutamate or histidine. The efficacy of the screening system 
led to one variant which had 500-fold improvement on the glutamate 
substrate with a 10-fold reduction on the native, whilst another was 20-
fold improved on the histidine substrate and 50-fold reduced on the 
native. 
TARGET 
SEQUENCE  
DIFFERENCES 
TO NATIVE 
SELECTION/ 
SCREENING 
SYSTEM 
MOST 
IMPROVED 
VARIANT 
ENLYFQD 1 Split repressor 3.4 - fold 
ENLYFQR 1 GFP-RFP FRET 1.8 - fold 
ENLYFES 1 YESS 500 - fold 
ENLYFHS 1 YESS 20 - fold 
Table E-2 | Previously achieved TEV protease specificity changes 
Improvement in a promiscuous cleavage activity in a variant isolated through directed 
evolution towards that sequence. Fold improvements calculated from reported kcat/KM 
activities for split repressor and YESS systems, calculated from ‘specific activity’ for GFP-
RFP FRET screening system. (Data from references114,214,224) 
A next step in controlling protease specificity is activity on substrates 
with multiple residue differences to the native preference sequence. 
Such substrates represent a far greater evolutionary challenge and so 
improved understanding of evolutionary potential and how to 
influence it is required. I therefore use protease specificity changes as 
a suitable measure of adaptive evolution when investigating 
evolvability. 
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2.4 CLINICAL APPLICATIONS 
Protease therapeutics and biotechnology tools provide a suitable 
benchmark for the practical application of evolvability research. The 
foremost application for the control of protease specificity is as an 
alternative to antibody therapeutics. Antibodies are protein binders 
that evolved in vertebrates as part of the immune system to identify and 
neutralise foreign objects in the body298. Antibody therapeutics work 
by binding to a pathogenic target cell or protein to prevent its action299. 
Use of antibodies as drugs started in 1989 with Muromonab-CD3, a 
mouse anti-CD3 antibody that acts as an immunosuppressant299,300. 
Since then, antibodies have proved highly successful with 
Adalimumab the 7th highest grossing drug (£41 billion in 2011)301 and 
over a hundred antibody drugs currently in clinical trials302,303. 
In a similar way, if a protease could be made to be specific to a single, 
chosen target (to avoid off-target effects), it should be able to perform 
much the same function by cleaving that target (Figure E-2). This 
would have the benefit over antibody therapeutics of being capable of 
multiple catalytic turnover, and so require a lower dose. 
 
Figure E-2 | Protease therapeutic concept 
A schematic of possible protease targets. A protease therapeutic could cleave a 
pathogenic soluble protein such as an overexpressed signal ligand. Alternatively, it could 
cleave the extracellular portion of a receptor in order to down-regulate it. (Adapted from 
reference304) 
Protease targets 
soluble signal 
protein in blood
Protease targets 
extracellular portion 
of membrane 
anchored receptor
Signal 
ligand
Signal 
receptor
Cell 
membrane
Signal 
receptor
(intracellular)
(extracellular)
 
Therapeutic antibody 
Use of antibodies to bind 
and neutralise target 
pathogenic proteins due to 
their high specificity and 
affinity 
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Generating bespoke antibodies is now routine as it is possible to 
manipulate the biological systems that already exist in nature for 
generating specific protein binders. Additionally, established selection 
protocols allow for affinity maturation in vitro to further enhance 
binding. Conversely, there are currently no such protocols for 
manipulating protease specificity (as mentioned in Section 2.3). The 
development of protease cleavage engineering will advance it as an 
alternative technology to binding-based biological therapeutics. 
In this work I apply experimental evolutionary techniques in an 
attempt to understand the evolution of evolvability and, in so doing, 
develop methods for protease specificity engineering. I use the TEV 
protease lineages that were neutrally evolved on the native sequence 
(generated in Chapter D) to investigate the changes in promiscuity, 
immediate evolvability and long-term evolvability as a product of neutral 
evolution. 
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3 RESULTS AND DISCUSSION 
3.1 TARGET SEQUENCE CHOICE 
As suitable targets for adaptive evolution, I searched for sequences in 
human proteins that had the following properties: 
 The sequence shows some level of promiscuous cleavage by wtTEV 
 Appears in a region that is flexible enough to be protease accessible 
 Cleavage of the protein is likely to have a biological effect 
I used the list of therapeutic antibody Stage 3 and Stage 4 targets 
(provided by Ralph Minter, Table E-3). If stoichiometric binding by an 
antibody gives a biological effect, then multiple turnover by a protease 
also has a high chance of effect. Therapeutic antibodies were excluded 
if the effect has been shown to not be due to simple binding. 
  SECRETED MEMBRANE 
  TARGET DISEASE GENERIC  COMMERCIAL  TARGET DISEASE GENERIC  COMMERCIAL  
A
P
P
R
O
V
ED
 
VEGF-A Cancer Bevacizumab Avastin a4b1 MS Natalizumab Tysabri 
IgE Asthma Omalizumab Xolair EGFR Cancer Cetuximab Erbitux 
TNFa RA Adalimumab Humira HER2 Cancer Trastuzumab Herceptin 
IL6 RA Tocilizumab Actemra BLyS SLE Belimumab Benlysta 
IL12/23 Psoriasis Ustekinumab Stelara         
IL1b CAPS Canakinumab Ilaris         
RANKL Osteoporosis Denusomab Prolia         
C5 PNH Eculizumab Soliris         
C
LI
N
IC
A
L 
TR
IA
LS
 
HGF Cancer Rilotumumab AMG102 CSF1R Cancer   AMG820 
IGF1/2 Cancer   MEDI-573 HER3 Cancer   AMG888 
Ang-2 Cancer     IGF1R Cancer Ganitumab AMG479 
CCL2 Cancer     FGFR Cancer   RG7444 
EGFL7 Cancer     C-Met Cancer Onartuzumab RG3638 
        Flt-3 Cancer   IMC-EB10 
        RON Cancer   IMC-RON8 
        PDGFRa Cancer   MEDI-575 
        VEGFR1 Cancer Icrucumab IMC-18F1 
        VEGFR2 Cancer Ramucirumab IMC-1121B 
        CTLA4 Cancer     
        CXCR4 Cancer     
        DLL4 Cancer     
        FGFR3 Cancer     
        PD1 Cancer     
        PDL1 Cancer     
Table E-3 | Target protein list 
Targets of antibody therapeutics (as of 2012). Excluded are antibody/complement-
directed cellular cytotoxicity targets and agonist mAb targets. Highlighted are the targets 
found to have sequences in loop regions which contain the sequence pattern 
[EDVQRSGT]-x-[LIVAHTYP]-[YLIHWFMVRKAT]-x-Q-{P} by ExPASy ScanProsite305 (Table E-4). 
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Flexible loop regions were identified by examining the published 
structures for regions with high B-factor (Figure E-3a). These loops 
were cross-correlated with computational predictions of disorder 
(IUPred306, Figure E-3b) and compiled into a list (Figure E-3c). 
 
Figure E-3 | Identification of flexible target loop regions 
Structure of PDL1 (PDB code 3bik). (a) B-factor map (a measure of disorder within the X-
ray crystal structure). Regions identified with high B-factor (e.g. 1, 2 & 3) (b) Predicted 
disorder score by primary sequence (IUpred306). Loops were cross-referenced with this 
disorder prediction (loops 1, 2 & 3 indicated). (c) Final loops shown on structure in red 
compiled into FASTA list which was searched for loops with sequence patterns that may 
be cleaved by wtTEV. Indicated is one such loop, PDL-1. 
In order to maximize the probability of finding some level of 
promiscuous activity by wtTEV I searched this list for sequence 
patterns of residues similar to the canonical cleavage sequence of 
wtTEV211,222,223: 
[EDVQRSGT]-[x]-[LIVAHTYP]-[YLIHWFMVRKAT]-[x]-[Q]-{P} 
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Residues are separated by dashes. Allowed residues are contained in [] 
brackets and disallowed residues in {} brackets ‘x’ indicates any amino 
acid. Four target proteins contained loops satisfying these criteria 
(Figure E-4), each with ≥4 differences to the native ENLYFQ\S 
sequence (Table E-4). 
     
Figure E-4 | Target structures and loop sequences 
The 4 target proteins identified as having putative cleavable loops (shown in red). (a) 
Programmed death inhibitory ligand, (b) Vascular endothelial growth factor receptor 2, 
(c) B lymphocyte stimulator, (d) Interleukin-23. (e) Cutaway of the binding tunnel of 
wtTEV (PDB code 1lvb). Substrate shown with residues in alternating light and dark blue 
and labelled. Triad shown in red. 
Table E-4 | Target sequences 
The 4 target sequences identified as having putative cleavable loops by wtTEV. Sequence 
similarity is denoted by ‘*’ = identical. ‘:’ = conservative. ‘.’ = semi-conservative. 
For eventual practical use of evolved TEV variants, the enzyme would 
need to cleave the sequence in the context of the true target structure. 
These experiments, however, concentrate on the evolution and 
manipulation of enzyme sequence specificity and so the sequences are 
only assayed in an idealized context of the flexible CFP-YFP linker. 
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3.2 PROMISCUOUS CLEAVAGE OF TARGET SEQUENCES 
The 4 loop sequences were cloned into the linker sequence between 
CFP and YFP in the pC-Y plasmid by synthesising the oligonucleotide 
sequences encoding the linker and ligating that directly into the 
digested plasmid. The substrate names and linker sequences are listed 
in Table E-5. Activity of wtTEV on C-Y(pdl) and C-Y(veg) was 97- and 
13,000-fold lower respectively compared to activity on the native 
sequence, C-Y(tev). Conversely, there was no detectable cleavage of the 
substrates with 5 residue differences, C-Y(il23) and C-Y(blys). 
GENE NAME 
LINKER 
SEQUENCE 
DIFFERENCE 
TO NATIVE KCAT /KM 
C-Y(tev) ENLYFQS  - 1.9x104 
C-Y(pdl) EDLKVQH 4 2.0x102 
C-Y(veg) RDLKTQS 4 1.5x100 
C-Y(blys) ETPTIQK 5 < 1x10-1 
C-Y(il23) DILKDQK 5 < 1x10-1 
Table E-5 | CFP-YFP target linker variants 
Amino acid sequences of C-Y linkers. Residues differing from the native preference 
sequence are underlined. kcat/KM in min-1 M-1. 
Since C-Y(veg) had the lowest detectable activity it was chosen as the 
largest challenge for the most in depth analyses, however directed 
evolution results will be presented on all 4 substrate sequences. 
3.3 NEUTRAL EVOLUTION ERODES AVERAGE PROMISCUITY 
TEV was previously neutrally evolved on the native cleavage sequence 
C-Y(tev) in Chapter D to generate lineages of neutral variants. For this 
specificity evolution study, I have used the µ=1.5%, Ne=104 lineage 
(mutations introduced at 1.5% per codon per round, 104 variants 
retaining wt-like activity selected each round). This population 
showed the greatest final tolerance to mutations (Chapter D & Figure 
D-8) and so was chosen to investigate the effects of neutral mutations 
on adaptive evolution for new substrate specificities. In this chapter I 
will refer to populations as ‘x,y’ where ‘x’ is the number of  rounds of 
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neutral evolution on C-Y(tev), and ‘y’ is the number of rounds of 
adaptive evolution on C-Y(veg) (Figure E-5). Hence, population 7,3 
indicates that seven rounds of evolution on C-Y(tev) were followed by 
three rounds of evolution on C-Y(veg), and so on. 
 
Figure E-5 | Summary and nomenclature of C-Y(veg) evolution lineages 
Schematic of neutral evolution on the native sequence (black) from which several 
evolutions for new function (green) were performed. Populations are named by these 
coordinates: rounds of evolution on C-Y(tev), on C-Y(veg). 
To test for detectability of promiscuous activities of wtTEV in this 
system, I first looked at cleavage of three ‘substrate libraries’. In each 
substrate library, two of the substrate residues were randomised (NNS 
codon) to generate 400 variant substrates. The library of substrates 
could be co-expressed with the wtTEV protease in the same way that 
previously I have expressed libraries of proteases with a single substrate 
and measures by FACS. 
Substrates showed a roughly bimodal distribution of cleavage, as seen 
in libraries of proteases in Chapter D. The percentage of substrates 
cleaved by wtTEV is an indicator of how many of these sequences are 
promiscuous substrates (Figure E-6a).  Equally, the same experiment 
with libraries of proteases shows the average promiscuity of the enzyme 
population on the substrate library. Although cleavage of these 
substrate libraries does not directly demonstrate which sequences were 
cleaved, sorting and sequencing cleaved substrates would allow 
measurement of sequence specificity222,223. 
-1
0
1
2
3
-1 0 1 2 3 4 5 6 7 8 9 10 11
Rounds of neutral evolution on C-Y(tev)
5,1
0,3 7,3
R
o
u
n
d
s 
o
f 
ad
ap
ti
ve
 e
vo
lu
ti
o
n
 o
n
 C
-Y
(v
eg
)
Chapter E - Adaptive evolvability and changing cleavage specificity 
129 
Since C-Y(P34xx) showed an intermediate number of substrates 
cleaved I used that substrate library to test how promiscuity of the 
neutrally evolving lineage changed over multiple rounds of neutral 
evolution (Figure E-6b). The neutrally evolving lineage showed slightly 
reduced and fluctuating promiscuity towards the C-Y(P34xx) library. 
  
Figure E-6 | Promiscuity on randomised substrate libraries 
(a) The percentage of substrates cleaved when wtTEV is co-expressed with C-Y(P56xx) 
(black), C-Y(P34xx) (grey), C-Y(P12xx) (white). (b) The percentage of substrates cleaved 
when neutrally evolved populations are co-expressed with C-Y(P34xx). 
The mixed enzyme populations of the neutral lineage (at rounds 0, 1, 
3, 5, 7, 9 & 11) were also purified in order to measure average kcat/KM 
activity on C-Y(veg) in vitro. The populations did not show any increase 
in activity on the promiscuous substrate, in fact the average 
promiscuous kcat/KM activity on C-Y(veg) falls below the detection 
threshold (Table E-6). Together, the reduction in promiscuity on the 
substrate C-Y(veg) and the substrate library C-Y(P34xx) indicate that 
the absence of selection leads to loss of promiscuity, not specificity. 
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POPULATION  
KCAT /KM  
C-Y(VEG) 
wtTEV  2.0x102 
1,0  < 1x10-1 
3,0  < 1x10-1 
5,0  < 1x10-1 
7,0  < 1x10-1 
9,0  < 1x10-1 
11,0  < 1x10-1 
Table E-6 | Population average promiscuous activity on C-Y(veg) 
Kcat/KM values (M-1 min-1) in vitro for mixed purified enzyme population cleavage of C-
Y(veg). 
3.4 NEUTRAL EVOLUTION GENERATES FLUCTUATING IMMEDIATE EVOLVABILITY 
Although the populations lost activity on C-Y(veg) on average, there 
might be minority members that do show promiscuous activity. To test 
whether promiscuity towards the target sequence C-Y(veg) changed 
significantly during the neutral evolution lineage, I performed a 
selection for C-Y(veg) cleavage on the enzyme populations without 
further mutagenesis (Figure E-7). Selection pressure was applied by 2 
rounds of FACS enrichment of the top 1% most active variants on C-
Y(veg). The response to selection for a particular substrate by a 
population is a measure of its immediate evolvability as it depends on 
whether there are fortuitous adaptive variants in the standing 
variation. 
 
Figure E-7 | Immediate evolvability along neutral evolution 
Median FRET ratio of populations being selected for activity on C-Y(veg) (two rounds of 
enrichment) after 0-11 rounds of neutral evolution on C-Y(tev). FRET ratio normalised to 
the median ratio of cells expressing wtTEV and C-Y(tev). The population from which 
variant Va was isolated is indicated. 
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Populations 5,0 and 11,0 responded to this selection pressure with an 
increase in the population average activity on C-Y(veg), demonstrating 
their high immediate evolvability. From population 5,0 (with the highest 
immediate evolvability) I isolated the most active single variant (TEV-
Va) which showed a 35-fold improvement in kcat/KM over wtTEV on C-
Y(veg). This is somewhat larger than the typical 2 to 5-fold 
promiscuous activity improvements found in variants isolated from 
standing variation in a neutrally evolved lineages188,290,291,293 (Table 
E-1). It is also higher than most previous attempts at protease 
specificity engineering114,214,224. The best of these experiments 
reported a 500-fold improvment224, however this was from first 
randomising the substrate and selecting to ensure an easy target and 
only altering a single residue of specificity. 
The non-linear increase in immediate evolvability as the population 
neutrally evolves indicates that mutations adaptive for C-Y(veg) 
activity are not directly selected for during neutral evolution. Lack of a 
consistent trend along the neutral lineage confirms that C-Y(veg) 
activity is truly an unselected promiscuous activity, i.e. is lost due to 
lack of selection. Therefore, even though the populations on average 
have no activity on C-Y(veg), some populations do contain members 
that do show improved activity. 
The immediate evolvability towards C-Y(veg) also does not correlate 
with the general promiscuity towards C-Y(P34xx), although both 
measures fluctuate along the neutral lineage (Figure E-6b & Figure E-7). 
Therefore, the level of promiscuity in the population does not appear 
to be a good predictor of whether promiscuity for a particular target 
substrate is more likely to be present. 
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3.5 NEUTRAL EVOLUTION INCREASES LONG-TERM EVOLVABILITY 
The immediate evolvability so far presented describes the prevalence of 
fortuitous mutations in a population and is the facet of evolvability 
most commonly addressed in previous studies. To expand upon these 
works, I also measured the potential for further beneficial mutations by 
performing 3 rounds of adaptive evolution on C-Y(veg) (Figure E-8a). 
At each round, diversity was introduced (µ=0.5% of codons per gene 
per round) after which the top 1% most active variants were sorted, re-
expressed and re-sorted to ensure stringent selection (N=106 screened, 
Ne=104 selected). As starting points I used wtTEV and populations 5,0 
and 7,0 from the neutral evolution lineage. These populations 
compared the long-term evolvability of populations which previously 
showed very different levels of immediate evolvability (Figure E-6c). 
    
Figure E-8 | Long-term evolvability on target sequences of neutrally evolved 
populations. 
Median FRET ratio on C-Y(veg) of populations being selected for (a) activity on C-Y(veg), 
(b) C-Y(pdl), (c) C-Y(blys), (d) C-Y(il23). Black circles indicate the lineage starting from 
wtTEV (0,00,3). Grey circles indicate the lineage starting from population neutrally 
evolved on C-Y(tev) for 5 rounds (5,05,3). White circles indicate the lineage starting 
from population neutrally evolved on C-Y(tev) for 7 rounds (7,07,3). The populations 
from which variants Vb, Vc, Vd and Pa were isolated are indicated. 
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For C-Y(veg), each round shows small increase in population median 
activity, however lineage 7,0⟶7,3 shows a fastest rate increase. The 
most active variant isolated from population 0,3 (TEV-Vb) has a 40-
fold faster kcat/KM than wtTEV. This is barely higher than that of Va 
indicating that, by the measure of most active isolatable variant, long-
term evolvability of wtTEV is barely higher than the immediate 
evolvability present in population 5,0 from variation generated by 
neutral evolution alone. 
Average cleavage increased faster for populations that had been 
neutrally evolved. In particular the lineage 5,0⟶5,3 improves rapidly 
but plateaus whereas lineage 7,0⟶7,3 reaches a higher average activity. 
The most active variants from populations 5,3 (TEV-Vc) and 7,3 (TEV-
Vd) were 37 and 203-fold improved respectively (Figure E-9 & Figure 
E-10a). Of note is that Vc (from population 5,3) is directly descended 
from Va (from population 5,0) but shows minimal activity 
improvement, merely slightly increased solubility. Therefore 
populations that have been neutrally evolved show faster adaptive 
evolution and yield more active variants (i.e. long-term evolvability). 
Long-term evolvability was also compared between wtTEV and 
population 7,0 for 3 rounds of adaptive evolution on C-Y(pdl), C-
Y(il23) and C-Y(blys). After 3 rounds of evolution on C-Y(pdl), 
population 7,3(pdl) contained a variant 25-fold improved on C-Y(pdl) 
(TEV-Pa), whereas 3 rounds of evolution from wtTEV yielded no 
improved variants (Figure E-8b). Neither wtTEV nor population 7,0 
showed any improvement on C-Y(il23) or C-Y(blys) after 3 rounds of 
evolution on those substrates (Figure E-8c,d). The higher long-term 
evolvability of population 7,0 appears to be an intrinsic property, rather 
than specific to C-Y(veg) since population 7,0 also showed higher long-
term evolvability for C-Y(pdl) activity than wtTEV. Both C-Y(il23) and 
C-Y(blys) proved too great an evolutionary challenge for this system. 
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Figure E-9 | Activity on C-Y(veg) and C-Y(pdl) for wtTEV and evolved variants 
Activity (kcat/KM) (a) wtTEV and (b) evolved variants on substrates C-Y(pdl) and C-Y(veg). 
Substrate indicated by bar colour (C-Y(tev) in white, C-Y(pdl) in purple, C-Y(veg) in green) 
The purified variants, though showing improved kcat/KM on their 
target sequences, have comparatively little change in the kcat/KM on C-
Y(tev) (Figure E-10b). This indicates that interactions with the new 
substrate are specific rather than a general increase in reactivity. 
   
Figure E-10 | Activity of variants after 3 rounds of evolution on target sequence 
(a) kcat/KM improvement of evolved variants on substrates C-Y(pdl) and C-Y(veg). (b) 
kcat/KM improvement on the original C-Y(tev) substrate of evolved variants. Top row 
indicates rounds of neutral evolution on C-Y(tev). Bottom row indicates rounds of 
adaptive evolution on C-Y(target). 
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3.6 STEPPING-STONES DID NOT AID EVOLUTION ON UN-CLEAVABLE SEQUENCES 
An attempt was also made at circumventing the constraints that 
prevent the evolution of activity on C-Y(il23) and C-Y(blys). Since both 
C-Y(pdl) and C-Y(veg) are cleaved to some extend by wtTEV it was 
possible to narrow down two residues in each substrate that were likely 
the main factors preventing activity. Each of these residues was 
individually introduced into C-Y(tev) as well as being individually 
removed from C-Y(il23) or C-Y(blys) (Table E-7). Residues that were 
preventing cleavage could be spotted by their strong reduction in 
activity when added to C-Y(tev), or their restoration of activity when 
removed from C-Y(target) (Figure E-11). 
 
Table E-7 | Stepping stone substrate CFP-YFP linker variants 
Amino acid sequences of C-Y linkers for il23 and blys ‘stepping stone’ substrates. Substrate 
residues hypothesised to be inhibiting cleavage were introduced to the canonical TEV 
cleavage sequence and removed from the target sequence to produce hybrid sequences. 
Residues differing from the native sequence are underlined. 
Figure E-11 | Stepping stone substrate cleavage in lysate by wtTEV 
Cleavage level of each ‘stepping stone’ substrate by wtTEV in in vitro lysate assay. Top red 
line indicates cleavage of C-Y(tev) native sequence. Lower, dark blue lines indicate 
cleavage of C-Y(il23) and C-Y(blys). Light blue lies indicate cleavage levels of stepping stone 
substrates, either native sequence with target residue added, or target sequence with 
native residue added. 
Some residues such as isoleucine in position P6 gave no change in 
cleavage either when added to C-Y(tev) or when removed from C-
Y(il23), indicating that it is not the cause of cleavage inhibition. 
Addition of proline at P4 almost completely prevented cleavage of C-
Y(tev), however its removal from C-Y(blys) failed to increase cleavage. 
Therefore, although the P4 proline is inhibitory (likely as a β-sheet 
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breaker), the blys sequence must contain several other residues that 
restrict cleavage. 
Of the 4 residues tested, the aspartate in P2 of C-Y(il23) seemed the 
most promising as it caused a 50% reduction in activity when added to 
the native sequence and restored 15% activity when removed from C-
Y(il23) (Figure E-11). Therefore, I performed 3 rounds of adaptive 
evolution on each of C-Y(t+D2) and C-Y(i-D2). I did this starting both 
from wtTEV and from population 7,0. After 3 rounds, however, none 
of these 4 lineages showed any detectable increase in cleavage. 
Together these results indicate that some target sequences are simply 
too challenging for the approaches used here. For activities too far away 
(e.g. C-Y(blys) and C-Y(il23)), neither robust variants nor the wild-type 
showed any evolvability, although it is possible that populations other 
than 7,0 might have greater evolvability for this target. Additionally, 
attempting several stepping stone sequences between C-Y(tev) and C-
Y(target) could make finding stepwise solutions more likely. 
3.7 MUTATIONS THAT UNDERLIE IMMEDIATE AND LONG-TERM EVOLVABILITY 
The isolated improved variants (TEV- Va, Vb, Vc & Vd) contain 
between 5 and 13 amino acid mutations (Figure E-12a-c). Populations 
previously neutrally evolved on C-Y(tev) yielded variants with the most 
mutations due to the accumulated neutral mutations before the 
adaptive evolution rounds.  
The isolated variants all showed mutations in their C-termini which 
forms the flexible lid region of the substrate binding tunnel in viral 
proteases (Figure E-12d-f). This has previously been shown to be 
important in substrate recognition and mutations have previously 
been observed in directed evolution or specificity switched in 
TEV214,224. 
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Additionally, all isolated variants contained N171D or N176I (Figure 
E-12a-c). These two asparagines are responsible for the recognition of 
the aspartate of the native cleavage sequence (ENLYFQ\S) (Figure 
E-13a). In C-Y(veg) the substrate sequence contains arginine in the 
place of aspartate rendering these residues counter-productive and 
removing cationic residues from the P5 binding pocket likely reduces 
repulsion of the C-Y(veg) substrate sequence. 
   
Figure E-12 | Mutation locations and viral substrate tunnel loop 
Mutation positions in isolated from indicated populations with the highest activity on C-
Y(veg) activity mapped onto wtTEV (PDB 1lvm) for (a) TEV-Va (5,0), (b) TEV-Vb (0,3), and 
(c) TEV-Vd (7,3). The C-terminal extension only present in viral members of the PA clan of 
chymotrypsin-like proteases as (d) surface with loop in blue (e) secondary structure and 
(f) b-factor putty (thicker indicates greater flexibility) for the structure of TEVC151A (1lvb). 
Substrate in black, active site triad in red. 
When either the N171D or N176I mutations were introduced into 
wtTEV, it increased activity on the C-Y(veg) substrate by more than an 
order of magnitude (Figure E-13b). N176I was neutral to activity on the 
native sequence but N171D changed specificity by reducing activity on 
C-Y(tev) by an order of magnitude (likely due to negative charge 
repulsion). Both mutations also reduced soluble expression of the 
protease (Figure E-13c). 
In order to understand the sequence changes giving rise to fluctuating 
immediate evolvability, I reanalysed data from Chapter D, 3.3. Looking 
at the population sequence variation in the neutrally evolving lineage, 
N171DN176IN176I N176I
ge f
a b c d
h
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it can be seen that position 171 is mostly purged of mutations (Figure 
E-13d) indicating strong constraint at that position. No single 
mutation accumulated above 1.5% and only in conjunction with 
known stabilising mutations (Figure E-13e). This agrees with the 
reduction in activity on the native substrate sequence by the N171D 
mutation. 
 
Figure E-13 | Substrate P6 binding by dual asparagines 
(a) N171 and N176 mapped onto wtTEV (PDB 1lvm) with all substrate to enzyme hydrogen 
bonds indicated. Note that N171 and N176 make bonds with the glutamate of C-Y(tev) 
but would be absent arginine of C-Y(veg). Measurements of (b) in vitro activity (kcat/KM), 
and (c) soluble expression by gel band quantification (ImageJ). (d) Percentage of 
population with non-arginine residues at positions 171 (light green) and 176 (dark green) 
after rounds of neutral evolution on C-Y(tev). Dashed line indicates non-wt residues 
averaged over whole TEV sequence. Data separated for each non-arginine residue at (c) 
N171 and (d) N176. 
Conversely, position 176 accumulated amino acid diversity at about 
the average rate for the whole gene during the neutral evolution (Figure 
E-13d). Because there was no direct selection for or against N176I, its 
concentration in the population fluctuated over the course of neutral 
evolution. The N176I mutation was most prevalent in population 5,0 
(Figure E-13f), the population with the highest immediate evolvability 
towards C-Y(veg) (Figure E-6c). The same N176I mutation was 
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therefore convergently evolved during adaptive evolution starting 
from wtTEV. Thus as neutral or slightly deleterious mutations 
stochastically fluctuate in concentration within the population, they 
have profound effects on immediate evolvability. 
When viewed as a phylogeny, it can be seen that Vd and Pa (the most 
active variants found for their target substrates) are both descended 
from β2 (Figure E-14), the robust variant identified in Chapter D. 
Variant Vc, however, is directly descended from Va and so offers an 
explination for why the 5,0⟶5,3 lineage plateaued in average cleavage, 
and yielded only a 37-fold improved variant. By being highy adapted, 
Va outcompeted less the well adapted but more robust variant, β2. 
Therefore the lineage had high immediate evolvability, enriching Va, 
but low long-term evolvability as robust variants were absent.  
  
Figure E-14 | Phylogeny of C-Y(veg) active mutants 
Phylogeny of lineage neutrally evolved on C-Y(tev) is indicated by lines (data as in Chapter 
D, Figure D-12b). Circles indicate sequences of plus top variants from populations then 
selected for activity on C-Y(veg) in green, and C-Y(pdl) in purple. 
The exceptionally high mutation tolerance of β2 may aid adaptive 
evolution both by having fewer deleterious mutations, and a greater 
proportion of beneficial mutations by buffering beneficial but 
5 nt mutations
β2
Vb
Va
Vd
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Vc
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destabilising mutations. This would explain both the fast rate of 
adaptation and highly active variant evolved from population 7,0.  
In this way, the causal factors for immediate and long-term evolvability 
can be antagonistic. Fortuitous standing variation leads to high 
immediate evolvability but its enrichment may come at the cost of 
robust variants that, though they are not active towards the new 
substrate, would have given higher long-term evolvability.  
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4 CONCLUSIONS 
4.1 EVOLUTION OF PROMISCUITY, AND IMMEDIATE AND LONG-TERM EVOLVABILITY 
In this chapter I show how neutral evolution affects immediate 
evolvability though genetic drift of sequences and long-term 
evolvability through the emergence of robustness. 
TEV protease is known for its high sequence specificity211,222,223 so 
unsurprisingly has very low promiscuous activity on alternative 
substrate sequences. Along the neutral evolution lineage, average 
promiscuity towards a set of 400 test substrates fell slightly indicating 
the general loss of promiscuous activities as did promiscuity towards a 
specific test substrate sequence, C-Y(veg). This is perhaps explained by 
the slight drop in native activity (Chapter D) which may cause some 
minor promiscuous activities to drop below the detection threshold. 
However, as the population evolved through the local neutral network, 
adaptive standing variation (e.g. N176I) appeared and disappeared 
introducing chance increases in promiscuous cleavage activities into 
some members of the population (cryptic variation). These members 
(e.g. TEV-Va from population 5,0) could be isolated by selection to 
indicate the large fluctuations in immediate evolvability. 
Simultaneously, later populations contained variants with mutations 
that improved robustness (Chapter D, 3.4) and influenced long-term 
evolvability. The mutation tolerance lead to a faster increase in 
population average activity and the isolation of the most active 
variants, Vd and Pa, after 3 rounds of adaptive evolution on C-Y(veg) 
and C-Y(pdl) from population 7,0. Therefore, in this case, longer 
durations of neutral evolution did increase long-term adaptive 
evolvability due to the emergence of robustness. 
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Immediate and long-term evolvability do not correlate as they represent 
two orthogonal library properties (likelihood of bearing a variant with 
altered specificity vs. improvement in mutational tolerance). Evidence 
comes from the long-term evolvability of population 7,0, which is higher 
than wtTEV despite population 7,0 starting with no greater immediate 
evolvability. Indeed there is evidence of antagonism between the two 
properties as population 5,0 shows the highest immediate evolvability, 
yielding variant Va, which outcompetes robust variants (such as β2) 
and lowers long-term evolvability. 
4.2 RELEVANCE TO PROTEIN ENGINEERING 
These experiments compare favorably with previously reported 
evolution attempts114,214,224. Although I was able to isolate the enzyme 
Va (35-fold improved on C-Y(veg)) from standing variation alone (also 
somewhat higher than is typical for adaptive variation in neutral 
evolution Table E-1), the inconsistency of immediate evolvability 
explains the limited adaptive potential of some previous neutral 
evolution experiments293. However, in later rounds, the enrichment of 
the descendants of robust variants does improve long-term evolvability. 
Starting from wtTEV, 3 rounds of adaptive evolution produced no 
improved variants on C-Y(pdl) and only a 40-fold improved variant on 
C-Y(veg) (Vb). The same adaptive evolution starting from population 
7,0 found a 25-fold improved Pa (on C-Y(pdl)) and the >200-fold more 
active Vd (on C-Y(veg)), both descended from the robust variant β2. 
Therefore, characterising the exploration of the local neutral network 
by an evolving population of genes allowed insight into the 
relationship between neutral evolution and adaptive evolvability. 
Additionally, it highlights the generation of robust enzymes as a key 
goal in improving long-term evolvability in practical applications of 
experimental evolution.  
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Chapter F -  Discussion and outlook 
1 SUMMARY 
In this chapter I will draw together the results presented in this thesis 
into two themes. Firstly I present how my results advance the 
understanding of protein evolution by describing relevant features of the 
fitness landscape surrounding TEV protease. Secondly I discuss the 
relevance of these findings to future protein engineering efforts. 
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2 EVOLUTION AND EVOLVABILITY 
Development of the multi-format FRET screening system in Chapter 
B allowed the generation of an integrated set of data using the same 
fluorescent assay. It was therefore possible to use the same substrate for 
high throughput FACS screening all the way to detailed kinetics 
studies. Although the results presented here are specific to TEV 
protease, in conjunction with other published works they shed light on 
several general aspects of enzymology. 
2.1 NEUTRAL FITNESS PLATEAU 
In the case of TEV protease the distribution of mutant phenotypes is 
bimodal with mutations either reducing activity to background levels 
or affecting it so little that a wt-like phenotype remains (in several 
different assay formats – Chapter D). This indicates a local fitness 
landscape that is mainly comprised of flat, high plateaus (a neutral 
network) traversed by deep fitness canyons (sudden, complete loss of 
function) (Figure F-1a,b). 
This is similar to previous observations of a bimodal distribution of 
fitness effects of mutations on proteins and organisms79,153,278. In such 
landscape it has been predicted that populations will evolve towards 
regions of higher mutational tolerance149. This robustness is 
equivalent to the population moving in the landscape to regions with 
fewer nearby fitness cliffs and more so neutral neighbours263 and as 
such, the evolution of robustness can be an emergent property of 
landscape topology. 
One way of moving away from fitness cliffs if to move towards the 
centre of a neutral network. A relatively smooth, additive landscape 
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forms a neutral network with a coherent peak (Figure F-1c). In this case 
it would be expected that intermediate sequences between the starting 
enzyme (wtTEV) and the robust variant (e.g. TEV-β2) would be 
progressively more robust. In the lineage that produced β2, the 
phylogeny gives no evidence of particularly mutation tolerant 
intermediates. This result is more in line with a rugged, epistatic 
landscape which creates a complex, irregular neutral network in which 
the population is funnelled towards a different area with fewer cliffs 
(Figure F-1d) and would not necessarily show more robust 
intermediates. 
 
Figure F-1 | Bimodal distribution of fitness effects as a landscape 
A representation of a broad fitness peak (a) and a detailed view of the top plateau of a 
fitness peak (b) shows that even at high fitness, many single mutations can completely 
inactivate the enzyme causing cliffs that take fitness from ≈1 to ≈0. (c) A neutral network 
generated by a smooth, additive landscape that forms a ‘round’ peak. Each circle 
represents a functional gene variant and lines represents point mutations between them. 
Light grid-regions have low fitness, dark regions have high fitness. White circles have few 
neutral neighbours, black circles have many. Light grid-regions contain no circles because 
those sequences have low fitness (as in Chapter A, Figure A-16). (d) An alternative 
scenario, in which a large neutral network is criss-crossed with ‘fitness cliffs’ due to 
epistasis (a neutral network representation of (b)). In this case it is also possible for a 
population to evolve to regions with fewer local cliffs. 
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2.2 RUGGED FITNESS VALLEY 
By forcing TEV into a local fitness valley (TEVSer) and experimentally 
evolving for activity recovery in Chapter C, I have been able to map out 
an uphill trajectory (TEVSer→TEVSerX) which lies parallel to a nearly 
flat neutral trajectory (TEVCys↔TEVCysX). In this case I can plot an 
explicit transect of a fitness landscape (Figure F-2) showing that the 
mutations accumulated in TEVSerX are nearly-neutral to activity using 
the original cysteine nucleophile. In this case TEVSerX could be 
described as being robust to nucleophile exchange, an alternative and 
far more specific facet of robustness than the more general structural 
robustness to random mutagenesis described in Chapter D. 
  
Figure F-2 | Explicit transect of a fitness landscape TEVSer→TEVSerX 
Activity recovery of the TEVSer→TEVSerX directed evolution lineage and TEVCys back-
mutants. Kinetic activity of purified enzyme variants is plotted as a transect of the local 
fitness landscape. Solid arrows indicate the route taken in handicap-recover experiment 
starting with (a) deleterious TEVCys→TEVSer mutation, then (b) TEVSer→TEVSerX recovery to 
arrive at neutral neighbours TEVSerX↔TEVCysX capable of using either nucleophile. (c) 
Dashed arrow indicates alternative, nearly-neutral TEVCys↔TEVCysX route that does not 
require any large drops in activity. Values are kcat/KM of TEVCys variants and kobs2 of TEVSer 
variants (measured at pH 8, 25°C), standard deviations were below 15% (Chapter C, Figure 
C-5). 
These observations contrast with the weak negative trade-offs between 
old and new function that are typical for evolution for altered substrate 
specificity or catalytic activity26,54. When selective pressure is applied 
for new function, typically the lack of selection the old activity leads to 
its loss by genetic drift as mutations re-organise the active site53. Given 
the specialisation of natural serine protease towards their nucleophile, 
we might expect that further evolution would start to show a trade-off. 
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Mutations that are adaptive, or even neutral towards use of the new 
serine nucleophile may gradually erode the potential to use the original 
cysteine. However the main constraints in this case were observed in 
the enzyme core and mutations in contact with the catalytic triad. The 
lack of a trade-off (so far) between old and new function indicates that 
active site optimisation around the serine nucleophile doesn’t disrupt 
the use of cysteine. It also suggests that neutral evolution could bridge 
widely differing active sites in natural evolution. 
High throughput screening and sequencing in conjunction with 
traditional directed evolution approaches allowed characterisation of 
the local fitness landscapes flanking this trajectory (Figure F-3).  
 
Figure F-3 | Schematic of fitness landscape flanking TEVSer→TEVSerX trajectory  
Although the wider fitness landscape is unknown, HT-SAS analysis reveals the topology of 
the local landscape (within white border). (a) HT-SAS of TEVSer characterises the local 
fitness landscape (dashed arrows indicate screened mutants, solid arrow represents the 
fittest chosen for the trajectory). (b) HT-SAS for each variant along the directed evolution 
trajectory reveals how the flanking fitness landscape changes round by round. High 
epistasis (non-additive effects of mutations) means that close genotypes can vary widely 
in fitness causing a rugged (as opposed to smooth) landscape and the most beneficial 
paths are not always in the same direction. High adaptive potential (many possible 
beneficial mutations) means that at each step there are many nearby uphill pathways. 
Constraints and trends (e.g. for changes in triad second shell but not in the core) mean 
that despite the rugged landscape, in general more peaks exist in one direction than 
others. 
The analysis characterises the fitness valley around TEVSer as having a 
rugged topology yet an abundance of uphill pathways directed by 
constrains in core structural residues and adaptive potential in the 
active site perimeter. This underlying landscape guided the trajectory 
towards one possibility in a set of many but similar solutions. 
Therefore, although only one evolutionary pathway was characterised 
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in detail, it is likely representative of a large class of equivalent 
trajectories. 
2.3 ALTERNATIVE FITNESS PEAKS 
Finally, in Chapter E, I show evolution towards several nearby fitness 
peaks with alternative sequence specificities. By measuring both 
immediate and long-term evolvability I show that some variants with 
altered specificity could be found within the neutrally evolving lineage 
(e.g. TEV-Va), but that movement of population to regions of high 
robustness gave eventual access to better variants (e.g. TEV-Vc). 
Fluctuating immediate evolvability also aids our understanding of 
divergent evolution after gene duplication. It suggests that in the 
evolutionary history of a population of enzyme variants, promiscuous 
activities are constantly being introduced and purged at random. As 
genes duplicate at a roughly constant rate, redundant copies are mostly 
inactivated by pseudogenisation. The chance periods of high 
promiscuity, however, may lead to greater likelihood of sub- and neo-
functionalisation. 
Immediate and long-term evolvability have different requirements. 
Immediate evolvability is achieved by a diverse, polymorphic population 
in order to fortuitously find rare beneficial mutations. Long-term 
evolvability, however, is improved by a robust starting enzyme 
(Chapter D) that, at the least has fewer deleterious mutations, and at 
most may have more beneficial ones compared to wtTEV. 
Consequently, it is possible that these even trade-off against one 
another if some active variants (higher immediate evolvability) displace 
less active but robust variants (higher long term evolvability) early in an 
adaptive evolutionary period. 
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3 ENZYMES AND ENGINEERING 
3.1 NEUTRAL EVOLUTION AND CONTROLLING PROTEASE SPECIFICITY 
The relevance of ‘neutral drift’ for protein engineering has been a 
contentious topic188,274,290,293 with conflicting results as to whether the 
accumulation of neutral mutations increases evolvability, especially in 
a protein engineering context. By measuring the sequence evolution of 
populations (Chapters D & E) and reconstructing their phylogenies I 
was able to partly resolve this issue. Specifically, neutral evolution 
displayed two distinct processes with independent evolvability effects. 
The first process is a classical genetic drift as the population 
accumulated neutral and nearly-neutral mutations. As an engineering 
tool this method has several drawbacks. Firstly, mutations have to be 
neutral to the original function as well as beneficial to the new. Though 
this is true of many mutations54,291, it is certainly not true of all292,293. 
Additionally, neutral mutations appear and disappear stochastically in 
the population as they are under no specific selection for retention 
(Chapter E). This leads to large fluctuations in the immediate 
evolvability from standing variation and arbitrary lengths of neutral 
evolution are not guaranteed to explore productive regions of 
sequence space. Hence, screening for new activities after an arbitrary 
number of generations may miss adaptive potential that was present in 
earlier rounds. This stochastic element of neutral evolution can 
accurately be called ‘neutral drift’ since it describes non-directional 
diffusion in the neutral network. As an engineering technique then, 
the ‘drift’ part of neutral evolution is inefficient, as observed for 
previous experimental evolution of B-glucuronidase to B-
galactosidase293. 
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The second process is a directional movement of populations towards 
enzymes with higher robustness (Chapter D). This is a process of 
second-order selection for extinction resistance186 and so the label of 
‘drift’188,274,290,291,293 is misleading. The neutral evolution of 
robustness is more promising as an engineering technique since it 
reduces the proportion of mutations that are deleterious to function 
and enables faster adaptation to a new activity as well as reaching a 
more active final variant, improving long-term evolvability.  
Finally, none of the variants evolved in Chapter E showed re-
specialisation to the new sequence, activity was improved on the new 
sequence, sometimes by several orders of magnitude, but the native 
activity never varied more than 2-fold. This may be in issue in 
applications where tight specificity is required but could be solved with 
appropriate counter-selection224. However, the >200-fold 
improvement of TEV-Va on its target sequence (4 residue differences 
to native sequence) compares favourably with previous works that 
change the substrate specificity at only one substrate residue. This 
gives some optimism that the large specificity changes desired in 
protease engineering are possible.  
3.2 MANIPULATING ACTIVE SITE CHEMISTRY 
Chapter C shows the sensitivity of the enzyme to nucleophile 
mutation, exchange of a single atom amongst the tens of thousands in 
the enzyme. Results are consistent with previous nucleophile 
mutagenesis studies212,238–249 and with the difficulties of de novo 
enzyme design in which a designed active site307 is docked into existing 
protein structures308,309. Together, these results highlight that 
engineering of optimised catalysis is more than precise orientation, but 
also correct activation and tuning of chemistry101,310,311. 
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Nevertheless, directed evolution of the enzyme was able to adapt the 
active site to accommodate a new nucleophile despite constraints such 
as epistasis and negative pleiotropy between activity and solubility. The 
proportion of beneficial mutations is at the high end of previous 
measurements and reflects that the local sequence space is much richer 
in solutions to this chemical problem than originally expected. The 
adaptive mutations for nucleophile re-optimisation were 
disproportionately located in the active site periphery (in strong 
contrast to the neutral evolution lineages in Chapter D where such 
mutations were purged). 
Additionally, the lack of a strong trade-off between use of the original 
and new nucleophile supports manipulation of core catalytic 
machinery as an avenue of protein engineering105. In particular it may 
allow access to alternative chemistries, not normally associated with a 
particular protein scaffold or specificity. 
4 SYNOPSIS 
To close, I have demonstrated the utility of integrating traditional and 
high-throughput techniques both for directed evolution (Chapters D 
& E) and for measuring fitness landscapes to aid the understanding of 
the process and outcomes of directed evolution (Chapter C). I have 
used these techniques to help create an integrated picture of neutral 
evolution, the emergence of robustness, evolvability, active site 
evolution, and substrate specificity. Together these aid our 
understanding both of enzyme evolution and engineering. 
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Chapter G -  Materials and methods 
1 PLASMIDS 
NAME RELEVANT FEATURES SOURCE 
pET28-MBPTEV Kanmx, T7 lac promoter, MBP-TEV fusion This project 
pET28-STEV Kanmx, T7 lac promoter, PelB export 
sequence, TEV 
This project 
pET28-STEVa Kanmx, T7 lac promoter, PelB export 
sequence, C151A TEV 
This project 
pMAA Bla, Ara promoter, MBP, AraC Novagen 
pMAT(MBPTEV) Bla, Ara promoter, MBP-TEV fusion, AraC Gatti-Lafranconi 
pMAA(MBPTEV) Bla, Ara promoter, MBP-TEV fusion, AraC Gatti-Lafranconi 
pMAA(MBPTEVs) Bla, Ara promoter, MBP-TEVSer fusion, AraC This project 
pMAA(MBPTEVa) Bla, Ara promoter, MBP-TEVAla fusion, AraC This project 
pMAA(TEV) Bla, Ara promoter, TEV, AraC Gatti-Lafranconi 
pMAA(TEVs) Bla, Ara promoter, TEVSer, AraC This project 
Table G-1 | Protease plasmids 
pMAA(MBPTEVs) was used to express all variants in Chapter C except for protein 
expression for thermal denaturation, when protease genes were subcloned into 
pMAA(TEVs). Similarly for Chapter C pMAA(MBPTEV) and pMAA(TEV) were used. 
 
NAME RELEVANT FEATURES SOURCE 
pC-Y(cleavage) CAT, Dual-GFP FRET fusion, AraC Gatti-Lafranconi 
pGR32 CAT, lac promoter, BLIP, LacI Palzkill 
pJET1.2/Blunt Blunt ligation plasmid Fermentas 
pSU18 CAT, Novagen 
pUC18 Bla, Novagen 
pJET-bla Bla (+ required restriction sites) This project 
pSB-wtBLIP Bla , CAT, LacI,  lac promoter, BLIP This project 
pSB-iBLIP Bla , CAT, LacI,  lac promoter, iBLIP This project 
Table G-2 | Substrate plasmids 
pC-Y(cleavage) represents a set of plasmids all encoding the CFP-YFp substrate but with 
different cleavage sequences as the linker. The full table of linker sequences is detailed in 
Chapter C. 
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2 PRIMERS 
NAME TM/°C SEQUENCE 
ins1F 71 ACTUCCAGAATGCCCCGACGCTCACCCTCGC 
ins1R 71 AAGUACAGATTCTCGCTCGGGGCCAGCAGCTTCTCC 
ins2F 69 ACTUCCAGAATGCCGACGCGAAGGTGGACTCG 
ins2R 71 AAGUACAGATTCTCGGCGGCGCTGGTGAAGCCG 
blaF 60 GATCGATCAAGCTTGGTCTGACGCTCAGTGGAACG 
blaR 58 GCTGCTGATCTAGATGGTTTCTTAGACGTCAGGTGG 
blipF 68 GCGATTCGGATCCTCTCCGGGAGCTGCATGTGTTCAG 
blipR 68 GTTGTACCCGCGGTGCAGGTCGACTCTAGAATACAAGGTCCC 
   
tevF 60 GTTCCGAGGGGATCCATGGG 
tevR 59 CCCCGATCCCTCGAGAAGC 
restF  66 TGAATAGAGATCTTACTGACTCGAGCCGTTTTTCCATAGGCTCCG 
restR  67 AGGCTACAGATCTCCTGATATCGATCTCGAATACAAGGTCCCACTGCCG 
   
tevaF 63 GGGCAGGCTGGATCCCCATTAGTATCAACTAGAGATGGG 
tevaR 64 CTAATGGGGATCCAGCCTGCCCATCCTTGGTTTGAATCC 
tevsF 63 GGGCAGTCTGGATCCCCATTAGTATCAACTAGAGATGGG 
tevsR 64 CTAATGGGGATCCAGACTGCCCATCCTTGGTTTGAATCC 
   
shufF 60 GAACATCCCGCAGATGTCCGC 
shufR 59 GTTATGCTAGTTATTGCTCAGCGG 
   
seqXF 60 CGTATCGCCTCCCTCGCGCCATCAG(MID-X)GTTCCGAGGGGATCCATGGG 
seqXR 59 CTATGCGCCTTGCCAGCCCGCTCAG(MID-X)CCCCGATCCCTCGAGAAGC 
Table G-3 | Primers mentioned in report 
Primers were designed with NetPrimer (primer TM was calculated under standard 
conditions, 1.5nM Mg2+) and synthesised by Invitrogen Life Technologies. Sequencing 
results were analyzed with FinchTV and CLC sequence viewer 6. Primers seqXF and seqXR 
contain multiplex identifier sequences (MID-X) detailed in Table G-4. 
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MID-X SEQUENCE 
1 ACGAGTGCGT 
2 ACGCTCGACA 
3 AGACGCACTC 
4 AGCACTGTAG 
5 ATCAGACACG 
6 ATATCGCGAG 
7 CGTGTCTCTA 
8 CTCGCGTGTC 
9 TCTCTATGCG 
10 TGATACGTCT 
11 CATAGTAGTG 
12 CGAGAGATAC 
13 ATACGACGTA 
14 TCACGTACTA 
15 CGTCTAGTAC 
16 TCTACGTAGC 
17 TGTACTACTC 
18 ACGACTACAG 
19 CGTAGACTAG 
20 TACGAGTATG 
Table G-4 | Multiplex identifier sequences 
Standard multiplex sequences that are each differ by at least two nucleotides. Used to 
sequence multiple different populations simultaneously by 454 sequencing. The mixed 
sequences can then be separated afterwards (de-multiplexed) by grouping sequences by 
their MID. Each group then corresponds to a population before the samples were mixed 
for sequencing. 
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3 BUFFERS 
LYSIS 
50 mM Tris 
300 mM NaCl 
5 mM Imidazole 
pH 8 
WASH 
50 mM Tris 
300 mM NaCl 
50 mM Imidazole 
pH 8 
ELUTION 
50 mM Tris 
300 mM NaCl 
300 mM Imidazole 
pH 8 
96W-LYSIS 
50 mM NaH2PO4 
300 mM NaCl 
pH 8 
96W-WASH 
83 mM NaH2PO4 
500 mM NaCl 
10 mM Imidazole 
pH 7 
96W-ELUTION 
50 mM NaH2PO4 
300 mM NaCl 
150 mM Imidazole 
pH 7 
96W-MES 
20 mM MES 
100 mM NaCl 
150 mM Imidazole 
pH 5 
TEV STORAGE 
50 mM Tris 
1 mM EDTA 
10% sucrose 
pH 8  
TEV ACTIVITY 
50 mM Tris 
1 mM EDTA 
10% sucrose 
pH 8 with HCl  
1 mM DTT (freshly added) 
RF1 
100 mM RbCl 
30 mM Potassium acetate 
10 mM CaCl2 
50 mM MnCl2  
10% glycerol 
pH 5.8 with acetic acid 
Filter sterilised 
RF2 
10 mM MOPS 
10 mM RbCl 
75 mM CaCl2  
10% glycerol 
pH 6.8 with acetic acid 
Filter sterilised 
PBS 
137 mM NaCl 
2.7 mM KCl 
10 mM NaH2HPO4 
1.8 mM KH2PO4 
pH 8 
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4 MOLECULAR BIOLOGY 
4.1 GENE AMPLIFICATION 
PCR using primers containing the desired restriction sites was performed in an Eppendorf 
Mastercyler (25 rounds of: 30 s at 94 °C, 30 s at (TM-5) °C, 1 min per kb of amplicon at 72 °C) using 
0.4u Pfu Turbo (Agilent), 1 µM each primer, 4 mM dNTPs, 100 ng total plasmid template in 20 µl. 
Refer to Table G-3 for primer TM values. 
4.2 USER MUTAGENESIS 
Performed as published312. Briefly, the plasmid was amplified by PCR in an Eppendorf Mastercyler 
(30 s at 94 °C, 30 s at 56 °C, 360 s at 68 °C) using Pfu CX polymerase according to the manufacturer’s 
instructions and uracil-containing primers. DpnI (1 µl) and USER (1 µl) were then added to the crude 
product (20 µl) and incubated 1hr at 37 °C. DNA was purified using the QIAquick PCR purification 
kit and eluted in H2O (30 µl). DNA ligase buffer and T4 DNA ligase (1 µl) was added and incubated 
12 h at 16 °C. 
4.3 TARGETED MUTAGENESIS 
For targeted mutagenesis, a two-step, overlap-extension method was used. This requires each half 
of a gene to be amplified using outside primers and inside mutagenic primers that introduce the 
desired mutation. The two gene fragments are then used as primers for each other to generate the 
full length mutant gene. PCR was performed in an Eppendorf Mastercyler using flanking primers 
and primers containing the desired mutations tevF+(mutagenic primer) and tevR+(mutagenic 
primer) was performed (10 rounds of: 30 s at 94 °C, 30 s at (TM-5) °C, 60 s at 72 °C) using 0.4u Pfu 
Turbo (Agilent), 1 µM each primer, 4 mM dNTPs, 100 ng amplicon template in 20 µl. These 
amplificates were mixed and overlap extension PCR with the flanking primers tevF+tevR completed 
the gene (10 rounds of: 30 s at 94 °C, 30 s at (TM-5) °C, 60 s at 72 °C) using 0.4u Pfu Turbo (Agilent), 
1 µM each primer, 4 mM dNTPs, 100 ng total plasmid template in 20 µl. The product was ligated 
into pMAA as described below. 
4.4 RANDOM MUTAGENESIS 
Error prone PCR in an Eppendorf Mastercyler using flanking primers tevF+tevR was performed (30 
rounds of: 30 s at 94 °C, 30 s at 50 °C, 90 s at 72 °C, 30 rounds) using 0.4u Mutazyme II polymerase 
(Agilent), 1µM each primer, 0.8 mM dNTPs, 400ng plasmid template in 20 µl. The product was 
ligated into pMAA as described below. 
4.5 SHUFFLING 
The genes of interest were each amplified by PCR using external primers shufF+shufR (30 rounds 
of: 30 s at 94 °C, 30 s at (TM-5) °C, 90 s at 72 °C) using 4u Pfu Turbo (Agilent), 1 µM each primer, 4 
mM dNTPs, 1 µg amplicon template in 200 µl. The PCR products for the two genes to be shuffled  
were mixed such that product genes would have 2-3 amino ‘back-mutations’ from the earlier round 
shuffle parent on average, (total 4 µg) and digested in 50 µl with DNAase (0.005 units) for 10 
minutes. The digested DNA was separated by gel electrophoresis and fragments between 50 and 
70 bp were excised and purified. Assembly of the purified fragments was achieved by a 35 round 
PCR as above, except using a modified annealing step (65, 62, 59, 56, 53, 50, 47, 44, 41 °C each for 
30s) using 1u Pfu Turbo (Agilent), 4 mM dNTPs, in 50 µl. 10% of the product was used as the 
template for a PCR reaction using the nested primers tevF+tevR to amplify the gene for cloning (30 
rounds of: 30 s at 94 °C, 30 s at (TM-5) °C, 60 s at 72 °C) using 1u Pfu Turbo (Agilent), 1 µM each 
primer, 4 mM dNTPs, in 50 µl. The product was ligated into pMAA as described below. 
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4.6 LIGATION AND CLONING 
Unless otherwise stated in results sections, the following protocol was used as a standard protocol 
for ligating genes into plasmids (library creation/evolution/shuffling etc). PCR product was purified 
by spin column (Zymo research), digested with XhoI, NcoI and DpnI (1u each, Fermentas) at 37°C 
for 1 hr, purified again, and ligated into the XhoI, NcoI digested pMAA vector at 16 °C for 16 h, 1u 
T4 ligase (NEB), 10 ng of each vector and insert in 10 µl. This was used to transform electro-
competent E. cloni (lucigen) as per the manufacturer’s instructions. Restriction digests were 
performed according to the manufacturer’s instructions. DNA was analysed by agarose (0.5%) gel 
electrophoresis and stained with SybrSafe (1%) against a Hyperladder I (Bioline) standard. DNA was 
purified after each enzymatic reaction (QIAquick PCR purification kit) according to manufacturer’s 
instructions. DNA concentrations were determined by measuring the absorption at 260 nm with a 
Nanodrop spectrophotometer (Thermo Scientific). Ligations into JET1.2/Blunt vector were 
performed according to manufacturer’s instructions. All other ligations were performed using 
equimolar vector and insert DNA (10 ng) with T4 DNA ligase (1 μl) in ligase buffer (total 10 μl) and 
incubation for 16 h at 16 °C. When synthetic oligonucleotides were used as insert, 20 ng (in 10 μl 
H2O) was prepared by heating the mix of forward and reverse oligonucleotides to 95 °C, cooling to 
37 °C over 1 h and then phosphorylating by addition of PNK (3u) and T4 ligase buffer followed by 
incubation for 1 h at 37 °C. 
4.7 PREPARATION OF CHEMO-COMPETENT CELLS 
LB (500 ml, containing the appropriate antibiotics) was inoculated with cells (5 ml from overnight 
inoculum) and incubated at 37 °C (200 rpm) until OD600=0.4. The culture was divided into 50 ml 
aliquots and incubated on ice for 15 min then pelleted (25 min centrifugation at 3500 rpm). Pellets 
were resuspended in RF1 solution (8 ml per aliquot), incubated on ice again for 15 min and re-
pelleted as before. Pellets were resuspended in RF2 solution (3 ml per aliquot), incubated on ice 
again for 15 min and 50 µl aliquots in PCR tubes were snap-frozen using liquid nitrogen.  
4.8 PREPARATION OF ELECTRO-COMPETENT CELLS 
LB (1 L, containing the appropriate antibiotics) was inoculated with cells (10 ml from overnight 
inoculum) and incubated at 37 °C (200 rpm) until OD600=0.4. The culture was divided into 50 ml 
aliquots and incubated on ice for 30 min then pelleted (25 min centrifugation at 3500 rpm). Pellets 
were resuspended in distilled H2O (25 ml per aliquot), incubated on ice again for 15 min and re-
pelleted. The previous step is repeated, with resuspension in 12.5 ml, 2.5 ml then 100 µl of distilled 
H2O +10% glycerol. 50 µl aliquots in PCR tubes were snap-frozen using liquid nitrogen.  
4.9 TRANSFORMATION 
Chemo-competent cells (50 µl) were incubated with DNA (1-100 ng) on ice for 15 min, heat-shocked 
for 30s at 42 °C then 60s on ice and incubated in LB (1 ml) for 1 h at 37 °C before plating on LB-agar 
containing the appropriate antibiotic. 
Electro-competent cells (50 µl) were incubated with DNA (1-100 ng) on ice for 1 min in an 
electroporation cuvette. Electroporation of 1800v was followed immediately by the addition of 
Invitrogen ‘Recovery Medium’ (300 µl) and incubation for 1 h at 37 °C before plating on LB-agar 
containing the appropriate antibiotic. 
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5 BIOCHEMISTRY AND ASSAYS 
5.1 PROTEIN EXPRESSION AND PURIFICATION 
LB (1 l, containing the appropriate antibiotics) was inoculated with cells (from an overnight 
inoculum) and incubated at 37 °C and 200 rpm for 4 hours. The cells were induced by addition of 
L-arabinose (0.2%) and incubated at 30 °C for a further 4 hours. The cells were pelleted and frozen 
for storage. The cell pellet was thawed and resuspended in 10 ml lysis. Cells were lysed on ice by 
sonication (2 s on, 10 s off, 5 min) and pelleted. The supernatant was loaded onto a HisTrap (GE Life 
Sciences, 5ml) column, washed in wash buffer (6 column volumes) and eluted with elution buffer 
(500 µl fractions). Protein content was monitored by A280. Fractions containing the protein of 
interest were pooled and exchanged into TEV Storage buffer using a HiTrap desalting column (GE 
Life Sciences, 5 ml). 100 µl aliquots in PCR tubes were snap-frozen using liquid nitrogen. 
5.2 96-WELL EXPRESSION AND PURIFICATION 
In a 96-deepwell plate, LB (1 ml per well, containing the appropriate antibiotics) was inoculated 
with the cells to be tested and incubated for 12 hours at 30 °C. The cells were induced by addition 
of 50 µl L-arabinose (0.2% final concentration) and incubated at 25 °C for a further 16 hours. Cells 
were pelleted, then resuspended in 300 µl PBS + Bugbuster (Novagen) and incubated for 1 hour at 
25 °C. Finally, cells were pelleted and the supernatant separated and 700 µl 96w-lysis buffer added 
to each.  
A 96-well TALON resin plate (BD Biosciences) was used for parallel purification of enzymes. Liquid 
was drawn through using a vacuum manifold (BD Biosciences). The plate was prepared by washing 
with H2O (3 times 300 µl per well) then washing with 96w-lysis buffer (3 times 300 µl per well). The 
cell supernatants (1 ml each) were loaded into the wells and incubated on ice (10 min). The 
supernatant was then drawn through using the vacuum manifold and washed with 96w-lysis buffer 
(3 times 300 µl per well) then washed with 96w-wash buffer (6 times 300 µl per well). 300 µl 96w-
elution buffer was added to each well and incubated on ice (10 min). The elutant was then drawn 
through using the vacuum manifold into individual tubes. Protein concentration of each sample 
was assayed by adding 30 µl elutant to 200 µl Bradford reagent (Sigma) and absorbance was 
measured by spectrophotometer (Spectromax M5 at 595 nm). The TALON plate was washed with 
96w-MES (3 times 300 µl per well) then washed with H2O (3 times 300 µl per well). 
5.3 FLUORESCENCE 96-WELL PLATE SCREENING 
In a 96-deepwell plate, LB (1 ml per well, containing the appropriate antibiotics) was inoculated 
with the cells to be tested and incubated for 12 hours at 30 °C. The cells were induced by addition 
of 50 µl L-arabinose (0.2% final concentration) and incubated at 25 °C for a further 6 hours. Cells 
were pelleted, then resuspended in 300 µl PBS + Bugbuster (Novagen) and incubated for 1 hour at 
25 °C. Finally, cells were pelleted and the supernatant was assayed in a Spectramax M5 (Molecular 
Devices, excitation 414 nm, observation 475 nm and 525 nm). 
5.4 FLUORESCENCE IN VITRO KINETICS 
CFP-YFP substrate was thawed overnight at 4 °C. Unless otherwise stated, 1 µM substrate was 
added to 1, 2, 4 and 8 µM purified enzyme in 200 µl TEV Storage buffer + 1 mM DTT in a 96-well 
plate. Solutions were assayed by spectrophotometer (Spectromax M5 - excitation 414 nm, 
observation 475 nm and 525 nm) reading every minute for 12 hours at 25 °C for 12 hours. 
Concentration of product was calculated using Equation G-1. Kinetic traces were fit first to simple 
Micaelis -Menten kinetics, Equation G-2. 
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[𝑃] = [S]
𝑅0 − 𝑅𝑡
𝑅0 − 𝑅∞
 
Equation G-1 | Product concentration 
[P] = Concentration of product 
[S] = Concentration of substrate 
R0 = FRET ratio of substrate (at t=0) 
R∞ = FRET ratio of product (at t=∞) 
Rt = FRET ratio at time t 
 
[𝑃] = [𝑃]𝑚𝑎𝑥 − 𝑒−[𝐸]𝑘𝑐𝑎𝑡/𝐾𝑀𝑡 
Equation G-2 | Michaelis Menten interpolation (also C-1) 
The serine variants were found to exhibit biphasic kinetics, so were better fit by the two-
exponential modification of Equation G-2, named Equation G-3. 
[𝑃] = [𝑃]𝑚𝑎𝑥 − (𝐴1𝑒
−[𝐸]𝑘𝑜𝑏𝑠1𝑡 + 𝐴2𝑒
−[𝐸]𝑘𝑜𝑏𝑠2𝑡) 
Equation G-3 | Biphasic modification of Equation G-2 (also C-2) 
[P] = Concentration of product 
[P]max = Final concentration of product (should be = starting substrate) 
A1 = Jump amplitude (ie. how much turnover is performed in first kinetic step) 
A2 = Second jump amplitude (should = [P]max-A1) 
[E] = Concentration of enzyme 
kcat/KM = Rate of overall reaction 
kobs1 = Rate of first kinetic step 
kobs2 = Rate of second kinetic step 
t = Time 
5.5 FLUORESCENCE ACTIVATED CELL SORTING (FACS) 
Transformed cells were scraped off the agar plate in LB (2 ml), 4 µl of which was used to inoculate 
fresh culture in a 96-depwell plate, LB (1 ml per well, containing the appropriate antibiotics) After 
4 hours at 37 °C, 4 µl of this culture was used to inoculate 1 ml fresh LB (+antibiotic) and incubated 
for 4 hours at 30 °C. The cells were induced by addition of L-arabinose (0.2%) and incubated at 20 
°C overnight (16 hours). For FACS a MoFlo MLS (BeckmanCoulter) was used. Samples were diluted 
50:50 with PBS and flowed at 1000-3000 cells per second (70 µm nozzle, 60 psi (4 bar), 514 nm ssc 
trigger). Excitation at 406 nm (100 mW Krypton laser) was monitored using filters at 470±10 nm 
(FL4) and 546±5 mn (FL5). Excitation at 514 nm (200 mw Argon laser) was monitored by filters at 
546±5 nm (FL1). Cells expressing pMAA + pCtY and pMAA-TEV + pCtY were used as negative and 
positive controls, respectively. Sorting was performed by gating firstly above FL1 to ensure 
expression and secondly on the FL5/FL4 to select the 1% of cells with the lowest FRET ratio. Cells 
were sorted into LB (containing 100 µg/ml ampicillin and 37 µg/ml chloramphenicol) and incubated 
overnight at 37 °C before being harvested. 
5.6 GEL BAND DENSITOMETRY 
In a 96-deepwell plate, LB (1 ml per well, containing the appropriate antibiotics) was inoculated 
with the cells to be tested and incubated for 12 hours at 30 °C. The cells were induced by addition 
of L-arabinose (0.2%) and incubated at 25 °C for a further 4 hours. Cells pelleted by centrifugation 
and then resuspended in PBS (250 µl) + Bugbuster (Novagen) and incubated for 1 hour at 25 °C. 
Cells were pelleted and the supernatant (10 µl) was run on a polyacrylamide gel (1.5%). Gels were 
stained with InstantBlue (Expedion) according the manufacturer’s instructions. Stained gels were 
photographed on a lightbox and the image analysed with ImageJ. 
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5.7 DIFFERENTIAL SCANNING FLUORIMETRY 
Sypro Orange (Sigma) was added to purified protein (20 µl of 100 mg/ml). Samples were analysed 
in a real time PCR machine (Corbett Research 2plex HRM) by increasing temperature from 25 °C to 
95 °C in 0.5 °C steps over 70 minutes (i.e. increasing 1 °C/min). The fluorescence curves were fitted 
to Equation G-4 to calculate the temperature at which half of the protein is melted (TM). 
𝑌 = 𝑌𝑚𝑖𝑛 + 
𝑌𝑚𝑎𝑥 − 𝑌𝑚𝑖𝑛
1 + (
𝑇
𝑇𝑀
)
−ℎ  
Equation G-4 | Thermal denaturation sigmoidal curve 
Y = Fluorescence 
Ymin = Minimum fluorescence 
Ymax = Maximum fluorescence 
T = Temperature 
TM = Melting temperature (infection point) 
h = Hill coefficient (unfolding cooperativity) 
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6 BIOINFORMATICS AND DATA ANALYSIS 
6.1 PA CLAN ALIGNMENT AND PHYLOGENY 
An alignment based on structural homology to TEV protease (PDB 1lvm) was generated using 
DALIprotein251. From this primary homology assessment, sequences lacking known structures were 
added based on amino acid sequence similarity to several proteases from the phylogeny (Table 
G-5) using BLASTp search of non-redundant sequences. Columns with >90% gaps were removed 
(Gapstreeze313 online). The amino acid sequence alignment was used to generate a maximum 
likelihood phylogeny in MEGA5314. 
BLAST QUERY PDB NO. SEQUENCES ADDED 
Tobacco etch 1lvm 75 
Astrovirus 2w5e 14 
Rhinovirus 2A* 2hrvB 14 
Sesbania mosaic 1zyo 12 
Rhinovirus 3C* 1cqqA 10 
Alkaline Protease 3cp7 8 
Norovirus 2fyq 6 
Achromobacter 1arc 5 
Hepatitus C 2obq 4 
Human BB fragment 1rtk 3 
Equine arteritis 1mbm 3 
Hepatitis A 1hav 2 
Table G-5 | Sequences added to DALI alignment by BLASTp 
The Protein sequences of each query were used to search the non-redundant sequence 
data base by BLASTp. * Rhinovirus has two paralogous copies of its protease. Protease 2A 
is smaller than 3C and has a different substrate specificity. 
6.2 HIGH THROUGHPUT SEQUENCING AND DATA ANALYSIS 
The plasmids to be sequenced by 454 were amplified by PCR using tevF+tevR (10 rounds of: 30 s at 
94 °C, 30 s at (TM-5) °C, 60 s at 72 °C) using 0.4u Pfu Turbo (Agilent), 1 µM each primer, 4 mM dNTPs, 
100 ng template in 20 µl. This product was purified to remove primer and used as the template for 
a second PCR to add the 454 recognition sequences seqXF+seqXR, each population using the 
appropriate multiplex identifier sequences (see Table G-4) (10 rounds of: 30 s at 94 °C, 30 s at (TM-
5) °C, 60 s at 72 °C) using 0.4u Pfu Turbo (Agilent), 1 µM each primer, 4 mM dNTPs in 20 µl. The 
products were mixed in equimolar ratios and sequenced using a GS Junior (Roche) by the 
Cambridge University Biochemistry Department Sequencing Facility. Sequencing generated 
forward reads for the first 400nt and reverse reads for the last 400nt of the 800nt total amplicon. 
Reads were aligned to the TEVCys DNA sequence using AVA aligner (Roche). Columns with >90% 
gaps were removed (Gapstreeze online) and remaining gaps replaced with ‘n’s in order to prevent 
frameshifts upon translation to protein. The alignments were used to generate a quantitative 
consensus (Jalview) which was exported to Excel (Microsoft) for analysis. Enrichment scores were 
calculated for each codon in the gene as the proportion of non-wt residue at each position after 
selection divided by the proportion before selection. To reflect the sensitivity of sequencing and to 
avoid dividing by zero, the minimum frequency of non-wt residues is set as 0.001. Protein regions 
were identified using PyMol315 for nucleophile and triad shells, IUPred306 for disordered regions, 
GetArea316 for solvent accessibility, Jalview for conserved regions, and FoldX317 for regions sensitive 
to alanine mutation in silico. Statistical significance was calculated by heteroscedastic t-test (since 
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equal variance could not be guaranteed) when comparing the average effect of a subset of 
mutations in a protein regions the whole protein. Similarly, χ2 was used when comparing the 
number of beneficial mutations in a protein region to the whole protein. A 3-category χ2 test was 
used for analysing the distribution of the 15 mutations accumulated in the DE lineage. 
6.3 FOLDX 
PDB file 1lvm was edited to remove the second chain and subjected to iterative rounds of the FoldX 
"repair" routine until energy levels reached a stable minimum. This PDB file was then used for the 
determination of total energies of all mutants in the serine lineage (and corresponding revertants) 
by FoldX. Two structures were generated for each mutant, and average values used for analysis. As 
the sequence of TEVCys used in this work differs from 1LVM, the ΔG of TEVCys was calculated and 
used as reference (set to zero). A single PDB file for each mutant was then used in the alanine 
scanning routine to calculate the contribution of each position to global stability. 
6.4 FACS MUTATION TOLERANCE ANALYSIS 
The FL5/FL4 ratio of cells above the FL1 threshold was recorded (Summit 4.3) and exported to Excel. 
The histogram was fitted to Equation G-5 to calculate the relative populations of active and inactive 
variants. 
𝑦 =
𝐴1
𝜎1√2𝜋
𝑒
−
1
2
(
𝑥−𝜇1
𝜎1
)
2
+  
𝐴2
𝜎2√2𝜋
𝑒
−
1
2
(
𝑥−𝜇2
𝜎2
)
2
 
Equation G-5 | Bimodal normal distribution 
y = frequency 
x = FRET ratio 
[A1] = Size of active population 
[A2] = Size of inactive population  
σ1 = standard deviation of active population 
σ2 = standard deviation of inactive population 
µ1 = mean FRET ratio of active population 
µ2 = mean FRET ratio of inactive population 
 
When the sequence before mutagenesis is a single gene and the library afterwards has been 
sequenced, the proportion of variants that retained wt-like activity was fit to Equation D-1 to 
determine the tolerance to random amino acid substitution. When a library was generated from a 
mixed population it is not possible to know which variants acquired which number of mutations 
and so τsub cannot be calculated. In these cases tolerance is simply given at the mutation rate (τ0.5 
for µ=0.5% and τ1.5 for µ=1.5%). 
𝑆 = ∑ 𝑓𝑛
𝑛=0
(𝜏𝑠𝑢𝑏)
𝑛 =  𝑓0(𝜏𝑠𝑢𝑏)
0 + 𝑓1(𝜏𝑠𝑢𝑏)
1 + 𝑓2(𝜏𝑠𝑢𝑏)
2 … +𝑓𝑛(𝜏𝑠𝑢𝑏)
𝑛 
Equation G-6 | The probability of enzyme activity retention after random mutation 
(also D-1)  
S = the fraction of enzyme variants displaying wt-like activity 
n = number of mutations 
fn = the fraction of enzyme variants with n mutations  
τsub = the probability that a random mutation will be neutral 
Nb. Frameshift mutations will cause underestimation τsub, however, these were rare 
enough that they made no difference to these estimates 
6.5 PROCRASTINATION 
Avoiding work was mostly achieved through the news sites: BBC, Ars Technica and Nature news. 
On slow news days Facebook was occasionally required. For a full list see browser history. 
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